ACR Meeting Abstracts

ACR Meeting Abstracts

Session » ACR Convergence 2022

11:30AM-1:00PM
Abstract Number: 0001
12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT)
11:30AM-1:00PM
Abstract Number: 0002
Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy
11:30AM-1:00PM
Abstract Number: 0004
mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activation Syndrome
11:30AM-1:00PM
Abstract Number: 0003
Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial
11:30AM-1:00PM
Abstract Number: 0005
The Rheumatology Access Expansion (RAE) Initiative: Improving Rheumatoid Arthritis Care on Navajo Nation Through Primary Care Provider Education
1:00PM-3:00PM
Abstract Number: PP20
‘It Is Due to Stress’ – But Which Type of Stress? Cumulative childhood stress is a risk factor for autoimmune disease
1:00PM-3:00PM
Abstract Number: 0213
“The Best Part Is Feeling Like I Could Go out There and Maybe Really Help Somebody”: Training Peer Coaches to Deliver the Moving Well Total Knee Replacement Telephone-Based Coaching Program
1:00PM-3:00PM
Abstract Number: 0139
A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)
1:00PM-3:00PM
Abstract Number: PP09
A Matter of Life and Death: Why Diversity, Equity and Inclusion Matter for Health Care Providers
1:00PM-3:00PM
Abstract Number: 0371
A Phase 2, Double-blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101/Lenabasum in Systemic Lupus Erythematosus, an Autoimmunity Centers of Excellence Study (ALE09)
1:00PM-3:00PM
Abstract Number: 0479
A Prospective Study Evaluating the Utility of Ultrasound in Monitoring Newly-Diagnosed GCA
1:00PM-3:00PM
Abstract Number: 0311
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zunsemetinib, an Investigational Oral MK2 Inhibitor, at 80 Mg and 120 Mg Twice Daily Dose Levels in Healthy Subjects
1:00PM-3:00PM
Abstract Number: 0194
A Survey of Patients with Ehlers Danlos Syndrome and Their Interest in Multidisciplinary Care
1:00PM-3:00PM
Abstract Number: 0457
A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis
1:00PM-3:00PM
Abstract Number: 0487
A Systematic Literature Review to Generate Descriptors for the Development of New Response Criteria in Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0106
A Systematic Review of Racial and Ethnic Disparities in Disease Related Outcomes Among Patients with SLE
1:00PM-3:00PM
Abstract Number: 0142
A Systemic Autoinflammatory Syndrome Caused by NEMO Exon 5 Skipping
1:00PM-3:00PM
Abstract Number: 0225
A Transitions Retreat: Preparing Rheumatology Fellows for Career Planning and the Scholarly Phase of Training
1:00PM-3:00PM
Abstract Number: 0218
A Web-based Education Program Improves Health Care Provider Knowledge for the Care of Cancer Patients Receiving Immunotherapy Who Develop Rheumatic Immune-related Complications, and Those with Pre-existing Rheumatic Disease: An Initiative of CanRIO
1:00PM-3:00PM
Abstract Number: 0397
Aberrant Global DNA Methylation in Peripheral Blood Cell Subpopulations of Patients with Axial Spondyloarthritis
1:00PM-3:00PM
Abstract Number: 0057
Accelerating AxSpA Diagnosis: Exploring At-home Self-sampling, Symptom Checkers, Medical Student-visits and Asynchronous Report-based Assessment
1:00PM-3:00PM
Abstract Number: 0195
Acceptance of Virtual Reality for Managing Their Disease Among People with Rheumatologic Conditions with and Without Prior Experience Using Virtual Reality
1:00PM-3:00PM
Abstract Number: 0167
Accuracy of Multi-Centric Local Determination of Anti-Synthetase Autoantibodies in Patients with Anti-Synthetase Syndrome and Other Autoimmune Diseases
1:00PM-3:00PM
Abstract Number: 0410
Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity Is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
1:00PM-3:00PM
Abstract Number: 0114
Addressing Healthcare Disparities Through Implementation of a Medical Student-Based Patient Navigator Program
1:00PM-3:00PM
Abstract Number: 0033
Adenosine A2A Receptor Signaling Enhances Expression of an Endogenous p53 Mouse Variant in Bone Marrow Mesenchymal Stem Cells
1:00PM-3:00PM
Abstract Number: 0454
Advantages and Disadvantages in Applying 2022 ACR/EULAR Classification Criteria to Conventionally Diagnosed Japanese GPA Patients
1:00PM-3:00PM
Abstract Number: 0128
Advantages of Alternate-Day Glucocorticoid Treatment Strategy for IgG4-Related Disease: A Preliminary Retrospective Study ID: 1287015
1:00PM-3:00PM
Abstract Number: 0448
All-Cause and Cause-Specific Mortality in ANCA-Associated Vasculitis: A Population-based Study
1:00PM-3:00PM
Abstract Number: 0467
All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study
1:00PM-3:00PM
Abstract Number: 0180
Alterations of Nutritional Status in Patients with Idiopathic Inflammatory Myopathies and Their Association with Disease-related Features
1:00PM-3:00PM
Abstract Number: 0273
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderately to Severely Active RA
1:00PM-3:00PM
Abstract Number: 0490
Analysis of Emergency Department Visits by Patients with Giant Cell Arteritis: A National Population-based Study
1:00PM-3:00PM
Abstract Number: 0383
Analysis of the Performance of an Artificial Intelligence Algorithm for the Detection of Radiographic Sacroiliitis in an Independent Cohort of axSpA Patients Including Both Nr-axSpA and r-axSpA
1:00PM-3:00PM
Abstract Number: 0331
Anti-dsDNA Antibodies by Multiplex Flow Immunoassay and Critihidia Luciliae Assays in NYU Lupus Registry: Discordance, Association with Nephritis, and Disease Flare Predictive Value
1:00PM-3:00PM
Abstract Number: 0035
Anti-Peroxiredoxin 6 and Anti- Myosin Light Polypeptide 6 Autoantibodies with Interstitial Lung Disease and Severe Disease in Juvenile Dermatomyositis
1:00PM-3:00PM
Abstract Number: 0154
Anti-SMN Autoantibodies in Mixed Connective Tissue Disease Are Associated with a Scleromyositis Phenotype
1:00PM-3:00PM
Abstract Number: 0164
Anti-SSa/SSb and Ro52 Status and Pulmonary Function Tests in Patients with Interstitial Lung Disease and Idiopathic Inflammatory Myopathies
1:00PM-3:00PM
Abstract Number: 0456
Application of Adult ACR/EULAR 2022 Classification Criteria in Pediatric Vasculitis Patients
1:00PM-3:00PM
Abstract Number: 0406
Are the BASDAI & BASFI Capturing the Full Impact of Disease Activity on Quality of Life in Women with Axial Spondyloarthritis?
1:00PM-3:00PM
Abstract Number: 0322
Are Virtual Cognitive Assessments Comparable to In-person Assessments in a Systemic Lupus Erythematosus Cohort?
1:00PM-3:00PM
Abstract Number: 0228
Are We Choosing Wisely? Results of a Survey of Internal Medicine Residents in a Single Center
1:00PM-3:00PM
Abstract Number: 0393
Are We Meeting Patients’ Treatment Goals with Guideline-Based Therapy for Psoriatic Arthritis?
1:00PM-3:00PM
Abstract Number: 0399
ASAS Recommendations for Requesting and Reporting Imaging in Patients with Suspected Axial Spondyloarthritis
1:00PM-3:00PM
Abstract Number: 0485
Assessing the Effectiveness of Tocilizumab in Newly Diagnosed Giant Cell Arteritis versus Refractory/recurrent Giant Cell Arteritis in Clinical Practice
1:00PM-3:00PM
Abstract Number: 0330
Assessing the Utility of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Impairment in Patients with SLE Using a Bayesian Item-Response Theory Model
1:00PM-3:00PM
Abstract Number: 0223
Assessment During Rheumatology Fellowship After the Reforms in the French National Medical Curriculum: Has Anything Changed?
1:00PM-3:00PM
Abstract Number: 0466
Assessment of Probability Scores to Predict Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0345
Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis
1:00PM-3:00PM
Abstract Number: 0287
Association Between Short-Term Response to Upadacitinib Treatment and Long-Term Clinical Outcomes in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy
1:00PM-3:00PM
Abstract Number: 0034
Association of Anti-Tropomyosin Alpha-4 Autoantibodies with Cutaneous Manifestations in Juvenile Dermatomyositis
1:00PM-3:00PM
Abstract Number: 0091
Association of Area-Level Heat and Social Vulnerability with Recurrent Hospitalizations Among Individuals with Rheumatic Conditions
1:00PM-3:00PM
Abstract Number: 0095
Association of Urban vs. Rural Residence with New DMARD Initiation in US Veterans with Active Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0027
Associations of Serum C3f with Selected Biomarkers and Radiographic and Clinical Features of Knee Osteoarthritis
1:00PM-3:00PM
Abstract Number: 0359
Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets
1:00PM-3:00PM
Abstract Number: 0333
Autoantibody Trajectories Associate with Classification and Treatment Response in Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 0149
Autoinflammatory Diseases Associated with NOD2 and Other Concurrent Genetic Mutations
1:00PM-3:00PM
Abstract Number: 0159
B Cell Phenotype in Adult Patients with Idiopathic Inflammatory Myositis (IIM) Before and After Belimumab
1:00PM-3:00PM
Abstract Number: 0011
B Cell Subsets Contributing to the Autoreactive Plasma Cell Pool in Lyn-/- Mice
1:00PM-3:00PM
Abstract Number: 0019
Bacterial Peptidoglycan in Synovial Tissue at Time of Total Knee Arthroplasty Is Associated with Inflammatory Synovitis and Younger Patient Age
1:00PM-3:00PM
Abstract Number: 0046
Baricitinib Ameliorates Residual Neuropathic Pain in Collagen Antibody-Induced Arthritis Mice by Suppressing Inflammation of the Dorsal Root Ganglion
1:00PM-3:00PM
Abstract Number: 0125
Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Initiating Mepolizumab
1:00PM-3:00PM
Abstract Number: 0276
Baseline Characteristics of and Early Outcomes in the First 200 Patients with RA Treated with Filgotinib in a Prospective Observational Study
1:00PM-3:00PM
Abstract Number: 0460
Baseline Glucocorticoid Toxicity in the Treatment of Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
1:00PM-3:00PM
Abstract Number: 0022
Beneficial Structural Impact of Liraglutide, a GLP1 Receptor Agonist, in Three Inflammatory and Post-traumatic OA Animal Models
1:00PM-3:00PM
Abstract Number: 0409
Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
1:00PM-3:00PM
Abstract Number: 0412
Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
1:00PM-3:00PM
Abstract Number: 0411
Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study
1:00PM-3:00PM
Abstract Number: 0013
Binding of CXCL13 with Heparan Sulfate of Syndecan-1 Plays an Important Role in Pathogenesis of Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 0340
Birth Order Is a Risk Factor for Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 0094
Black Patients Are Less Satisfied with the Hospital Experience After Primary Hip and Knee Arthroplasty
1:00PM-3:00PM
Abstract Number: 0157
Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale
1:00PM-3:00PM
Abstract Number: 0477
Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis?
1:00PM-3:00PM
Abstract Number: 0267
Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register
1:00PM-3:00PM
Abstract Number: 0069
Capturing Clinical Reasoning in Real Time Reveals Low Rate of Serious Adverse Reactions Requiring B/tsDMARD Discontinuation in Inflammatory Joint Disease: An Analysis of the OPAL Real-World Dataset
1:00PM-3:00PM
Abstract Number: 0171
Cardiac Involvement in Idiopathic Inflammatory Myopathies: When Should We Look for It?
1:00PM-3:00PM
Abstract Number: 0445
Cardiovascular Burden in Patients with ANCA-Associated and Non-ANCA Associated Vasculitis
1:00PM-3:00PM
Abstract Number: 0008
CD11c+ T-Bet+ B Cells Traffic to Human Bone Marrow
1:00PM-3:00PM
Abstract Number: 0047
Cenerimod, a Novel Selective S1P1 Receptor Modulator, Prevents or Attenuates Joint Inflammation in Several Preclinical Models of Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0363
Centrally-Acting Angiotensin Converting Enzyme Inhibitor (cACEi) and Angiotensin Receptor Blocker (cARB) Use and Cognitive Dysfunction in Patients with Systemic Lupus
1:00PM-3:00PM
Abstract Number: 0088
Challenges in the Management of Psoriatic Arthritis in Latin America: A Systematic Review
1:00PM-3:00PM
Abstract Number: 0380
Changes in Disease Activity and Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Ixekizumab in a Real-World US Cohort
1:00PM-3:00PM
Abstract Number: 0163
Changes in Juvenile Dermatomyositis After the COVID-19 Pandemic
1:00PM-3:00PM
Abstract Number: 0285
Characteristics and Outcomes of Patients with Rheumatoid Arthritis Treated with Upadacitinib in a Global Real-World Setting
1:00PM-3:00PM
Abstract Number: 0296
Characteristics and Treatment-selection in Patients with Rheumatoid Arthritis and with Inadequate Response to Janus Kinase Inhibitors
1:00PM-3:00PM
Abstract Number: 0189
Characteristics Associated with a Positive PEST Screening Among Patients with Psoriasis Without a Diagnosis of Psoriatic Arthritis: Results from the Global Psoriasis and Beyond Study
1:00PM-3:00PM
Abstract Number: 0438
Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies
1:00PM-3:00PM
Abstract Number: 0092
Characterizing Levels of Specialist Care Received by Patients with Systemic Lupus Erythematosus: Clinical Characteristics, Emergency Care, Hospitalization, and Costs Among Commercially-insured Adults in the United States
1:00PM-3:00PM
Abstract Number: 0029
Characterizing the Anti-fibrotic Effect of Tofacitinib in TGF-β Stimulated Fibroblast-like Synoviocytes from Patients with OA
1:00PM-3:00PM
Abstract Number: 0497
Classification Criteria and Existing Pre-Test Probability Stratification Tools Perform Poorly in Diagnosing Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0354
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients by Cumulative Corticosteroid Dose over 1 Year: Real-World Observation of Commercially Insured Adults in the United States
1:00PM-3:00PM
Abstract Number: 0341
Clinical Applications of Urine SERPINC1/ORM1 in MRL-lpr Lupus Nephritis-Prone Mice
1:00PM-3:00PM
Abstract Number: 0436
Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study
1:00PM-3:00PM
Abstract Number: 0172
Clinical Characteristics and Outcomes of Inflammatory Myositis Related Interstitial Lung Disease: A 15 Year Retrospective Study
1:00PM-3:00PM
Abstract Number: 0439
Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and Without Alpha-1 Antitrypsin Deficiency Alleles
1:00PM-3:00PM
Abstract Number: 0162
Clinical Features Associated with the Presence of anti-SSA/Ro60 Antibodies in anti-Jo-1 Antibody-positive Myositis
1:00PM-3:00PM
Abstract Number: 0281
Clinical Outcomes of Filgotinib in Patients with RA Aged ≥65 Years: A Post Hoc Subgroup Analysis of Phase 2 and 3 Clinical Trials and Ongoing Long-Term Extensions
1:00PM-3:00PM
Abstract Number: 0085
Closing the Gender Gap in Global Rheumatology Leadership- Are We There Yet?
1:00PM-3:00PM
Abstract Number: 0433
Clustering of Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis – Using a Pre-processed Harmonised Dataset
1:00PM-3:00PM
Abstract Number: 0048
Combination of Repetitive Inhalant Endotoxin Exposure and Collagen-induced Arthritis Interact in a Testosterone-dependent Manner to Drive Inflammatory Lung Disease Processes and Arthritis Severity in Mice
1:00PM-3:00PM
Abstract Number: 0134
Combination Treatment with Baricitinib and Pulse Steroids in Severe COVID19: A
1:00PM-3:00PM
Abstract Number: 0246
Comorbidity Clusters in Patients with Rheumatoid Arthritis Predict Survival Prognosis
1:00PM-3:00PM
Abstract Number: 0367
Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use
1:00PM-3:00PM
Abstract Number: 0349
Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 0284
Compared Mortality and Cardiovascular Safety of JAK Inhibitors and Tocilizumab in Patients with RA : A Systematic Review and Network Meta-analysis
1:00PM-3:00PM
Abstract Number: 0062
Comparing Alzheimer’s Disease Risk in Patients with Chronic Inflammatory Autoimmune Diseases: A Medicare Cohort Study
1:00PM-3:00PM
Abstract Number: 0169
Comparison of Diagnostic Criteria Sets in Diagnosing Antisynthetase Syndrome
1:00PM-3:00PM
Abstract Number: 0093
Comparison of Faculty and Fellow Prescribing Patterns for Rheumatoid Arthritis in an Urban, Academic Hospital
1:00PM-3:00PM
Abstract Number: 0324
Comparison of NCounter® and BioFire® Technologies for the Measurement of Type I Interferon Signature
1:00PM-3:00PM
Abstract Number: 0398
Comparison of Spondyloarthritis, Rheumatoid Arthritis and Knee Osteoarthritis Occurring in the Setting of HIV Infection
1:00PM-3:00PM
Abstract Number: 0288
Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study
1:00PM-3:00PM
Abstract Number: 0473
Comprehensive Assessment of Cranial and Orbital Vasculature on MRI in Patients with Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0140
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON
1:00PM-3:00PM
Abstract Number: PP15
Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic
1:00PM-3:00PM
Abstract Number: 0339
Corneal Confocal Microscopy: A Potential Ophthalmic Imaging Biomarker of Neurodegeneration for Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 0067
Cost Per Responder in RA Patients Failing First Line Treatment
1:00PM-3:00PM
Abstract Number: 0100
COVID Vaccinations in Patients with Rheumatologic Diseases- perspectives and Disparities in a Safety-net Tertiary Care Hospital in Memphis, Tennessee
1:00PM-3:00PM
Abstract Number: 0188
COVID-19 and Autoimmune Rheumatic Patients: Behavioral Changes Adopted by Patients in the Midst of the Pandemic
1:00PM-3:00PM
Abstract Number: 0219
COVID-19 Impact on Second Year Medical Students Experience with Interactive Patient Encounters as a Supplement to Teaching the Skin and Rheumatology Course
1:00PM-3:00PM
Abstract Number: 0440
COVID-19 in Patients with ANCA Associated Vasculitis – Single Center Experience
1:00PM-3:00PM
Abstract Number: 0177
COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey
1:00PM-3:00PM
Abstract Number: 0083
COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Practice Network
1:00PM-3:00PM
Abstract Number: 0208
Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) and Associated Patient-Reported Outcomes and Biomarkers in a Phase 2 Clinical Trial in Dermatomyositis (DM)
1:00PM-3:00PM
Abstract Number: 0173
Cutaneous Manifestations, Clinical Trials, Safety Efficacy and Safety of Lenabasum in the Phase 3 DeterMine Trial in Dermatomyositis
1:00PM-3:00PM
Abstract Number: 0263
DAS28 (disease Activity Score) Elevations in Patients with Rheumatoid Arthritis (RA) Who Have Comorbid Fibromyalgia Are Explained by Elevated Tender Joint Counts as Much as by Elevated Patient Global Assessment
1:00PM-3:00PM
Abstract Number: 0021
DB-2306, a Novel Anti-TNFα Monoclonal Antibody Drug Conjugate, Is a Promising Novel Therapeutic Approach for Autoimmune Disease
1:00PM-3:00PM
Abstract Number: 0032
Defective Chaperone-mediated Autophagy Is a Hallmark of Joint Disease in Patients with Knee Osteoarthritis
1:00PM-3:00PM
Abstract Number: 0096
Delayed Referral of Female Rheumatoid Arthritis Patients: Where Are We Now? A Study Spanning Three Decades
1:00PM-3:00PM
Abstract Number: 0098
Delays in Access to Specialized Care and Diagnosis in Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 0166
Detection of the Novel Autoantibodies Against Transcription Factor Sp4 Is Related with Low Risk of Cancer in Idiopathic Inflammatory Myopathy Patients
1:00PM-3:00PM
Abstract Number: 0211
Determinants of COVID-19 Vaccine Hesitancy in a Predominantly Black Population with Cutaneous Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 0224
Developing and Evaluating a Rheumatology Nurse Competency Framework to Guide Professional Development and Career Progression
1:00PM-3:00PM
Abstract Number: 0318
Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data
1:00PM-3:00PM
Abstract Number: 0176
Diagnostic Accuracy and Clinical Relevance of Muscle Biopsy in Patients with Suspected Myositis
1:00PM-3:00PM
Abstract Number: 0377
Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
1:00PM-3:00PM
Abstract Number: 0206
Differences in Medicinal Cannabis Use According to Demography, Rationale, and Patient-Physician Interactions Between the United States and Canada
1:00PM-3:00PM
Abstract Number: 0015
Differential Antigen Binding of Closely Related Monoclonal ACPA
1:00PM-3:00PM
Abstract Number: 0068
Differential Diagnostic Coding Patterns and Associated Sociodemographic Factors in Childhood-Onset Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 0428
Difficult to Treat Spondyloarthritis: Patients with a High Biologic Switch Rate and the Factors Influencing It; A Real World as Clinic Experience
1:00PM-3:00PM
Abstract Number: 0423
Direct and Indirect Effect of TNFi on BASMI Components in People with Axial Spondyloarthritis: A Longitudinal Study
1:00PM-3:00PM
Abstract Number: 0401
Direct to Patient Screening of Psoriatic Arthritis: Clinical Findings and Outcomes of Patient-Driven Rheumatology Referrals
1:00PM-3:00PM
Abstract Number: 0179
Discordant Monozygotic Twins with Juvenile Dermatomyositis: Genetic and Clinical Studies
1:00PM-3:00PM
Abstract Number: 0031
Discovery of GSTT1 Gene That Promotes Osteogenic Differentiation of Adipose Stem Cells
1:00PM-3:00PM
Abstract Number: 0488
Discrepancies in Temporal Artery Biopsy Positivity Rate Among White and Black Patients Suspected of Having Giant Cell Arteritis: Experience from a Tertiary Academic Medical Center
1:00PM-3:00PM
Abstract Number: 0117
Disparities in Prescription Medications Among Myositis Patients in a Large Urban Medical Center
1:00PM-3:00PM
Abstract Number: 0016
Distinct Transcriptomic and Epigenetic Profiles Mediated by Disease Activity in SLE
1:00PM-3:00PM
Abstract Number: 0122
Documentation of Social Determinants of Health Among Individuals with Systemic Rheumatic and Musculoskeletal Diseases
1:00PM-3:00PM
Abstract Number: 0110
Does Access Reduce Excess Use? Lupus Outcomes in Two Distinct Socioeconomic Groups Seen by University Rheumatologists
1:00PM-3:00PM
Abstract Number: 0087
Does Limited English Proficiency Lead to Additional Health Inequity in Medically Vulnerable Populations in Outpatient Rheumatology?
1:00PM-3:00PM
Abstract Number: 0312
Dose-dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Phase 2 Study in Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0037
Dual (and Dueling) Fibroblast Differentiation Is Integral to the Pathogenesis of Anti-Ro Mediated Congenital Heart Block and Provides a Novel Biomarker of Severity
1:00PM-3:00PM
Abstract Number: 0391
Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data
1:00PM-3:00PM
Abstract Number: 0148
Dysferlin Associated Autoinflammatory Disease Causing Systemic Inflammation and Sterile Lung Abcesses Through Impaired Efferocytosis
1:00PM-3:00PM
Abstract Number: 0356
Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials
1:00PM-3:00PM
Abstract Number: 0238
Educational Experience and Engagement in the First Two Years of RheumMadness, an Online Community of Inquiry
1:00PM-3:00PM
Abstract Number: 0407
Effect of Biologics in MRI/CRP Subgroups of Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
1:00PM-3:00PM
Abstract Number: 0050
Effect of Disease-modifying Anti-rheumatic Drugs on Lung Microenvironment of SKG Mice
1:00PM-3:00PM
Abstract Number: 0279
Effect of Filgotinib on Body Weight and BMI and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in RA
1:00PM-3:00PM
Abstract Number: 0190
Effect of Shared Decision-making on Trust in Physician in the Clinical Practice of Systemic Lupus Erythematosus: The TRUMP2-SLE Study
1:00PM-3:00PM
Abstract Number: 0158
Effect of Type I IFN on Mitochondria and Muscle Weakness in Myositis
1:00PM-3:00PM
Abstract Number: 0305
Effect of Upadacitinib on Bone Erosion Repair in Rheumatoid Arthritis: A Pilot Study
1:00PM-3:00PM
Abstract Number: 0297
Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
1:00PM-3:00PM
Abstract Number: 0301
Effectiveness and Safety of Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Third Interim Analysis of a German Non-Interventional, Prospective, Multicenter Study (ESCALATE-RA)
1:00PM-3:00PM
Abstract Number: 0129
Effectiveness of Golimumab in the Treatment of Patients with Active Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis Who Failed Initial TNFα Therapy: A Pooled Analysis of European Prospective Observational Studies (the GO BEYOND Program)
1:00PM-3:00PM
Abstract Number: 0298
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Interim Results from the CLOSE-UP Post-Marketing Observational Study
1:00PM-3:00PM
Abstract Number: 0303
Effectiveness of Upadacitinib in the Treatment of Rheumatoid Arthritis: Analysis of 6-Month Real-World Data from the United Rheumatology Normalized Integrated Community Evidence (UR-NICETM) Database
1:00PM-3:00PM
Abstract Number: 0416
Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
1:00PM-3:00PM
Abstract Number: 0403
Efficacy and Safety of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis: 16-Week Results from a Phase 3 Study
1:00PM-3:00PM
Abstract Number: 0413
Efficacy and Safety of Non-Pharmacological and Non-Biological Therapy: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
1:00PM-3:00PM
Abstract Number: 0422
Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort
1:00PM-3:00PM
Abstract Number: 0405
Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Baseline BMI: A Post Hoc Analysis of Phase 2 and Phase 3 Trials
1:00PM-3:00PM
Abstract Number: 0421
Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Prior bDMARD Treatment: Analysis of a Phase 3 Trial
1:00PM-3:00PM
Abstract Number: 0286
Efficacy and Safety of Upadacitinib in Patients Across Races with Rheumatoid Arthritis: A Post Hoc Analysis of Six Phase 3 Clinical Trials
1:00PM-3:00PM
Abstract Number: 0414
Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis
1:00PM-3:00PM
Abstract Number: 0282
Efficacy and Safety of Upadacitinib in TNFi-IR Patients with Rheumatoid Arthritis from Three Phase 3 Clinical Trials
1:00PM-3:00PM
Abstract Number: 0364
Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Systemic Lupus Erythematosus (SLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part A)
1:00PM-3:00PM
Abstract Number: 0419
Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Objective Signs of Inflammation at Baseline
1:00PM-3:00PM
Abstract Number: 0052
Elucidating Androgen Effects on Focal Erosions in TNF-Induced Inflammatory Arthritis
1:00PM-3:00PM
Abstract Number: 0119
Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions Varies by Geographic Location of Residence
1:00PM-3:00PM
Abstract Number: 0185
Empowered2work: Development and Delivery of a Multi-faceted Peer-coaching Workshop Focusing on Health Promotion and Ergonomic Issues in the Workplace
1:00PM-3:00PM
Abstract Number: PP17
Engaging with the Spoon Theory: How I Make Decisions Using a Cost-Benefit Analysis That Works to Improve My Mental Health While Living with RA
1:00PM-3:00PM
Abstract Number: 0484
Epidemiology and Predictors of Relapse in Giant Cell Arteritis: A Systematic Review and Meta-analysis
1:00PM-3:00PM
Abstract Number: 0120
Epstein Barr Virus Reactivation in Native American Rheumatic Disease Patients Is Associated with Systemic Disease and Rheumatoid Arthritis but Not Other Rheumatic Diseases
1:00PM-3:00PM
Abstract Number: 0113
Escalation to Biologics After Methotrexate Among US Veterans with Rheumatoid Arthritis Living in Rural versus Urban Areas
1:00PM-3:00PM
Abstract Number: 0186
Evaluating the Effectiveness & Impact of an In-Person Peer Support Group That Transitioned to a Virtual Platform During the COVID-19 Pandemic
1:00PM-3:00PM
Abstract Number: 0124
Evaluation of Comorbidity Burden and Its Effect on Lung Disease Progression and Mortality in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features
1:00PM-3:00PM
Abstract Number: 0253
Evaluation of Patients with Rheumatoid Arthritis in Teleconsultation During the First Wave of the COVID-19 Pandemic
1:00PM-3:00PM
Abstract Number: 0452
Evaluation of the 2022 ACR/EULAR Classification Criteria for ANCA-Associated Vasculitis in a Population-based Cohort from Sweden
1:00PM-3:00PM
Abstract Number: 0290
Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study)
1:00PM-3:00PM
Abstract Number: PP11
Exercise as a Supportive Treatment for My Ankylosing Spondylitis
1:00PM-3:00PM
Abstract Number: 0337
Expanded Autoantibody Profiling in Incomplete Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 0275
Exploratory Analysis of Filgotinib Safety Data in Patients with Moderately to Severely Active RA and an Increased Risk of Cardiovascular Events: Data from Phase 2 and 3 Clinical Trials
1:00PM-3:00PM
Abstract Number: 0184
Exploring Patient Journeys and Education Needs of Hispanic Individuals with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0024
Exposure to Pollutants with Endocrine Disrupting Properties Is Associated with Early Cartilage Defects and Chondrocyte Inflammatory and Oxidative Activation
1:00PM-3:00PM
Abstract Number: 0300
Exposure-Response Analyses of Upadacitinib Effects on Plasma Biomarkers in Rheumatoid Arthritis Patients
1:00PM-3:00PM
Abstract Number: 0266
Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression
1:00PM-3:00PM
Abstract Number: 0175
Extracorporeal Membrane Oxygenation for Acute Lung Injury in Idiopathic Inflammatory Myopathies – a Potential Lifesaving Intervention
1:00PM-3:00PM
Abstract Number: 0084
Facilitators and Barriers of Vaccine Uptake in Patients with Chronic Inflammatory Rheumatic Disease: A Scoping Review
1:00PM-3:00PM
Abstract Number: 0115
Facilitators of Immunosuppressive Medication Adherence in Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers and Clinic Staff
1:00PM-3:00PM
Abstract Number: 0373
Factors Associated with Adverse Outcomes in Uveitis Related to Spondylarthritis (SpA-U)- Development of a Prognostic Outcome Score in Patients with SpA-U
1:00PM-3:00PM
Abstract Number: 0469
Factors Associated with Corticosteroid Dosing in the Management of Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0382
Factors Associated with Diagnostic Delay in Axial Spondyloarthritis: Impact of Clinical Factors and Social Vulnerability
1:00PM-3:00PM
Abstract Number: 0319
Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy
1:00PM-3:00PM
Abstract Number: 0193
Factors Influencing Visit Preference in Patients with Rheumatic Diseases: A Qualitative Study
1:00PM-3:00PM
Abstract Number: 0203
Feasibility and Acceptability of Integrating Patient Reported Outcomes Within Routine Care of Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0240
Few and Far Between: Addressing the Pediatric Rheumatology Workforce Gap with a Spotlight on Medicine-pediatrics Residency Trained Rheumatologist Career Paths
1:00PM-3:00PM
Abstract Number: 0030
Fluidic Shear Stress Reduces TNFα-mediated Cartilage Damage in a 3D Model of Degenerative Joint Disease
1:00PM-3:00PM
Abstract Number: 0044
Follistatin-like Protein 1 Alters T Cell Receptor Signaling Dynamics in Vitro, While Expression in Vivo Correlates with Disease and Deficiency Increases Acute Inflammation in a Mouse Model of Kawasaki Disease
1:00PM-3:00PM
Abstract Number: PP18
From Devastated to Empowered: How Patient Engagement in Research Changes Lives
1:00PM-3:00PM
Abstract Number: PP05
From Practical Tips to Heartfelt Encouragement: How Social Media Can Improve Quality of Life with Rheumatic Disease
1:00PM-3:00PM
Abstract Number: 0317
Full Characterization of the Three Pathways of Complement System in Patients with Systemic Lupus Erythematosus: Relation to Disease Expression
1:00PM-3:00PM
Abstract Number: 0111
Gender Equity in the Asia Pacific: Comparison of Indian and Philippines Rheumatology Conferences
1:00PM-3:00PM
Abstract Number: 0104
Gender Representation of the Editors and Editorial Boards of the Top 45 Rheumatology-Focused Journals
1:00PM-3:00PM
Abstract Number: 0361
Gene Expression Pathways Modulated by Anifrolumab in Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 0486
Gene Expression Profile of Temporal Artery Tissue and Whole Blood in Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0072
Geographical Patterns of Healthcare Utilization Among RA and OA Patients
1:00PM-3:00PM
Abstract Number: 0489
Giant Cell Arteritis Phenotypes and Diagnosis of Aortitis Among 1852 Patients Before and After 2016 Across 10 French Referral Centers
1:00PM-3:00PM
Abstract Number: 0496
Giant Cell Arteritis Relapse Risk – Could the Extent of Vessel Involvement on Temporal and Axillary Arteries Ultrasound Be a Prognostic Marker?
1:00PM-3:00PM
Abstract Number: 0483
Giant Cell Arteritis: Physical Examination of the Superficial Temporal Arteries Can Predict Temporal Artery Biopsy Result
1:00PM-3:00PM
Abstract Number: 0481
Glucocorticoid-related Adverse Events in Giant Cell Arteritis: Application of the Glucocorticoid Toxicity Index in a Monocentric Cohort of 140 Patients
1:00PM-3:00PM
Abstract Number: 0150
Growth and Differentiation Factor 15, an Emerging Biomarker of Mitochondrial Dysfunction- Associated Myopathies: Implications for Juvenile Dermatomyositis
1:00PM-3:00PM
Abstract Number: 0058
Health System Improvement in Inpatient ANA and Serologic Test Utilization
1:00PM-3:00PM
Abstract Number: 0059
Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 0257
High Density Lipoprotein Bound miR-1246 Is Enriched in Patients with Rheumatoid Arthritis and Is Proinflammatory
1:00PM-3:00PM
Abstract Number: 0310
Higher Baseline Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Predict Therapeutic Efficacy of Abatacept in Moderate to Severe Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0449
Higher Disease Acuity at Presentation and Increased Lower Respiratory Involvement in Hispanic and Black Patients with ANCA-Associated Vasculitis
1:00PM-3:00PM
Abstract Number: PP10
How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology
1:00PM-3:00PM
Abstract Number: PP13
How Becoming Engaged in My Care with Specialized Tools and Support Helped Me Find My Personal Lupus Triggers and Regain Control of My Health
1:00PM-3:00PM
Abstract Number: 0395
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
1:00PM-3:00PM
Abstract Number: 0051
Identification of a Transcription Factor That Drives Polarization Toward Tissue-destructive Fibroblasts in Arthritis
1:00PM-3:00PM
Abstract Number: 0249
Identification of Distinct Peripheral Blood Myeloid Cell Subpopulations in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease
1:00PM-3:00PM
Abstract Number: 0244
Identification of Novel Response Predictors via Cardiovascular Biomarker Proteomic Analysis of Serum Samples from Patients with Early, Seropositive RA Treated with Abatacept or Adalimumab
1:00PM-3:00PM
Abstract Number: 0221
Identifying and Addressing Gaps in Systemic Lupus Erythematosus Care via Multimodal Continuing Medical Education
1:00PM-3:00PM
Abstract Number: 0066
Identifying Childhood-Onset Systemic Lupus Erythematosus, Lupus Nephritis, and End-Stage Kidney Disease Definitions Within an Administrative Claims Database
1:00PM-3:00PM
Abstract Number: 0323
Identifying Distinct Phenotypes of Patients with Juvenile Systemic Lupus Erythematosus: Results from a Cluster Analysis by the Egyptian College of Rheumatology (ECR) Study Group
1:00PM-3:00PM
Abstract Number: 0049
IL-18 Receptor-α Signaling Pathway Contributes to Autoantibody-induced Arthritis via Neutrophil Recruitment
1:00PM-3:00PM
Abstract Number: 0259
Impact of Comorbidity on Disease Activity and Functional Status in Patients with Rheumatoid Arthritis Receiving Biologic DMARDs, a Longitudinal Analysis of the KOBIO-RA
1:00PM-3:00PM
Abstract Number: 0099
Impact of Multimodal Independent Medical Education on Improving Outcomes and Reducing Disparities in Systemic Lupus Erythematosus and Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 0156
Impact of Polymyositis and Dermatomyositis in Patients Admitted with Congestive Heart Failure: An Insight from the National Database
1:00PM-3:00PM
Abstract Number: 0102
Impact of Racial Implicit Bias on Juvenile Idiopathic Arthritis Patients’ Treatment Recommendations
1:00PM-3:00PM
Abstract Number: 0082
Impact of the COVID-19 Pandemic on Healthcare Utilization Among Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients
1:00PM-3:00PM
Abstract Number: 0081
Impact of the COVID-19 Pandemic on Rheumatology Services in a Universal Healthcare Setting in Canada: A Population-based Study
1:00PM-3:00PM
Abstract Number: 0260
Impacts of Poor Prognostic Factors in Rheumatoid Arthritis on Clinical Outcomes and Treatment Choices from an Observational Cohort of Korean Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0063
Implementability of a SLE Medication Adherence Intervention
1:00PM-3:00PM
Abstract Number: 0365
Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participants with Cutaneous Lupus Erythematosus (CLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part B)
1:00PM-3:00PM
Abstract Number: 0346
Improving Eye Screening Compliance in Patients Taking Hydroxychloroquine in a Community Hospital Setting
1:00PM-3:00PM
Abstract Number: 0265
In Patients with Rheumatoid Arthritis, Clinical Examination of the Feet Is Important for Understanding Individual Disease Burden, but Does Not Provoke a Change in Therapy in Most Cases
1:00PM-3:00PM
Abstract Number: 0394
In Radiographic Axial Spondyloarthritis Spinal Mobility Measures Correlate Well with the Whole Spine CT Syndesmophyte Score (CTSS)
1:00PM-3:00PM
Abstract Number: 0451
Incidence and Prevalence of ANCA-associated Vasculitis in Southern Sweden – a 23-year Study
1:00PM-3:00PM
Abstract Number: 0372
Incidence and Risk of Overall Infections in Patients with Ankylosing Spondylitis Receiving Biologic Therapies: A Real-world Prospective Observational Study Using KOBIO Registry
1:00PM-3:00PM
Abstract Number: 0450
Incidence of Solid and Hematologic Tumors in Patients with ANCA: A 10-year Retrospective Cohort Study
1:00PM-3:00PM
Abstract Number: 0388
Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States
1:00PM-3:00PM
Abstract Number: 0123
Increase of Serum Endothelin-1 Levels in Patients with Interstitial Lung Disease Associated with Autoimmune Diseases
1:00PM-3:00PM
Abstract Number: 0462
Increasing Incidence of Large Artery Manifestations in Patients with Giant Cell Arteritis, a Population-based Cohort over 70 Years
1:00PM-3:00PM
Abstract Number: 0442
Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey
1:00PM-3:00PM
Abstract Number: 0241
Inequity in Disease Impact Between Male and Female Rheumatoid Arthritis Patients
1:00PM-3:00PM
Abstract Number: 0384
Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study
1:00PM-3:00PM
Abstract Number: 0245
Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD
1:00PM-3:00PM
Abstract Number: 0017
Intra-articular Injection of Bacterial DNA Amplified from Human OA Patient Cartilage Worsens OA Outcomes in Mice
1:00PM-3:00PM
Abstract Number: 0174
Intra-rater Validation of Calcinosis Durometer Measurements in Juvenile and Adult Dermatomyositis
1:00PM-3:00PM
Abstract Number: 0146
Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: PP04
Invisible to Invincible: The Role of Virtual Events in Autoimmune Advocacy, Education and Community Building
1:00PM-3:00PM
Abstract Number: 0255
Is Abatacept as Effective and Safe in Rheumatoid Arthritis Patients with Previous Malignancy as in Those Without?
1:00PM-3:00PM
Abstract Number: 0141
Is Rituximab Associated with Worse Outcomes in COVID-19 Patients? A Meta-analysis
1:00PM-3:00PM
Abstract Number: 0197
Is Similar the Same? How We Incorporated Feedback from 250 Patients into a CME Activity on Biosimilars
1:00PM-3:00PM
Abstract Number: 0447
Is Systemic Vasculitis a Risk Factor for Myocardial Infarction? A Retrospective Cohort Study from the National Inpatient Sample
1:00PM-3:00PM
Abstract Number: 0400
Is There Any Influence of Gender on the Sociodemographic and Clinical Characteristics of Psoriatic Arthrithis?
1:00PM-3:00PM
Abstract Number: 0199
Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 0464
JAKINIB in Refractory Giant Cell Arteritis. National Multicenter Study of 15 Cases and Literature Review
1:00PM-3:00PM
Abstract Number: 0135
Janus Kinase Inhibitors in Severe and Refractory Inflammatory Ocular Pathology. Cases Reports and Literature Review
1:00PM-3:00PM
Abstract Number: 0090
Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 0202
Learning Needs Assessment for Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
1:00PM-3:00PM
Abstract Number: PP08
Learning to Advocate for Myself and the Young Adult Community While Finding My Place as a Patient Partner at CARRA (Childhood Arthritis and Rheumatology Research Alliance)
1:00PM-3:00PM
Abstract Number: 0161
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells
1:00PM-3:00PM
Abstract Number: 0226
Linguistics Biases in Letters of Recommendation Written for Rheumatology Fellowship Applicants
1:00PM-3:00PM
Abstract Number: 0254
Lipids and Vascular Inflammation in Patients with RA Using Triple Therapy vs Methotrexate + TNFi: A Secondary Analysis of the TARGET Randomized Active Comparator Trial
1:00PM-3:00PM
Abstract Number: PP19
Living with Rheumatoid Arthritis in a Rural Farming Community: How I Found a Rheumatologist and Got Targeted Treatment
1:00PM-3:00PM
Abstract Number: 0408
Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
1:00PM-3:00PM
Abstract Number: 0272
Long-Term Efficacy of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Bdmards: Results from RA-BEYOND up to 6.9-Years of Treatment
1:00PM-3:00PM
Abstract Number: 0470
Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial
1:00PM-3:00PM
Abstract Number: 0431
Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept
1:00PM-3:00PM
Abstract Number: 0309
Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study
1:00PM-3:00PM
Abstract Number: 0358
Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 0293
Long-term Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs: Results Through 5 Years from SELECT-BEYOND
1:00PM-3:00PM
Abstract Number: 0355
Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
1:00PM-3:00PM
Abstract Number: 0018
Longitudinal Development of Cartilage Microbial DNA Profiles Following Oral Microbiome Inoculation
1:00PM-3:00PM
Abstract Number: 0492
Longitudinal Tends of Hospitalizations for Giant Cell Arteritis: A 21-year Longitudinal National Population-based Study
1:00PM-3:00PM
Abstract Number: 0360
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 0165
Low Paraoxonase-1 Enzyme Activity in Patients with Idiopathic Inflammatory Myopathies Associates with Cancer Diagnosis
1:00PM-3:00PM
Abstract Number: 0060
Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission
1:00PM-3:00PM
Abstract Number: 0270
Lower mRNA-anti SARS-Cov2 Induced IgG Antibody Responses to S1, S2 and RBD May Result from a Delayed IgA and IgM Class Switch in Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0183
LupusConnect™: A 24/7 Online Lupus Support Community
1:00PM-3:00PM
Abstract Number: 0321
M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort
1:00PM-3:00PM
Abstract Number: 0261
Machine Learning and Computational Pathology Can Reveal Synovial Pathotypes in Mice and Humans
1:00PM-3:00PM
Abstract Number: 0336
Machine Learning Approach for the Prediction of Lupus Nephritis Renal Flares Using Polygenic Risk Score and Electronic Health Record
1:00PM-3:00PM
Abstract Number: 0306
Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry
1:00PM-3:00PM
Abstract Number: 0277
Malignancy Events in the Filgotinib Rheumatoid Arthritis and Ulcerative Colitis Clinical Development Programs
1:00PM-3:00PM
Abstract Number: 0292
Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
1:00PM-3:00PM
Abstract Number: 0212
Managing Psoriatic Arthritis: Patients’ Views and Attitudes to Using an Online Wellness Program
1:00PM-3:00PM
Abstract Number: 0326
Mapping Anti-Mitochondrial Antibodies over Time in a Lupus Inception Cohort
1:00PM-3:00PM
Abstract Number: 0491
Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis
1:00PM-3:00PM
Abstract Number: 0054
MDSCs in Inflammatory Joints of SKG Mice Suppress T Cells and Differentiate into Osteoclasts
1:00PM-3:00PM
Abstract Number: 0320
Metabolomics in Systemic Lupus Erythematosus and Pregnancy – A Prospective Observational Longitudinal Study
1:00PM-3:00PM
Abstract Number: 0028
Microenvironmental Stiffness Modulates Macrophage Responsiveness and Communication with Mesenchymal Stem Cells
1:00PM-3:00PM
Abstract Number: 0170
Minimal Clinically Important Difference in Myositis Response Criteria
1:00PM-3:00PM
Abstract Number: 0252
Mitochondrial Content in Skeletal Muscle of Individuals with Rheumatoid Arthritis Is Associated with Physical Activity Level
1:00PM-3:00PM
Abstract Number: 0041
Modeling Juvenile Dermatomyositis with Engineered Human Skeletal Muscle: Effects of Type I Interferonβ and Janus Kinase Inhibitors
1:00PM-3:00PM
Abstract Number: 0233
Monoarthritis Virtual Teaching Module for Rheumatology Learners
1:00PM-3:00PM
Abstract Number: 0248
Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA
1:00PM-3:00PM
Abstract Number: 0381
Most Disease Outcome Measures but Not ASDAS Are Influenced by Gender in Patients with Axial SpA: Results from ASAS-PerSpA
1:00PM-3:00PM
Abstract Number: 0493
MRI Is Superior to Ultrasound of Supraaortic Arteries in Detecting Giant Cell Arteritis – Experience of a Single Center
1:00PM-3:00PM
Abstract Number: 0342
Multi-Parametric Interrogation of the Systemic Lupus Erythematosus (SLE) Immunome Reveals Multiple Derangements
1:00PM-3:00PM
Abstract Number: 0335
Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile
1:00PM-3:00PM
Abstract Number: 0178
Muscle Fibres Play a Critical Role in Therapeutic Response of Myositis to Glucocorticoids Through Polarisation of the Inflammatory Infiltrate by a Paracrine Mechanism
1:00PM-3:00PM
Abstract Number: 0143
National Multicenter Study of 80 Patients with Refractory Uveitis Due to Immune-Mediated Inflammatory Diseases Treated with Certolizumab Pegol
1:00PM-3:00PM
Abstract Number: 0053
Natural Microbial Exposure Increases Susceptibility of C57BL/6 Mice to Collagen-induced Arthritis
1:00PM-3:00PM
Abstract Number: 0242
Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis by Using Magnetic Resonance Imaging
1:00PM-3:00PM
Abstract Number: 0023
New Biomarkers in Hand Osteoarthritis: The Micro-RNA Signature
1:00PM-3:00PM
Abstract Number: 0182
Newly Diagnosed with Inflammatory Arthritis. Development of a Complex Self-management Intervention
1:00PM-3:00PM
Abstract Number: 0429
No Change in Serum Levels of Bone Turnover Markers Corrected for Age and Gender During the First Year of Secukinumab Treatment in Patients with Ankylosing Spondylitis
1:00PM-3:00PM
Abstract Number: 0043
Non-invasive Tape Strip Gene Expression Profiling of Lesional Juvenile Dermatomyositis Skin Identifies Immunoregulatory Module That Associates with Skin, Muscle and Global Disease Activity
1:00PM-3:00PM
Abstract Number: 0207
Novel Digital Technologies for the Assessment of Objective Measures and PROs in Patients with Rheumatoid Arthritis: A Pilot Study Using Smart Devices and a Bespoke Mobile App
1:00PM-3:00PM
Abstract Number: 0151
Novel Innate Immunity Predictors of Infections in Idiopathic Inflammatory Myopathies Patients: A Cohort Study
1:00PM-3:00PM
Abstract Number: 0251
Nuclear Factor of Activated T Cells Cytoplasmic 1 as a Potential Biomarker of Increased Cardiovascular Risk in Patients with Early Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0153
Obesity Is Associated with Higher Odds of Malignancy Development Among Dermatomyositis Patients
1:00PM-3:00PM
Abstract Number: 0314
Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
1:00PM-3:00PM
Abstract Number: 0313
Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial
1:00PM-3:00PM
Abstract Number: 0230
Online Educational Module on Axial Spondyloarthritis Improves the Knowledge and Confidence of Non-rheumatology Providers
1:00PM-3:00PM
Abstract Number: 0215
Online Teaching of Hand Examination Using Student-recorded Videos and Remotely Delivered Feedback: A Pilot Study
1:00PM-3:00PM
Abstract Number: 0435
Onset of ANCA-associated Vasculitides in Systemic Sclerosis: Phenotype, Management and Outcomes
1:00PM-3:00PM
Abstract Number: 0073
Opioid and Pain Medication Prescribing by Rheumatologists for Medicare Part D Beneficiaries from 2013 to 2019
1:00PM-3:00PM
Abstract Number: 0402
Opioid Use and Healthcare Utilization in Adults with PsA and AS
1:00PM-3:00PM
Abstract Number: 0006
Oral Administration of a Novel Pyrrolopyrimidine Derivative That Inhibits BAFF Signaling Suppresses B Cell Differentiation and Production of Autoantibody in Autoimmune Model Mice
1:00PM-3:00PM
Abstract Number: 0325
Ordering Practices and Diagnostic Utility of Cardiac MRI in SLE Patients at a Single Academic Institution
1:00PM-3:00PM
Abstract Number: 0437
Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
1:00PM-3:00PM
Abstract Number: 0086
Patient and Provider Perspectives on Barriers to Communication and Care of Latinx Patients with Lupus and Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: PP02
Patient Mobilization for Vaccine Access and Improved Care During the COVID Pandemic
1:00PM-3:00PM
Abstract Number: 0181
Patient Perspective of Unique Support and Education Needs of Latinx/Latino(a)/Hispanic Rheumatoid Arthritis Patients: Implications for a Culturally Tailored and Disease Specific Intervention
1:00PM-3:00PM
Abstract Number: 0198
Patient Perspectives on Janus Kinase Inhibitor Use in the Treatment of Inflammatory Arthritis
1:00PM-3:00PM
Abstract Number: 0187
Patient-reported Outcomes and Quality of Life in Patients with Rheumatoid Arthritis Treated with GP2015: Final Results from a Real-world Study
1:00PM-3:00PM
Abstract Number: 0441
Patient-Reported Outcomes in ANCA-Associated Vasculitis: Interactions Between Patients’ and Physicians’ Perspectives in a Mexican Cohort
1:00PM-3:00PM
Abstract Number: 0191
Patient-reported Outcomes to Assess Dyspnea in Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Hypertension, a Systematic Literature Review of Measurement Properties
1:00PM-3:00PM
Abstract Number: 0036
Patient-specific and Disease-related Determinants for Cardiovascular Disease (CVD) Risk Stratification in the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Clinical Trial Cohort
1:00PM-3:00PM
Abstract Number: PP22
Patients Raising Awareness for Patients – A Collaborative Partnership Between Take a Pain Check Foundation and Canadian Arthritis Patient Alliance
1:00PM-3:00PM
Abstract Number: 0256
Patients with ACPA-positive and ACPA-negative Rheumatoid Arthritis Show Different Circulating Auto-antibody Repertoires
1:00PM-3:00PM
Abstract Number: 0138
Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry
1:00PM-3:00PM
Abstract Number: 0455
Performance of 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Turkish Vasculitis Patients
1:00PM-3:00PM
Abstract Number: 0392
Performance of Clinical, Laboratory and Imaging Features for the Diagnosis of Axial Spondyloarthritis – A Systematic Literature Review
1:00PM-3:00PM
Abstract Number: 0334
Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records
1:00PM-3:00PM
Abstract Number: 0250
Performance of Fear Assessment in Inflammatory Rheumatic Diseases (FAIR) Questionnaire in a Cohort of Rheumatoid Arthritis Patients in Argentina
1:00PM-3:00PM
Abstract Number: 0476
Permanent Vision Loss in Giant Cell Arteritis: Why the Incidence Remains High
1:00PM-3:00PM
Abstract Number: 0204
Persistence of Fatigue, Sleep Disturbance and Mood Disorders in PMR Patients Despite Standard Treatment
1:00PM-3:00PM
Abstract Number: 0390
Persistent Post-Covid Symptoms in Psoriatic Arthritis Patients
1:00PM-3:00PM
Abstract Number: 0009
Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0366
Phase II Trial of Enpatoran in Patients Hospitalized with COVID-19 Pneumonia
1:00PM-3:00PM
Abstract Number: 0379
Physical Activity Is Associated with Physical and Global Function in Patients with Axial Spondyloarthritis, Independent of Disease Activity
1:00PM-3:00PM
Abstract Number: 0056
Pilot Study to Implement the Type 1 & 2 SLE Model in an Academic Rheumatology Clinic
1:00PM-3:00PM
Abstract Number: 0040
Plasma Proteomic Signatures in Juvenile Dermatomyositis Highlight Novel Proteins and a Protein Module That Associate with Skin and Global Disease Activity
1:00PM-3:00PM
Abstract Number: PP16
Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 0132
Pleuroparenchymal Fibroelastosis: A Special Clinical Situation in Patients with Interstitial Lung Disease Associated with Connective Tissue Diseases. Descriptive Study from a Referral Centre
1:00PM-3:00PM
Abstract Number: 0152
Pm/Scl Patients Have an Expanded Population of CD19+CD21lo/negCD11c+CD11b+ Cells Expressing a Monocyte, Not B Cell, Transcriptome
1:00PM-3:00PM
Abstract Number: 0137
Polyarticular Arthritis and Osteolysis Caused by Mutations in the ASAH1 Gene: Farber Disease Clinical Presentations in the First-ever Natural History Study
1:00PM-3:00PM
Abstract Number: 0070
Post-operative Delirium and Cognitive Impairment: An Analysis of Predictors and 120-day Outcomes in England Using the National Hip Fracture Database (NHFD)
1:00PM-3:00PM
Abstract Number: 0269
Practical Cut-off Points for Using the Rheumatoid Arthritis Impact of Disease (RAID) Questionnaire in Remote Consult Triage
1:00PM-3:00PM
Abstract Number: 0328
Predicting Progression from Undifferentiated to Definitive Connective Tissue Diseases: A Systematic Review and Meta-analysis
1:00PM-3:00PM
Abstract Number: 0432
Predictive Factors of Eosinophilic Granulomatosis with Polyangiitis Long-term Evolution: Data from a European Cohort
1:00PM-3:00PM
Abstract Number: 0458
Predictive Models for Thromboembolic Events in Giant Cell Arteritis: A US Veterans Health Administration Population-Based Study
1:00PM-3:00PM
Abstract Number: 0262
Predictors of Fragility Fracture Amongst Patients with Rheumatoid Arthritis: An Observational Cohort Study
1:00PM-3:00PM
Abstract Number: 0370
Preliminary Findings from a Randomized Clinical Trial Show a Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus
1:00PM-3:00PM
Abstract Number: 0378
Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain in Chiropractic Clinics
1:00PM-3:00PM
Abstract Number: 0444
Prevalence of Frailty and Associated Factors in Patients with Vasculitis
1:00PM-3:00PM
Abstract Number: 0231
Primary Care Physician’s Perspective and Needs on Early Rheumatoid Arthritis Diagnosis: REUCARE Program for Early Referral
1:00PM-3:00PM
Abstract Number: 0222
Primary Care Provider Utilization of Musculoskeletal Ultrasound for the Diagnosis of Acute Gout Flares: A Novel Opportunity for Rheumatology-Focused Educational Curricula
1:00PM-3:00PM
Abstract Number: 0235
Procedure-Based Musculoskeletal Ultrasound Curriculum for Rheumatology Fellows
1:00PM-3:00PM
Abstract Number: 0443
Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis
1:00PM-3:00PM
Abstract Number: 0055
Protective Role for Mast Cells in TNF-induced Inflammatory-Erosive Arthritis and Its Associated Lymphatic Dysfunction in Mice
1:00PM-3:00PM
Abstract Number: 0386
Quantitative Proteomic Screening Uncovers Diagnostic and Monitoring Serum Biomarkers of Ankylosing Spondylitis
1:00PM-3:00PM
Abstract Number: 0131
Racial Differences in Bone Health of Sarcoidosis Patients: A Retrospective Study
1:00PM-3:00PM
Abstract Number: 0116
Racial Differences in Medication Beliefs and Barriers to Taking Medications Among Patients with SLE
1:00PM-3:00PM
Abstract Number: 0089
Racial Disparities in Rheumatology Clinical Trials
1:00PM-3:00PM
Abstract Number: 0299
Radiographic Change in Patients with Rheumatoid Arthritis and Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc Analysis of Two Phase 3 Trials of Filgotinib
1:00PM-3:00PM
Abstract Number: 0243
Real World Evidence of Treatment Effectiveness and Unfavorable Clinical Events for Elderly-onset Early Rheumatoid Arthritis in Japan: Results from the IORRA Study
1:00PM-3:00PM
Abstract Number: 0418
Real World Evidence on Disease Activity in Patients with Ankylosing Spondylitis Treated with Tumour Necrosis Factor Inhibitors and/or Nonsteroidal Anti-Inflammatory Drugs in Routine Care
1:00PM-3:00PM
Abstract Number: 0076
Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database
1:00PM-3:00PM
Abstract Number: 0289
Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry
1:00PM-3:00PM
Abstract Number: 0347
Real-World Effectiveness of Belimumab in Patients with SLE in the United States
1:00PM-3:00PM
Abstract Number: 0201
Real-World Evidence from Social Media Provides Insights into Patient Mental Health Outcomes in the Management of Gout
1:00PM-3:00PM
Abstract Number: 0075
Real-World Treatment Patterns Among Patients with Connective Tissue Disorder–Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis
1:00PM-3:00PM
Abstract Number: 0074
Real-World Treatment Patterns, Healthcare Resource Utilization (HCRU) and Costs in Patients with Systemic Lupus Erythematosus (SLE) in the US
1:00PM-3:00PM
Abstract Number: 0274
Real-world Utilisation and Switching Between Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in the Australian OPAL Dataset
1:00PM-3:00PM
Abstract Number: 0264
Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0427
Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Axial Spondyloarthritis: Results at Week 104 from a Randomized Placebo-controlled Withdrawal Study
1:00PM-3:00PM
Abstract Number: 0020
Redoxosomes Mediate a Feed-forward Loop of Cartilage Matrix Destruction Through α5β1 Integrin Signaling in Response to a Fibronectin Matrikine
1:00PM-3:00PM
Abstract Number: 0307
Reduction in Structural Damage Progression and Improvement in Clinical Response with Abatacept Treatment in Patients with ACPA+, Early RA: Results from a Post Hoc Analysis of the AVERT-2 Study by Baseline Erosion Scores
1:00PM-3:00PM
Abstract Number: PP07
Remissions and Vigilance
1:00PM-3:00PM
Abstract Number: 0103
Retention in Rheumatology Care and Receipt of Lupus-Specific Serologic Testing Among Young Adults with Systemic Lupus Erythematosus: A Medicare Cohort Study
1:00PM-3:00PM
Abstract Number: 0133
Retention Rate of Targeted Therapies in Erdheim-Chester Disease
1:00PM-3:00PM
Abstract Number: 0061
Rheumatic Diagnostic Code Trajectories for Patients with RA and SLE in a U.S. Rheumatology Registry
1:00PM-3:00PM
Abstract Number: 0077
Rheumatoid Arthritis – Are We Getting to Target?
1:00PM-3:00PM
Abstract Number: 0247
Rheumatoid Arthritis as a Modifier of the Cognition-Daily Function Association
1:00PM-3:00PM
Abstract Number: 0258
Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents
1:00PM-3:00PM
Abstract Number: 0121
Rheumatoid Arthritis Care Experiences of Black People Living in Canada: A Qualitative Study to Inform Treatment Guidelines
1:00PM-3:00PM
Abstract Number: 0065
Rheumatoid Arthritis Clinical Care Pathway Implementation: A Step Towards Improved Outcomes and Value-Based Care
1:00PM-3:00PM
Abstract Number: 0045
Rheumatoid Arthritis Patient-derived Anti-citrullinated Protein Antibodies (ACPAs) Ameliorate Joint Inflammation in Early Collagen-antibody Induced Arthritis (CAIA)
1:00PM-3:00PM
Abstract Number: 0304
Rheumatoid Arthritis Patients Who Switched Treatment from Adalimumab to Upadacitinib Demonstrate a Robust Reduction of Inflammation-related Biomarkers: Proteomics Analysis from the SELECT-COMPARE Phase 3 Study
1:00PM-3:00PM
Abstract Number: 0239
Rheumatology Fellowship Programs – What Are Our Missions and What Are We Missing? A Mixed Methods Analysis of Publically-Available Mission Statements from the 126 Adult Rheumatology Fellowships in the United States
1:00PM-3:00PM
Abstract Number: 0232
RheumMadness: Early Learner Experience and Impact
1:00PM-3:00PM
Abstract Number: 0308
Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies
1:00PM-3:00PM
Abstract Number: 0494
Risk for Visual Loss in Patients with Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0302
Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0268
Risks of Mortality in Elderly-onset Rheumatoid Arthritis: Analysis from the TRA Clinical Electronic Registry
1:00PM-3:00PM
Abstract Number: 0147
Rituximab in IgG4-Related Diseae: An Open-Label Non-Randomized Observational Study
1:00PM-3:00PM
Abstract Number: 0482
Role of miR-146a and miR-146b in Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0012
Role of Type L IFN Signaling on B Cell Pathogenicity in Early Sjögren’s Disease in Mouse Model
1:00PM-3:00PM
Abstract Number: 0294
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
1:00PM-3:00PM
Abstract Number: 0295
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study
1:00PM-3:00PM
Abstract Number: 0280
Safety of Filgotinib in Patients with RA: Laboratory Analysis Results from a Long-Term Extension Study
1:00PM-3:00PM
Abstract Number: 0136
Sarcoidosis Incidence After mTOR Inhibitor Treatment
1:00PM-3:00PM
Abstract Number: 0160
Sarcopenia in Myositis Patients: A Marker of Muscle Damage Associated with Myositis Severity and Disability
1:00PM-3:00PM
Abstract Number: 0329
Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression
1:00PM-3:00PM
Abstract Number: 0234
Scouting Reports as a Social Constructivist Teaching Tool in RheumMadness
1:00PM-3:00PM
Abstract Number: PP06
Search for a New Rheumatologist; What Happened When My Trusted Rheumatologist Retired
1:00PM-3:00PM
Abstract Number: 0495
Seasonal Variation in the Incidence of GCA in the UK and Ireland
1:00PM-3:00PM
Abstract Number: 0168
Semiquantitative Thigh Magnetic Resonance Imaging (tMRI) in Determining Skeletal Muscle Outcomes at Baseline and on Follow up in Idiopathic Inflammatory Myopathies (IIMs)
1:00PM-3:00PM
Abstract Number: 0209
Sensitivity of Three Skin-Specific Efficacy Outcomes to Detect Patient- and Physician-Reported Improvement in Overall Skin Disease in Dermatomyositis
1:00PM-3:00PM
Abstract Number: 0471
Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)
1:00PM-3:00PM
Abstract Number: 0343
Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Damage, and Mortality in Systemic Lupus Erythematosus: Data from 660 Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
1:00PM-3:00PM
Abstract Number: 0097
Sex and Race/ethnicity Differences in Knee Symptoms, Function, and Radiographic Features: Preliminary Descriptive Data from the Johnston County Health Study
1:00PM-3:00PM
Abstract Number: 0434
Sex Based Differences in Cardiovascular Conditions Associated with Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Analysis of the National Inpatient Sample
1:00PM-3:00PM
Abstract Number: 0118
Sex-Based Variations in Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions
1:00PM-3:00PM
Abstract Number: 0107
Short-, Intermediate- and Long-Term Renal Outcomes in Hispanics from Puerto Rico with Lupus Nephritis: Induction Therapy with Cyclophosphamide vs. Mycophenolate Mofetil
1:00PM-3:00PM
Abstract Number: 0126
Should Arthrocentesis Be Attempted in the Symptomatic but Non-Effusive Knee?
1:00PM-3:00PM
Abstract Number: 0200
Should Independence Play a Role in Assessing Remission in Rheumatoid Arthritis?
1:00PM-3:00PM
Abstract Number: 0348
Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
1:00PM-3:00PM
Abstract Number: 0026
Silencing of WISP-2 Induces Inflammatory Mediators and Catabolic Factors in Cartilage
1:00PM-3:00PM
Abstract Number: 0404
Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial
1:00PM-3:00PM
Abstract Number: 0387
Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity
1:00PM-3:00PM
Abstract Number: 0327
SMART-SLE: Serology Monitoring and Repeat Testing in Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 0220
Social Media Use in Academic Rheumatology
1:00PM-3:00PM
Abstract Number: 0332
Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in Cerebrospinal Fluid Relating to Development of Diffuse Psychiatric/Neuropsychological Syndromes in Patients with Systemic Lupus Erythematosus (diffuse NPSLE)
1:00PM-3:00PM
Abstract Number: 0478
Sonographic Prevalence of Subclinical GCA in Newly Diagnosed PMR
1:00PM-3:00PM
Abstract Number: 0350
Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 0353
Steroid-Induced Diabetes in Lupus Nephritis Patients: Classic Risk Factors or a Different Type of Diabetes?
1:00PM-3:00PM
Abstract Number: 0038
STING Antagonist (IFM4490) Inhibits STING Activation and STING Dependent Signal Transduction in Patients with STING-associated Vasculopathy with Onset in Infancy (SAVI)
1:00PM-3:00PM
Abstract Number: 0108
Study of the Level of Antibody Response to COVID-19 Vaccine in a Minority Population with Rheumatological Disorders
1:00PM-3:00PM
Abstract Number: 0105
Supplemental Primary Dose of the COVID-19 Vaccine in Immunosuppressed Patients on DMARDs and Biologic Agents
1:00PM-3:00PM
Abstract Number: 0385
T Cell Receptor Sequencing Identifies Two Classes of T Cells Enriched in HLA-B27-associated Inflammation
1:00PM-3:00PM
Abstract Number: 0316
Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF) – a Novel Treatment Approach for Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 0271
Temporal Trends and Risk of Rheumatoid Arthritis in Celiac Disease Patients: A Nationwide Population-based Study
1:00PM-3:00PM
Abstract Number: 0127
The Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study) Supports Multidimensional Disease Symptomatology with High Levels of Pain and Fatigue, and Low Levels of Function
1:00PM-3:00PM
Abstract Number: 0283
The Association Between the Usage of Biological Disease Modified Anti Rheumatic Drug or JAK Inhibitor and the Burden of Treatment Costs on Daily Life (financial Toxicity) in RA Patients: A Cross-sectional Study Using the National Database of Rheumatic Diseases in Japan (NinJa)
1:00PM-3:00PM
Abstract Number: 0415
The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events in Ankylosing Spondylitis
1:00PM-3:00PM
Abstract Number: 0144
The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease
1:00PM-3:00PM
Abstract Number: 0374
The BASDAI Index During Pregnancy
1:00PM-3:00PM
Abstract Number: 0446
The Burden of Coronary Artery Calcification in ANCA-Associated Vasculitis
1:00PM-3:00PM
Abstract Number: 0472
The Common Carotid Artery in the Ultrasound Evaluation of Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0430
The Course of Bone Mineral Density During 8 Years of Treatment with TNF-α Inhibitors in Patients with Ankylosing Spondylitis
1:00PM-3:00PM
Abstract Number: 0352
The Effect of Belimumab (BEL) on Kidney Outcomes in SLE: Results of a Large Integrated Analysis
1:00PM-3:00PM
Abstract Number: 0351
The Effect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus: A Single-center Retrospective Study
1:00PM-3:00PM
Abstract Number: 0229
The Effect of Interactive E-learning on Resident’s Practical Performance in Musculoskeletal Ultrasound- a Randomized Study
1:00PM-3:00PM
Abstract Number: 0461
The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0424
The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort
1:00PM-3:00PM
Abstract Number: 0014
The Expanded CD21 Low B Cell Subpopulation in Ankylosing Spondylitis Consists Mainly of Antigen-Inexperienced Cells
1:00PM-3:00PM
Abstract Number: 0196
The Impact of Barometric Pressure Waves on Connective Tissue Disorders
1:00PM-3:00PM
Abstract Number: 0315
The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab
1:00PM-3:00PM
Abstract Number: 0109
The Impact of Marginalization on Health Outcomes in Childhood-onset Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 0010
The Inflammation Induced by Monosodium Urate and Calcium Pyrophosphate Crystals Depends on Osmolarity and Aquaporin Channels
1:00PM-3:00PM
Abstract Number: 0369
The Longitudinal Measurement Properties and Clinical Application of the PROMIS Fatigue 13a and 10a in Lupus
1:00PM-3:00PM
Abstract Number: 0042
The Pathogenic Role of Lymphatic Vessels in Autoimmune Valvular Carditis
1:00PM-3:00PM
Abstract Number: 0375
The Presence of Heel Enthesitis on Physical Exploration Is Associated with Poorer Outcomes After 2 Years of Follow-up in Patients with Radiographic Axial Spondyloarthritis
1:00PM-3:00PM
Abstract Number: 0216
The Rejected Manuscripts: Its Quality, Its Fate, and Empirical-based Suggestions for Improvement
1:00PM-3:00PM
Abstract Number: 0426
The Relative Efficacy of Biologic and Targeted Synthetic DMARDs in Ankylosing Spondylitis: A Network Meta-Analysis
1:00PM-3:00PM
Abstract Number: 0362
The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Renal Responses in Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 0227
The Rheumatology Workforce: Analyzing Geographic and Temporal Variations Among the Rheumatology Physician Workforce in the United States
1:00PM-3:00PM
Abstract Number: 0376
The Socioeconomic Profile of Patients with Radiographic Axial Spondyloarthritis Is Associated with the Severity of the Disease and with the Permanent Disability. a Cluster Analysis in a National Spanish Registry
1:00PM-3:00PM
Abstract Number: 0214
The Structured Curriculum Development Significantly Increased the Pediatric Residents’ Competency and Confidence During a 4-week Pediatric Rheumatology Rotation
1:00PM-3:00PM
Abstract Number: 0278
The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in RA
1:00PM-3:00PM
Abstract Number: 0459
The Use of Intravenous Methylprednisolone in Patients with Giant Cell Arteritis: A Population-Based Study
1:00PM-3:00PM
Abstract Number: PP14
The Use of Social Support as Treatment
1:00PM-3:00PM
Abstract Number: 0210
Themes in Patients’ Discordance with Provider’s Rheumatoid Arthritis Treatment Goals Relate to Patient Age, Gender, and Ethnicity
1:00PM-3:00PM
Abstract Number: 0344
Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels
1:00PM-3:00PM
Abstract Number: 0130
Three Chinese Pedigrees of A20 Haploinsufficiency
1:00PM-3:00PM
Abstract Number: PP03
To Err Is Human: The Need for Patients with Rheumatic and Musculoskeletal Diseases to Continuously Monitor Their Health Care Records
1:00PM-3:00PM
Abstract Number: 0465
Tocilizumab in Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: Multicentric Observational Comparative Study
1:00PM-3:00PM
Abstract Number: 0291
Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients
1:00PM-3:00PM
Abstract Number: 0338
Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors
1:00PM-3:00PM
Abstract Number: 0417
Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Literature Review
1:00PM-3:00PM
Abstract Number: 0078
Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists: A Retrospective Study in Three Health Systems
1:00PM-3:00PM
Abstract Number: 0480
Treatment of Giant Cell Arteritis Patients with Ultra-short Glucocorticoids and Tocilizumab: Role of Imaging in a Prospective Study
1:00PM-3:00PM
Abstract Number: 0079
Treatment Persistence in First-Line Biologic and Targeted Synthetic DMARD Users with Dual-Seropositive RA in the Medicare Population
1:00PM-3:00PM
Abstract Number: 0101
Twenty-five Years of Mortality Data in Those with Lower Extremity Osteoarthritis: The Role of Socioeconomic Status
1:00PM-3:00PM
Abstract Number: 0039
Type I and Type II Interferon and NF-κB-Response Gene Scores and Serum Cytokine Levels in Patients with Various Systemic Autoinflammatory Diseases
1:00PM-3:00PM
Abstract Number: 0468
Ultrasound Wall Thickness in the Differential Diagnosis of Atherosclerosis and Large Vessel Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0425
Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis – Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2)
1:00PM-3:00PM
Abstract Number: 0192
Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 0474
Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients
1:00PM-3:00PM
Abstract Number: 0463
Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center
1:00PM-3:00PM
Abstract Number: 0080
Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in Patients with Rheumatoid Arthritis and Breast Cancer
1:00PM-3:00PM
Abstract Number: 0064
Utilization of Preventive Services in a Systemic Lupus Erythematosus Population-Based Cohort: A Lupus Midwest Network Study
1:00PM-3:00PM
Abstract Number: 0145
Vaccination Immune Response Against Sars-Cov-2 in Patients with Autoimmune Rheumatic Diseases
1:00PM-3:00PM
Abstract Number: 0389
Vaccine Effectiveness Among Patients with Psoriatic Disease: A Population-based Study
1:00PM-3:00PM
Abstract Number: 0453
Validation of the 2022 – American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA Associated Vasculitis
1:00PM-3:00PM
Abstract Number: 0396
Validity of Syndesmophyte Detection on Low Dose Computed Tomography in Patients with Radiographic Axial Spondyloarthritis
1:00PM-3:00PM
Abstract Number: 0155
Validity of the Mawdsley Calcinosis Questionnaire in Adult and Juvenile Dermatomyositis (DM, JDM) Patients with Calcinosis
1:00PM-3:00PM
Abstract Number: 0205
Virtually Training Peer Coaches to Use Motivational Interviewing Skills: Processes from a Rheumatoid Arthritis Intervention Training Program
1:00PM-3:00PM
Abstract Number: 0357
Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
1:00PM-3:00PM
Abstract Number: PP12
We Became Advocates, Educators, and a Support System for Hispanic/Latino Patients with Rheumatoid Arthritis and Their Caregivers Through Involvement in a Virtual Patient Advisory Board
1:00PM-3:00PM
Abstract Number: 0420
What Does It Mean – A Good Response to NSAIDs? A Systematic Comparison of Patients with Axial Spondyloarthritis and Controls with Chronic Back Pain
1:00PM-3:00PM
Abstract Number: 0112
What Drives Racial Disparities in Gout in the USA? – Population-Based, Sex-Specific, Casual Mediation Analysis
1:00PM-3:00PM
Abstract Number: PP21
What Lies Beneath: Making Rheumatoid Arthritis Visible for the Seronegative Patient Through Blood Work
1:00PM-3:00PM
Abstract Number: 0236
What Ultrasound Skills Can Be Learned Before Laying Hands on a Probe? Results of a Pilot Study of a Hybrid Online and in Person Curriculum to Teach Rheumatology Focused Knee Ultrasonography Skills to Internal Medicine Residents
1:00PM-3:00PM
Abstract Number: 0237
Whats Trending? A 12- year Analysis of International Medical Graduates Matching into Rheumatology Fellowship Programs in the United States
1:00PM-3:00PM
Abstract Number: 0217
Where Are the Reporting Guidelines in Rheumatology? An Analysis of Their Use in over 850 Published Manuscripts
1:00PM-3:00PM
Abstract Number: 0368
Which Are the Best Therapeutic Strategies for Systemic Lupus Erythematosus Severe Thrombocytopenia? A Ten Year Analysis
1:00PM-3:00PM
Abstract Number: 0475
Whole-country and Regional Incidences of Giant Cell Arteritis in French Continental and Overseas Territories: A Nationwide Database Analysis
1:00PM-3:00PM
Abstract Number: PP01
Why Communication Is the Most Important Thing in Healthcare
1:00PM-3:00PM
Abstract Number: 0025
Wnt Pathway/Innate Immunity Equilibrium in OA Articular Cells
1:00PM-3:00PM
Abstract Number: 0071
Workforce Changes and Characteristics of Adult Rheumatologists in a United States Medicare Claims Analysis
5:00PM-6:00PM
Abstract Number: PP26
Chronically Catherine: A Sex and the City-Inspired Autobiographical Column for Disabled Young Adults on Subjects We Really Care About – Like Disabled Dating and How Hot Cheetos Saved My Life
5:00PM-6:00PM
Abstract Number: PP25
From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective
5:00PM-6:00PM
Abstract Number: PP24
Planting Seeds of Self-Advocacy: Increasing Healthcare Engagement in Children and Adolescents Through Arthritis Camp
5:00PM-6:00PM
Abstract Number: PP23
The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient
9:00AM-10:30AM
Abstract Number: 0580
18F-FDG PET-MR Characterization of Aortitis in the IL1rn-/- Mouse Model of Giant-Cell Arteritis
9:00AM-10:30AM
Abstract Number: 0812
3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) – Data from the RELIANCE Registry
9:00AM-10:30AM
Abstract Number: 0856
A Cross-Sectional Description of Physical Activity (PA) in Children with Juvenile Idiopathic Arthritis (JIA): The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)
9:00AM-10:30AM
Abstract Number: 1051
A Deep Neural Network Classifier to Identify Intrinsic Molecular Subsets of Systemic Sclerosis Using Histological Images
9:00AM-10:30AM
Abstract Number: 0593
A New Cytokine Interleukin 40 Is Elevated in the Serum of Patients with Early Rheumatoid Arthritis and Associates with Autoantibodies and Neutrophil Activation
9:00AM-10:30AM
Abstract Number: 1047
A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression
9:00AM-10:30AM
Abstract Number: 0752
A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Immunogenicity of Ebdarokimab in Patients with Moderate to Severe Plaque Psoriasis
9:00AM-10:30AM
Abstract Number: 0628
A Positive-feedback Model for the Contribution of Virus-Specific T Cells to the Development of Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0987
A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases
9:00AM-10:30AM
Abstract Number: 0998
A Real-world Analysis Showing Significant Variance in Treatment Patterns Among over 1,000 Systemic Lupus Erythematosus (SLE) Patients in the US
9:00AM-10:30AM
Abstract Number: 0670
A Short Allelic Epitope Coded by HLA-DRB1*03:01 Activates a Systemic Lupus Erythematosus Cell Aberration Cascade
9:00AM-10:30AM
Abstract Number: 0874
A Tale of Many Canadas: Associations of Ethnicity with Juvenile Idiopathic Arthritis Categories and Disease Severity at Presentation in a Multicultural Universal Healthcare Setting: Results from ReACCh-Out
9:00AM-10:30AM
Abstract Number: 0878
A United States Nationwide Analysis of Total Knee Arthroplasty in Patients < 21 Years Old
9:00AM-10:30AM
Abstract Number: 0932
Accelerated Waning of Protective Immunity After SARS-CoV-2 mRNA Vaccination in Patients Treated with Biological and Targeted Synthetic Disease Modifying Antirheumatic Drugs
9:00AM-10:30AM
Abstract Number: 0751
Accessing Telehealth and In-Person Healthcare During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0707
Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0700
Accurate Identification of ANCA-Associated Vasculitis Cases from Clinical Notes Using Machine Learning
9:00AM-10:30AM
Abstract Number: 0773
Additional Dose of SARS-CoV-2 Vaccine Improves Cross-Variant Neutralization Titers in Immunosuppressed Patients with Chronic Inflammatory Disease
9:00AM-10:30AM
Abstract Number: 0829
Adult Onset Still’s Disease: A Retrospective Study of Objective Manifestations and Outcomes
9:00AM-10:30AM
Abstract Number: 0922
Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib
9:00AM-10:30AM
Abstract Number: 0621
Altered Immunological Circadian Rhythms and the Effect of Treatment with Glucocorticoids on Circadian Rhythms of Immune Cells in Patients with Rheumatoid Arthritis: Bring Back the Rhythm
9:00AM-10:30AM
Abstract Number: 0604
Altered Metabolic State in Myeloid Precursors and Mature Cells Within Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0598
An Arthritogenic Strain of Subdoligranulum Specifically Detectable in the Feces of Individuals At-risk for and with Rheumatoid Arthritis Is Bound by ACPA and Stimulates Th17 Cell Activation in Those with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0683
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases: Clinical and Serological Characteristics, Results from the APS ACTION Clinical Database and Repository
9:00AM-10:30AM
Abstract Number: 1073
Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
9:00AM-10:30AM
Abstract Number: 0810
Analysis of Factors Associated with Good Therapeutic Response to Immunosuppressive Drugs in Patients with Non-infectious Uveitis: A Survival Analysis
9:00AM-10:30AM
Abstract Number: 0682
Analysis of Recurrent Thrombotic Events in a Large Single-center Primary Antiphospholipid Syndrome Cohort: Results from APS-Rio Cohort After over Than 600 Patients-year of Follow-up
9:00AM-10:30AM
Abstract Number: 1067
Analysis of the Transcriptomic Profiles of Rheumatic Skin Diseases Reveals Disease-specific Endotypes
9:00AM-10:30AM
Abstract Number: 1093
ANCA Associated Vasculitis: Online CME Improves Rheumatologists’ Knowledge and Confidence
9:00AM-10:30AM
Abstract Number: 1076
ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain
9:00AM-10:30AM
Abstract Number: 1032
Anti-arthritogenic Effect of Smoking in Curdlan-Administered SKG Mice
9:00AM-10:30AM
Abstract Number: 0663
Anti-Erythrocyte Antibodies in Childhood Onset Systemic Lupus Erythematosus
9:00AM-10:30AM
Abstract Number: 0832
Anti-NOR 90 Antibodies: What Is the Clinical Significance in Rheumatic Inflammatory Conditions?
9:00AM-10:30AM
Abstract Number: 1068
Anti-vinculin Antibodies in Systemic Sclerosis: Associations with Slow Gastric Transit and Extra-Intestinal Clinical Phenotype
9:00AM-10:30AM
Abstract Number: 0686
Anti-β2GP1/HLA-DR Antibody Is Associated with Arterial Thrombosis in Female Patients with Connective Tissue Diseases: A Cross-Sectional Study in Japan
9:00AM-10:30AM
Abstract Number: 0688
Antibodies of the IgA Isotype Target Neutrophil Extracellular Traps in APS
9:00AM-10:30AM
Abstract Number: 0800
Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications
9:00AM-10:30AM
Abstract Number: 0681
Antiphospholipid Antibodies and Incident Cardiovascular Events in a Diverse Population: Results from the Dallas Heart Study
9:00AM-10:30AM
Abstract Number: 0732
Application of Natural Language Processing to Identify Varicella Zoster Infection in Clinical Notes
9:00AM-10:30AM
Abstract Number: 0697
Are Fibromyalgia and Depression as Common as Any Primary Diagnosis in Routine Rheumatology Care, Albeit as Secondary Diagnoses, but Which May Confound Clinical Assessment?
9:00AM-10:30AM
Abstract Number: 1023
Are We Treating-to-target in Spondyloarthritis (SpA)? A Cross Sectional Analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry
9:00AM-10:30AM
Abstract Number: 0973
Assessing Musculoskeletal Health Needs of Underserved Patients & Community Members Using a Community Based Participatory Research Approach
9:00AM-10:30AM
Abstract Number: 0959
Assessing the Association Between Hydroxychloroquine and Preeclampsia Risk in SLE Pregnancies Using Administrative Claims Data
9:00AM-10:30AM
Abstract Number: 0966
Assessment and Application of Royal College of Obstetricians and Gynaecologists (RCOG) Risk Scores in the Prevention of Venous Thromboembolism Peri- and Postpartum in Systemic Lupus Erythematosus
9:00AM-10:30AM
Abstract Number: 1063
Assessment of Calcinosis in Portuguese Patients with Systemic Sclerosis – a Multicenter Study
9:00AM-10:30AM
Abstract Number: 0885
Association Between Changes in Inflammatory Pathways Associated with a Reduction in CV Risk: Results from the LiiRA Study
9:00AM-10:30AM
Abstract Number: 0706
Association Between Metabolic Syndrome and Knee Pain over 10-13 Years in Middle-Aged Adults
9:00AM-10:30AM
Abstract Number: 1019
Association Between Stringent Clinical Measures of Disease Activity and Clinically Meaningful Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: Results from KEEPsAKE 1 and 2 Clinical Trials
9:00AM-10:30AM
Abstract Number: 0680
Association of Environmental Risk Factors with Antiphospholipid Antibodies and Thrombosis in 1199 International Patients Referred for Suspected Antiphospholipid Syndrome
9:00AM-10:30AM
Abstract Number: 0847
Association of Frontal Plane Trunk Motion During Gait with Abductor Strength, Fatigue, and Physical Activity in Women with Hip Osteoarthritis
9:00AM-10:30AM
Abstract Number: 0995
Association of Glucocorticoid Use with Healthcare Utilization Among Persons with Systemic Lupus Erythematosus
9:00AM-10:30AM
Abstract Number: 0639
Association of Gut Microbiome Streptococcus, Health Status, Cytokines, and HLA Class in Anti-Ro+ Mothers of Children with Neonatal Lupus: Insights into Progression of Clinical Autoimmunity
9:00AM-10:30AM
Abstract Number: 0839
Association of Tibial Acceleration During Walking to Knee Pain and Loading in Adults with Knee Osteoarthritis
9:00AM-10:30AM
Abstract Number: 0656
Association Study Identified HLA-DQA1 as a Genetic Risk of Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension
9:00AM-10:30AM
Abstract Number: 0912
Associations Between Fatty Acid Amide Hydrolase Variants and Response to Cannabis Use for Pain Management in Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 1055
Associations of Potential Risk Factors with Severe Outcomes in Scleroderma Renal Crisis: Results from a Single Center Study
9:00AM-10:30AM
Abstract Number: 0893
ATP-Binding Cassette G1 Membrane Transporter-mediated Cholesterol Efflux Capacity Influences Coronary Atherosclerosis and Cardiovascular Risk in RA
9:00AM-10:30AM
Abstract Number: 0592
Autoantibodies Targeting Malondialdehyde-modifications Are Potential Mediators of Inflammation and Bone Loss in RA, Acting via Macrophage and Osteoclast Regulatory Pathways
9:00AM-10:30AM
Abstract Number: 0972
Automated Joint Space Width Measurement for Hand Osteoarthritis: A Deep Learning Approach
9:00AM-10:30AM
Abstract Number: 0793
Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation
9:00AM-10:30AM
Abstract Number: 0958
Azathioprine Metabolite Levels and Outcomes During Pregnancies in Women with Rheumatic Disease
9:00AM-10:30AM
Abstract Number: 0780
B-cell Reconstitution Is Associated with COVID-19 Booster Vaccine Responsiveness in Previously Seronegative Rituximab Treated Rheumatic Disease Patients
9:00AM-10:30AM
Abstract Number: 0585
Baricitinib Inhibits Proinflammatoly Cytokine Production, Proliferation and Cell Migration in Human Lung Fibroblasts
9:00AM-10:30AM
Abstract Number: 0864
Baseline Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort
9:00AM-10:30AM
Abstract Number: 0938
Baseline Predictors of Disease Flare upon csDMARD Withdrawal in Patients with Rheumatoid Arthritis in Sustained Remission After DAS-driven Therapy: Role of the Systemic Autoimmune Status and Peripheral Joint Ultrasound Across a 5-year Follow-up
9:00AM-10:30AM
Abstract Number: 0869
Behavioral Health Outcomes and Social Determinants of Health in Children with Juvenile Arthritis Compared to Children with Diabetes and Healthy Children
9:00AM-10:30AM
Abstract Number: 0978
Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus
9:00AM-10:30AM
Abstract Number: 0979
Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
9:00AM-10:30AM
Abstract Number: 0718
Biomarkers Predict Worsening of Lumbar Spine Degeneration and Low Back Pain: The Johnston County Osteoarthritis Project
9:00AM-10:30AM
Abstract Number: 1065
Biosamples from VEDOSS Patients Show Pathological Signs of SSc: Opportunity for a Biololgical Diagnosis of Disease
9:00AM-10:30AM
Abstract Number: 0635
Blood RNA-sequencing Reveals Complex Immune Dysregulation in ANA-positive Individuals with Distinct Profiles Preceding Progression to SLE versus Stable Autoimmunity
9:00AM-10:30AM
Abstract Number: 0836
Bone Turnover and Physical Activity Before and After Anterior Cruciate Ligament Reconstruction
9:00AM-10:30AM
Abstract Number: 0783
Breakthrough SARS-CoV-2 Infections and Predicting Severe Outcomes During Rituximab Therapy in Autoimmune Rheumatic Diseases
9:00AM-10:30AM
Abstract Number: 0784
Breakthrough SARS-CoV-2 Infections in Immune Mediated Disease Patients Undergoing B Cell Depleting Therapy: A Retrospective Cohort Analysis
9:00AM-10:30AM
Abstract Number: 0607
Cadherin 6 Regulates Rheumatoid Arthritis Fibroblasts-Like Synoviocyte Aggressiveness
9:00AM-10:30AM
Abstract Number: 0767
Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) – A Retrospective Chart Review Study of Adults with Inflammatory Arthritis Associated with Cancer Immunotherapies
9:00AM-10:30AM
Abstract Number: 0813
Canakinumab in Patients with Tumor Necrosis Factor Receptor-associated Periodic Syndrome (TRAPS) – Long-term Efficacy and Safety Data from a RELIANCE Registry Interim Analysis
9:00AM-10:30AM
Abstract Number: 1066
Capillaroscopic Findings in Autoimmune Connective Tissue Diseases: Results from 20 Years of Experience in a Training Referral Center
9:00AM-10:30AM
Abstract Number: 0722
Cardiovascular and Oncologic Outocomes of Anti-TNF Alfa and JAK Inhibitors in Patients with Rheumatoid and Psoriatic Arthritis. Real World Data and Insights of BIOBADASAR 3.0 Registry
9:00AM-10:30AM
Abstract Number: 0888
Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)
9:00AM-10:30AM
Abstract Number: 1016
Cardiovascular Disease Proteome Profile Is Related to an Abnormal Methylome Pattern in Spondyloarthritis: Potential Biomarkers of Subclinical Atherosclerosis
9:00AM-10:30AM
Abstract Number: 0766
CCP+ Immune Checkpoint Inhibitor Arthritis Patients Have Less ACPA Epitope Expansion Than CCP+ Rheumatoid Arthritis Patients
9:00AM-10:30AM
Abstract Number: 0624
CD20+ T Cells in the Synovial Fluid of Patients with Rheumatoid Arthritis Suggest a Role for Trogocytosis in Disease Pathogenesis and Activity
9:00AM-10:30AM
Abstract Number: 0873
Celiac-Associated Arthritis: Clinical Features, Treatment, and Outcomes
9:00AM-10:30AM
Abstract Number: 0602
Cellworks Biosimulation Model (CBM) for Rheumatoid Arthritis (RA), Accurately Captures Patient’s Disease Activity at the Molecular Level Using Their Omics Data and Can Bring Personalization to Treatment Selection in RA
9:00AM-10:30AM
Abstract Number: 0855
Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
9:00AM-10:30AM
Abstract Number: 1086
Characteristics and Outcomes of Patients with ANCA Associated Vasculitis Treated with Plasma Exchange: An Analysis of the National Inpatient Sample Database
9:00AM-10:30AM
Abstract Number: 0860
Characteristics of Transitioning JIA Patients: Who Is Arriving on the Adult Rheumatologists’ Doorsteps?
9:00AM-10:30AM
Abstract Number: 1018
Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis: Results from the Ongoing FOREMOST Study
9:00AM-10:30AM
Abstract Number: 1034
Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice
9:00AM-10:30AM
Abstract Number: 0579
Characterization of Terminal Uridyl Transferase Function in Response to Tumor Necrosis Factor-α in Rheumatoid Arthritis Synovial Fibroblasts
9:00AM-10:30AM
Abstract Number: 0605
Citrullinated Peptide-Specific ACPA Are Present in the Female Genital Tract in Premenopausal Women with and Without RA
9:00AM-10:30AM
Abstract Number: 0675
Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort
9:00AM-10:30AM
Abstract Number: 1060
Clinical Characteristics and Prognosis of Patients with Systemic Sclerosis Sine Scleroderma: Data from the International EUSTAR Database
9:00AM-10:30AM
Abstract Number: 1058
Clinical Characteristics and Survival of Combined Pulmonary Arterial Hypertension and Interstitial Lung Disease in Systemic Sclerosis
9:00AM-10:30AM
Abstract Number: 1056
Clinical Characterization of a Cohort of Patient with Sclerotic-type Chronic Graft-versus-host Disease with Fascial/joint Involvement
9:00AM-10:30AM
Abstract Number: 0814
Clinical Correlation of Dense Fine Speckled (DFS) Pattern of ANA
9:00AM-10:30AM
Abstract Number: 1050
Clinically Recognized Depression and Mental Health Treatment in a Single Center Cohort of Patients with Systemic Sclerosis
9:00AM-10:30AM
Abstract Number: 0704
Clinically Suspect Arthralgia Patients with a Low Educational Attainment Have an Increased Risk to Develop Inflammatory Arthritis
9:00AM-10:30AM
Abstract Number: 0698
Cohort Study of Cigarette Smoking and the Risk of Developing Polymyalgia Rheumatica Among Women
9:00AM-10:30AM
Abstract Number: 1044
Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a Multicenter Case Series in Spain
9:00AM-10:30AM
Abstract Number: 0734
Comfort Levels and Practice Patterns for Osteoporosis-Related Care Among Persons Living with HIV in Peru: A National Physician Survey
9:00AM-10:30AM
Abstract Number: 0622
Commensal Reactive T-cells Display Diverse Phenotype in Rheumatoid Arthritis Patients
9:00AM-10:30AM
Abstract Number: 0887
Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database
9:00AM-10:30AM
Abstract Number: 1010
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies
9:00AM-10:30AM
Abstract Number: 1012
Comparison of Sacroiliac CT Findings in Patients with and Without Psoriatic Arthritis: Results of the CASIPSA Study
9:00AM-10:30AM
Abstract Number: 0659
Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets
9:00AM-10:30AM
Abstract Number: 0819
Connective Tissue Disease-Related Interstitial Lung Disease: Trends from an Urban Academic Tertiary Care Center
9:00AM-10:30AM
Abstract Number: 0857
Consensus-Driven Definition for Unequivocal Sacroiliitis on Radiographs for Classification in Juvenile Spondyloarthritis
9:00AM-10:30AM
Abstract Number: 0945
Contraception Documentation Patterns for Adult Females with Juvenile Idiopathic Arthritis on Teratogenic Medications in the Rheumatology Informatics System for Effectiveness (RISE) Registry
9:00AM-10:30AM
Abstract Number: 0956
Contribution of Antibody Titers/Specificities to Adverse Pregnancy Outcomes in a Multicenter Prospective Study of anti-Ro Positive Mothers
9:00AM-10:30AM
Abstract Number: 0937
Conventional Synthetic DMARDs Re-treatment for Rheumatoid Arthritis Flare During Drug-free Follow-up: Rate, Dynamics and Quality of Clinical Response
9:00AM-10:30AM
Abstract Number: 0600
Correlates Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Phenotypes: Data from the Accelerated Medicines Partnership
9:00AM-10:30AM
Abstract Number: 0667
Correlation Matrices Visualize Differential Degree of Cell and Pathway Heterogeneity in Skin of Cutaneous Lupus Erythematosus Treatment Subgroups
9:00AM-10:30AM
Abstract Number: 0895
COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0661
Cutaneous Type I IFN Responses in Systemic Lupus Erythematosus Are Associated with Inflammatory Phenotype and Altered Wound Healing Function of Lupus Fibroblasts from Non-Lesional Skin
9:00AM-10:30AM
Abstract Number: 0894
DAS28-gGT for the Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort
9:00AM-10:30AM
Abstract Number: 0657
DB-2304, a Novel anti-BDCA2 Monoclonal Antibody Drug Conjugate, Displayed Great Potency in Suppression of pDC Functions
9:00AM-10:30AM
Abstract Number: 0591
Deficiency of FUN14 Domain-Containing Protein 1-Mediated Mitophagy in Fibroblast-like Synoviocytes Causes Aggressive Behaviors Leading to Joint Destruction in Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0930
Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation
9:00AM-10:30AM
Abstract Number: 1021
Depression as a Modulator of Patient Reported, but Not Physician Observed, Outcomes in Psoriatic Arthritis
9:00AM-10:30AM
Abstract Number: 1000
Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study
9:00AM-10:30AM
Abstract Number: 0724
Development of a Global Strategy to Strengthen Health Systems for Prevention and Management of Musculoskeletal Health
9:00AM-10:30AM
Abstract Number: 0664
Development of a Novel Gene Expression-based Molecular Score That Characterizes Individual Lupus Patients
9:00AM-10:30AM
Abstract Number: 0947
Development of a Person-Centered Family Planning Decision Aid for Women with Rheumatic Diseases
9:00AM-10:30AM
Abstract Number: 0971
Development of a Theory-based Educational Intervention for Fatigue in Systemic Lupus Erythematosus (SLE) Using Human-centered Design Methodology
9:00AM-10:30AM
Abstract Number: 0788
Development of Autoantibodies and Their Association with Flare-ups of Rheumatic Diseases in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) and the General Population Following BNT162b2 mRNA COVID-19 Vaccination – Results of 1-year Prospective Follow-up Study
9:00AM-10:30AM
Abstract Number: 0582
Development of Novel Glucocorticoid as Immunology Antibody-Drug Conjugate Payload for the Treatment of Autoimmune and Inflammatory Diseases
9:00AM-10:30AM
Abstract Number: 0852
Development, Refinement and Weighting of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration
9:00AM-10:30AM
Abstract Number: 0902
Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method
9:00AM-10:30AM
Abstract Number: 1030
Diagnostic Usefulness of Anti-PPM1A-IgM in Patients with Ankylosing Spondylitis
9:00AM-10:30AM
Abstract Number: 0619
Differences Between Patients in Remission with Active Rheumatoid Arthritis by Histological and Molecular Comparisons
9:00AM-10:30AM
Abstract Number: 0999
Differences in Chromatin Accessibility Pre- and Post-Induction Therapy in Pediatric Lupus
9:00AM-10:30AM
Abstract Number: 0844
Differences in Skin Advanced Glycation End-Products Levels Between Subgroups of Achilles Tendinopathy
9:00AM-10:30AM
Abstract Number: 0668
Differential Expression of Interferon Related Genes in SLE Patients of Asian and European Ancestries Abstract
9:00AM-10:30AM
Abstract Number: 1039
Differential Retention of Adalimumab and Etanercept Biosimilars Compared to Originator Treatments: Results of a Retrospective French Multicentre Study
9:00AM-10:30AM
Abstract Number: 0833
Disability Among Persons with Chronic Severe Back Pain: Results from a Nationally Representative Population Based Sample
9:00AM-10:30AM
Abstract Number: 1070
Discordance of Patient, Physician and Nurse Practitioner Assessment of Disease Burden in Systemic Sclerosis
9:00AM-10:30AM
Abstract Number: 1013
Discriminatory Capacity of the ASAS Health Index in Patients with Axial Spondyloarthritis Treated in a Tight Control Setting versus Standard of Care
9:00AM-10:30AM
Abstract Number: 0712
Disease Prevalence and Patient Characteristics in Patients with and Without Scleroderma Renal Crisis – A National US-based Inpatient Comparison Study
9:00AM-10:30AM
Abstract Number: 1054
Distinct Differences in Complement Perturbation Between Scleroderma-related Interstitial Lung Disease with and Without Emphysema
9:00AM-10:30AM
Abstract Number: 0625
Distinct Effects of JAK Inhibitor and TNF Inhibitors on Circulating B Cell Phenotypes in Rheumatoid Arthritis Patients
9:00AM-10:30AM
Abstract Number: 0687
DNA- and NET-Binding Beta-2 Glycoprotein I in a Large Cohort of Antiphospholipid Antibody-Positive Patients
9:00AM-10:30AM
Abstract Number: 1003
Does LLDAS Definition Match the Rheumatologist Opinion? The First Visit Evaluation of a Longinudital Spanish Multicenter Study to Assess Reasons of Disagreement
9:00AM-10:30AM
Abstract Number: 0779
Early Experience of Breakthrough COVID-19 Infections in Patients Who Received Pre-exposure Prophylaxis with Tixagevimab/cilgavimab
9:00AM-10:30AM
Abstract Number: 0736
Educational Needs Among Health Professionals in Rheumatology: Low Awareness of EULAR Offerings and Unfamiliarity with Course Content as a Major Barrier – a EULAR Funded European Survey
9:00AM-10:30AM
Abstract Number: 0940
Effect of an 8-week Tailored Physical Therapy Program on Sexual Function in Women with Systemic Sclerosis and Idiopathic Inflammatory Myopathies: A Pilot Controlled Study
9:00AM-10:30AM
Abstract Number: 1001
Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)
9:00AM-10:30AM
Abstract Number: 0977
Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)
9:00AM-10:30AM
Abstract Number: 0900
Effect of Biologic Agents on Lipid Levels and Cardiovascular Risk in Rheumatoid Arthritis Patients
9:00AM-10:30AM
Abstract Number: 0982
Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression and Cardiovascular Events in Patients with Systemic Lupus Erythematosus
9:00AM-10:30AM
Abstract Number: 0863
Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study
9:00AM-10:30AM
Abstract Number: 0994
Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus
9:00AM-10:30AM
Abstract Number: 0719
Effect of Patient-reported Outcomes on Changes in DMARD Therapy Among Rheumatoid Arthritis Patients Treated in Routine Clinical Practice
9:00AM-10:30AM
Abstract Number: 0739
Effect of Tailored Self-Management Interventions on Health Outcomes in Individuals with Chronic Musculoskeletal Conditions
9:00AM-10:30AM
Abstract Number: 0699
Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
9:00AM-10:30AM
Abstract Number: 0921
Effects of Methotrexate on the Liver Function and Disease Activity of Newly Diagnosed RA Patients Depending on the Cardiometabolic Profile
9:00AM-10:30AM
Abstract Number: 1009
Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixekizumab Treated Biological Naïve Patients with Radiographic Axial Spondyloarthritis Achieving Clinically Important Pain at Night Reduction at Week 16: Results from COAST-V Trial
9:00AM-10:30AM
Abstract Number: 1072
Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
9:00AM-10:30AM
Abstract Number: 0918
Efficacy and Safety of Filgotinib in Patients with Inadequate Response to Methotrexate, with 4 or < 4 Poor Prognostic Factors: A Post Hoc Analysis of the FINCH 1 Study
9:00AM-10:30AM
Abstract Number: 1036
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by History of Cigarette Smoking
9:00AM-10:30AM
Abstract Number: 1035
Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies
9:00AM-10:30AM
Abstract Number: 1075
Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype
9:00AM-10:30AM
Abstract Number: 0626
Elucidating the Expression and Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Human Rheumatoid Arthritis Synovial Fibroblasts and a Rat Adjuvant-induced Arthritis Model
9:00AM-10:30AM
Abstract Number: 1008
Endothelial Dysfunction in Axial Spondyloarthritis and Its Association with Clinical Disease Characteristics
9:00AM-10:30AM
Abstract Number: 1025
Entheseal Biopsy Approach: An Ultrasound-guided Method for Retrieval of Entheseal Tissue from Psoriatic Arthritis Patients
9:00AM-10:30AM
Abstract Number: 0695
Epidemiology of Behçet’s Disease in Northern Spain
9:00AM-10:30AM
Abstract Number: 0942
Evaluation of Ovarian Reserve Using Anti-Mullerian Hormone Levels in Adolescents with Systemic Rheumatic Disease Compared to Healthy Controls
9:00AM-10:30AM
Abstract Number: 0694
Evaluation of the Effect of UCB4470 (anti-mouse FcRn) on Amelioration of Thrombosis in a Mouse Model of Antiphospholipid (aPL)-induced Thrombosis
9:00AM-10:30AM
Abstract Number: 0809
Ex Vivo Comparative Immunogenicity Assessment (EVCIA) to Determine Relative Immunogenicity in Chronic Plaque Psoriasis in Participants Receiving Humira® or Undergoing Repeated Switches Between Humira and AVT02
9:00AM-10:30AM
Abstract Number: 0846
Exercise Identity at the Start of Outpatient Physical Therapy Prospectively Predicts Physical Activity at 12-weeks After Total Knee Replacement
9:00AM-10:30AM
Abstract Number: 0599
Expansion of HLA-DR+CD45RAhi Non-lymphoid Cells in Patients with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0776
Expert Clinical Management of Immune-related Inflammatory Arthritis: Results from a Multicenter International Expert Survey
9:00AM-10:30AM
Abstract Number: 0933
Exploratory Study of the Usefulness of TNFAIP3 Genetic Variants in Predicting Response to Methotrexate in Early Arthritis Patients
9:00AM-10:30AM
Abstract Number: 0963
Exploring Reasons for Non-Use of Hydroxychloroquine in SLE Pregnancy
9:00AM-10:30AM
Abstract Number: 0735
Facilitators and Barriers to Weekly Monitoring of Disease Activity with Electronic Patient Reported Outcomes: A Focus Group Study of Patients with Inflammatory Arthritis
9:00AM-10:30AM
Abstract Number: 0901
Factors Associated with Household Work Limitations in Mexican Patients with Rheumatoid Arthritis: The Impact of the Disease on Women’s Life
9:00AM-10:30AM
Abstract Number: 0630
Ferroptosis of CD163+ Tissue Infiltrating Macrophages in Lupus Nephritis
9:00AM-10:30AM
Abstract Number: 0948
Fertility and the Use of Assisted Reproductive Technologies: Perceptions, Thoughts and Experiences of Men and Women with Rheumatic Disease
9:00AM-10:30AM
Abstract Number: 0917
Fifty-two-week Results from a Phase 3, Randomized, Double-blind, Active-controlled Clinical Trial to Compare BAT1806/BIIB800, a Proposed Tocilizumab Biosimilar, with a Tocilizumab Reference Product in Subjects with Moderate to Severe RA with an Inadequate Response to Methotrexate
9:00AM-10:30AM
Abstract Number: 1031
Foot Involvement in Psoriatic Arthritis- a Retrospective Study
9:00AM-10:30AM
Abstract Number: 0702
Fourth SARS-CoV-2 Vaccine Dose in Rituximab Treated Patients: An Open Label Extension Study
9:00AM-10:30AM
Abstract Number: 0882
Gender Differences in Rheumatology Authorship: A Bibliometric Analysis of High Impact Rheumatology Journals from 2019-2021
9:00AM-10:30AM
Abstract Number: 1038
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Ankylosing Spondylitis
9:00AM-10:30AM
Abstract Number: 1078
Glucocorticoid Use and Related Adverse Events in ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis
9:00AM-10:30AM
Abstract Number: 0879
Golimumab for Treatment of Polyarticular Juvenile Idiopathic Arthritis – Safety and Effectiveness Updates from a Comparative Study
9:00AM-10:30AM
Abstract Number: 0769
Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial
9:00AM-10:30AM
Abstract Number: 0964
High Rates of Fetal Growth Restriction in Systemic Lupus Erythematosus Pregnancies
9:00AM-10:30AM
Abstract Number: 0807
High Throughput Analyses for the Study of Synovial Tissue Biopsy from Inflammatory Arthritis Patients
9:00AM-10:30AM
Abstract Number: 0774
HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases
9:00AM-10:30AM
Abstract Number: 0743
Home-Based Telehealth in Rheumatology: A Systematic Review & Narrative Synthesis
9:00AM-10:30AM
Abstract Number: 1028
How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA?
9:00AM-10:30AM
Abstract Number: 0666
HRES-1/Rab4 Controls the Overexpression of CD38 and Depletion of IL-2 in CD4+ T Cells; Potential Involvement in Proinflammatory Lineage Development in SLE
9:00AM-10:30AM
Abstract Number: 0786
Humoral and T-cell Responses to SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0753
Humoral Immune Response Against BNT162b2 mRNA COVID-19 Vaccine in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: A Japanese Monocentric Study
9:00AM-10:30AM
Abstract Number: 0785
Humoral Immune Responses Following Four SARS-CoV-2 Vaccine Doses or COVID-19 Infection in Patients with Immune-Mediated Inflammatory Diseases on Immunosuppressive Therapy: A Prospective Cohort Study
9:00AM-10:30AM
Abstract Number: 0983
Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0815
Hyper-IgG4 in Patients with Systemic Autoinflammatory Disease
9:00AM-10:30AM
Abstract Number: 0923
Identification of Cell-Specific DNA Methylation Changes Associated with MTX Treatment Response in Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0638
Identification of New Candidate Drugs for SLE Using a Drug Repurposing Transcriptomic Approach on Blood, Skin and Kidney Samples from 3439 Patients
9:00AM-10:30AM
Abstract Number: 1087
Identification of Novel Proteomic Biomarkers of Disease Activity in ANCA-Associated Vasculitis Using a High Throughput Approach
9:00AM-10:30AM
Abstract Number: 0761
Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group
9:00AM-10:30AM
Abstract Number: 0594
Identification of Peptidylglycine Alpha-Amidating Monooxygenase as a Regulator of Tissue Damage Mediated by Rheumatoid Arthritis Synovial Fibroblasts
9:00AM-10:30AM
Abstract Number: 0633
Identification of Systemic Lupus Erythematosus Endotypes by Analysis of Inflammatory and Immunologic Gene Expression Signatures
9:00AM-10:30AM
Abstract Number: 0907
Identifying Trajectories of Remission in Patients with Rheumatoid Arthritis Treated in a Tertiary Care Centre
9:00AM-10:30AM
Abstract Number: 1091
IgG Antibody Subclass Glycan Modifications in Patients with ANCA-Associated Vasculitis in Active vs Remission States – a Proof-of-Concept Study
9:00AM-10:30AM
Abstract Number: 0641
IL-4 Receptor Signaling and IKAROS Transcriptomic Program Maintains Naïve B-cell Quiescence and Antagonizes SLE
9:00AM-10:30AM
Abstract Number: 0821
Imiquimod Exaggerates Obesity-associated Adipose Tissue Inflammation in Murine Psoriasis Model
9:00AM-10:30AM
Abstract Number: 0936
Immediate and Long-term Effects of the MTX Discontinuation for 1 vs. 2 Weeks on Vaccine Response to Seasonal Influenza Vaccine: A Non-inferiority Randomized Controlled Trial
9:00AM-10:30AM
Abstract Number: 0640
Immune Cell Heterogeneity in Lupus Nephritis Kidneys and Its Relation to Histopathological Features
9:00AM-10:30AM
Abstract Number: 0777
Immune Checkpoint Inhibition and Preexisting Autoimmune Disease: A Retrospective Cohort Study
9:00AM-10:30AM
Abstract Number: 0770
Immune Related Adverse Events in Checkpoint Inhibitor Treated Cancer Patients Increased in Patients with Underlying Autoimmune Disease and Positive Autoantibodies
9:00AM-10:30AM
Abstract Number: 0755
Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients
9:00AM-10:30AM
Abstract Number: 0672
Immune Thrombocytopenia Could Be an Independent Phenotype of Primary Antiphospholipid Syndrome
9:00AM-10:30AM
Abstract Number: 0763
Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
9:00AM-10:30AM
Abstract Number: 0791
Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy
9:00AM-10:30AM
Abstract Number: 0759
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) on Immunomodulatory Therapies (IMT): An Updated Cohort Study
9:00AM-10:30AM
Abstract Number: 0880
Impact of Characteristic Inflammatory and Structural Imaging Lesions on Expert Classification of Axial Juvenile Spondyloarthritis
9:00AM-10:30AM
Abstract Number: 0801
Impact of Diagnosis and Treatment of Tropheryma Whipplei Infection in Patients with Pre-existing Chronic Inflammatory Rheumatic Diseases: Data from the National Tw-IRD Registry
9:00AM-10:30AM
Abstract Number: 0913
Impact of Disease-modifying Antirheumatic Drugs on Immunogenicity to COVID-19 Vaccine in Patients with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0828
Impact of Hospitalization on Clinical Outcomes in Patients with Connective Tissue Disease-associated Interstitial Lung Disease
9:00AM-10:30AM
Abstract Number: 0984
Impact of Hydroxychloroquine on Interferon Pathway Expression of SLE Phenotypic Subsets in the Absence of Background Medications
9:00AM-10:30AM
Abstract Number: 0925
Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0934
Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
9:00AM-10:30AM
Abstract Number: 0862
Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: An Analysis of National United States Administrative Claims Data
9:00AM-10:30AM
Abstract Number: 1006
Impact of Uric Acid Levels on Clinical and Radiographic Characteristics in Psoriatic Arthritis and Response to Secukinumab: A Pooled “Post Hoc” Analysis from Five Phase 3 Studies
9:00AM-10:30AM
Abstract Number: 0794
Impact of Vaccination on Post-acute Sequelae of SARS CoV-2 Infection in Patients with Rheumatic Diseases
9:00AM-10:30AM
Abstract Number: 0986
Impact of Weight and Race on Renal Response to Cyclophosphamide in the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study (ACCESS)
9:00AM-10:30AM
Abstract Number: 1040
Impact of Weight and Sex on Long-term Persistence to Secukinumab Treatment in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis
9:00AM-10:30AM
Abstract Number: 0711
Improvement in Excess Mortality in Patients with Rheumatoid Arthritis over the Last Two Decades: A Danish Population-based Matched Cohort Study
9:00AM-10:30AM
Abstract Number: 0730
Improving Mental Health Services in Children and Adolescents with Systemic Lupus Erythematosus by Establishing a Mental Health Care Navigator
9:00AM-10:30AM
Abstract Number: 0804
Incidence and Risk Factors of Active Tuberculosis in Patients with Rheumatic Diseases Complicated with Tuberculosis Infection: A Multicenter Prospective Cohort Study
9:00AM-10:30AM
Abstract Number: 0886
Incidence of Depression and Anxiety in Rheumatoid Arthritis Patients over Three Decades: A Population-Based Study
9:00AM-10:30AM
Abstract Number: 0861
Incidence of Juvenile Idiopathic Arthritis During the COVID-19 Pandemic: An Analysis of National United States Administrative Claims Data
9:00AM-10:30AM
Abstract Number: 1081
Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide
9:00AM-10:30AM
Abstract Number: 0872
Incidence, Risk Factors, and Outcomes of Eosinophilia on IL-1 and IL-6 Inhibitors in Systemic and Non-Systemic Juvenile Idiopathic Arthritis
9:00AM-10:30AM
Abstract Number: 0944
Inconsistent Family Planning Documentation in Women with Interstitial Pneumonia with Autoimmune Features (IPAF)
9:00AM-10:30AM
Abstract Number: 0587
Increase of Intercellular Adhesion Molecule-1 Linked to Lung Damage of Interstitial Lung Disease in Patients with Autoimmune Diseases
9:00AM-10:30AM
Abstract Number: 0797
Increased Duration of Mycophenolate Hold Improves Antibody Response to SARS-CoV-2 Vaccination in Patients with Rheumatic and Musculoskeletal Disease
9:00AM-10:30AM
Abstract Number: 0943
Increased Prevalence of Thrombotic Events in Anti-Phospholipid Antibody-Positive SLE Patients on Estrogen-Containing Contraception
9:00AM-10:30AM
Abstract Number: 0816
Increased Risk of Hepatotoxicity with DMARDS in Patients with Previous Liver Toxicity with Isoniazid: Study in a Single University Hospital
9:00AM-10:30AM
Abstract Number: 0953
Increased Risk of Preterm Delivery Phenotypes and Hypertensive Disorders of Pregnancy in First Deliveries of Patients with Systemic Vasculitis
9:00AM-10:30AM
Abstract Number: 1005
Increasing the Proficiency for Scoring Sacroiliac Joint Radiographs According to the Modified New York Criteria for Ankylosing Spondylitis by Using an Online Real-time Iterative Calibration (RETIC) Module
9:00AM-10:30AM
Abstract Number: 0651
Inflammatory Dendritic Cell Drive Intra-renal T Cells to Double-negative T Cell in Lupus Nephritis
9:00AM-10:30AM
Abstract Number: 0721
Inflammatory Rheumatic Disease and the Risk of Death Related to Coronavirus Disease-19 (COVID-19): An Analysis of the UK Biobank with Stratification by Sex
9:00AM-10:30AM
Abstract Number: 0970
Influence of Sociodemographic and Clinical Features on Ground Reaction Force Variability Among Individuals with Symptomatic Knee Osteoarthritis: A Novel Computational Approach
9:00AM-10:30AM
Abstract Number: 0678
Inpatient Epidemiology, Expenditures and Resource Utilization of Antiphospholipid Syndrome: National Inpatient Sample 2019
9:00AM-10:30AM
Abstract Number: 0738
Integrated Behavioral Health Services for Patients with Chronic Musculoskeletal Pain: Rheumatology Provider Perspectives
9:00AM-10:30AM
Abstract Number: 0658
Integrative Analysis of Cell-Specific Human Endogenous Retrovirus Expression and Host Gene Expression Identifies Associations with Clinical SLE Phenotypes
9:00AM-10:30AM
Abstract Number: 0992
Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
9:00AM-10:30AM
Abstract Number: 0578
Interleukin-6 Trans-Signaling Induces Synovial Fibroblast Invasiveness by Utilizing Ets2 Protein
9:00AM-10:30AM
Abstract Number: 1092
Intrarenal Synthesis of Complement C3 Localized to Distinct Vascular Compartments in ANCA-associated Renal Vasculitis
9:00AM-10:30AM
Abstract Number: 1079
Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital
9:00AM-10:30AM
Abstract Number: 1002
Investigation of Pharmacodynamic Biomarkers in a Phase 2b Study in Patients with Moderate to Severe SLE Treated with the S1P1 Receptor Modulator Cenerimod
9:00AM-10:30AM
Abstract Number: 0876
Investigation of Predictive Factors for Active Disease Status Within 24 Months of Juvenile Idiopathic Arthritis Diagnosis
9:00AM-10:30AM
Abstract Number: 1014
Is Radiographic Axial Involvement Associated with Syndesmophyte Development After 2 Years in PsA Patients?
9:00AM-10:30AM
Abstract Number: 0838
Is SARS-CoV-2 Associated with Worse Outcomes After Total Knee Arthroplasty?
9:00AM-10:30AM
Abstract Number: 0802
Is There Any Relationship Between Helicobacter Pylori and Rheumatoid Arthritis?
9:00AM-10:30AM
Abstract Number: 0653
JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro
9:00AM-10:30AM
Abstract Number: 0617
Killer Cell Immunoglobulin Receptor and Class I HLA Genetic Variability in South-eastern Spanish Rheumatoid Arthritis Patients
9:00AM-10:30AM
Abstract Number: 0870
Knee Acoustic Emissions as a Noninvasive Biomarker of Articular Health in Juvenile Idiopathic Arthritis
9:00AM-10:30AM
Abstract Number: 0990
KPG-818, a Novel Cereblon (CRBN) Modulator, in Patients with SLE: Results of a Phase Ib Multiple Ascending Dose Study
9:00AM-10:30AM
Abstract Number: 0824
Lessons Learned from a Cohort of Adult Afro-Caribbean Patients Diagnosed Clinically with Dermatomyositis
9:00AM-10:30AM
Abstract Number: 0890
Long Term Efficacy of a 2-year MRI Treat-to-target Treatment Strategy on Disease Activity, MRI Inflammation and Physical Function in Rheumatoid Arthritis Patients in Clinical Remission: Five Year Follow-up of the IMAGINE-RA Cohort
9:00AM-10:30AM
Abstract Number: 0644
Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon
9:00AM-10:30AM
Abstract Number: 0806
Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression
9:00AM-10:30AM
Abstract Number: 1042
Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis
9:00AM-10:30AM
Abstract Number: 1088
Longitudinal Pattern of Circulating Complement Activation in ANCA Vasculitis
9:00AM-10:30AM
Abstract Number: 0782
Low Circulating B Cells Correlate with Unresponsiveness to COVID-19 Vaccination Among Patients Treated with Rituximab
9:00AM-10:30AM
Abstract Number: 1027
Low Dose Computed Tomography Hounsfield Units: A Reliable Methodology for Assessing Changes in Vertebral Bone Density in Radiographic Axial Spondyloarthritis
9:00AM-10:30AM
Abstract Number: 0693
Low Neutrophil Ectonucleotidase Activity Drives Neutrophil-Platelet Aggregation and Platelet Activation in Antiphospholipid Syndrome (APS)
9:00AM-10:30AM
Abstract Number: 0976
Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials
9:00AM-10:30AM
Abstract Number: 1062
Lung Magnetic Resonance Imaging in Systemic Sclerosis Associated Interstitial Lung Disease: Potentiality and Comparison with Other Imaging Techniques
9:00AM-10:30AM
Abstract Number: 0645
Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions
9:00AM-10:30AM
Abstract Number: 0654
Lymphatic Dysfunction and Immune Activation in Lupus
9:00AM-10:30AM
Abstract Number: 0830
Lymphopenia as a Marker of Disease Activity and Severity in Sarcoidosis
9:00AM-10:30AM
Abstract Number: 0609
Macrophage Response to MAA Modified Fibrinogen in the Presence of Peptidyl Arginine Deiminase Inhibitor
9:00AM-10:30AM
Abstract Number: 0831
Management of Hepatic Sarcoidosis, a Retrospective Analysis of Patients at a University Hospital
9:00AM-10:30AM
Abstract Number: 0748
Mapping Long COVID-19 Patient Journeys for Rheumatic Disease Patients
9:00AM-10:30AM
Abstract Number: 0606
Mechanism of Joint-Specific Homeobox D10 Regulation in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
9:00AM-10:30AM
Abstract Number: 0733
Median Patient Global Assessment Varies Far More According to FAST4 (fibromyalgia Assessment Screening Tool) and MDS2 (MDHAQ Depression Screen) on a Single MDHAQ (multidimensional Health Assessment Questionnaire) Than According to Primary Diagnosis
9:00AM-10:30AM
Abstract Number: 1007
Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study
9:00AM-10:30AM
Abstract Number: 0747
Methotrexate and Hydroxychloroquine Used as Single Agent May Diminish Breakthrough Infection After COVID-19 Vaccination
9:00AM-10:30AM
Abstract Number: 0926
Methotrexate Polyglutamates Exposure – Response Modelling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate
9:00AM-10:30AM
Abstract Number: 0915
Methotrexate Therapy Results in Disparate Methotrexate Polyglutamate Profiles in Peripheral Blood Mononuclear Cells Compared with Erythrocytes
9:00AM-10:30AM
Abstract Number: 1017
Minimal Important Difference (MID), Minimal Detectable Change (MDC), and Disease Activity Thresholds for Two Novel Composite Instruments (3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of Three Phase 3 Studies
9:00AM-10:30AM
Abstract Number: 0975
Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE
9:00AM-10:30AM
Abstract Number: 0646
Modulation of Type I IFN Production and Regulatory T Cells by the PKGI/ROCK Signaling Pathway
9:00AM-10:30AM
Abstract Number: 0590
Molecular Profiling of Normal Human Synovium Reveals Striking Impact of Adipocytes and Homeostatic Cortisol Signaling
9:00AM-10:30AM
Abstract Number: 0581
Mutants Improving Stability Enhance the Potency of Treg-Selective IL-2 Mutein for the Treatment of Autoimmune Disorders
9:00AM-10:30AM
Abstract Number: 1048
Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study
9:00AM-10:30AM
Abstract Number: 0620
Neovascularization Is Altered by Rheumatoid Arthritis Synovial Fibroblasts and Canstatin in Vitro and in Vivo
9:00AM-10:30AM
Abstract Number: 0968
Neuropsychological Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-administered Multidisciplinary Questionnaire in a Monocentric Cohort
9:00AM-10:30AM
Abstract Number: 0596
Neutrophil Extracellular Traps (NET) Trigger an Enhanced Pro-inflammatory Response in Macrophage Subpopulations in Rheumatoid Arthritis Patients via the Aryl Hydrocarbon Receptor (AhR) Pathway
9:00AM-10:30AM
Abstract Number: 0877
Neutrophils Extracellular Traps Formation May Serve as a Biomarker for Disease Activity in Oligoarticular Juvenile Idiopathic Arthritis
9:00AM-10:30AM
Abstract Number: 0772
New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
9:00AM-10:30AM
Abstract Number: 0818
NLRP12-associated Autoinflammatory Disease in Chinese Adult Patients: A Single-center Study
9:00AM-10:30AM
Abstract Number: 0764
No Impact of Prior DMARD Exposures on Mortality in US Veterans with Cancer Treated with Immune Checkpoint Inhibitors
9:00AM-10:30AM
Abstract Number: 0584
Non-Clinical Evaluations of Deucravacitinib and Janus Kinase Inhibitor Specificity in Inflammatory or Homeostatic Pathways
9:00AM-10:30AM
Abstract Number: 1024
Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Projection Based on Data from 65 Million People in the German Statutory Health Insurance
9:00AM-10:30AM
Abstract Number: 0950
Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry
9:00AM-10:30AM
Abstract Number: 0677
Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual
9:00AM-10:30AM
Abstract Number: 0601
Occupational Inhaled Agents Constitute Major Risk Factors for Rheumatoid Arthritis, Particularly in the Context of Genetic Predisposition and Smoking
9:00AM-10:30AM
Abstract Number: 0673
Occurrence and Severity of Bleeding in Adults with Immunogenic Thrombocytopenic Purpura with or Without Antiphospholipid Autoantibodies
9:00AM-10:30AM
Abstract Number: 0865
Opioid Use in Youth with Inflammatory Bowel Disease (IBD)-related Arthritis
9:00AM-10:30AM
Abstract Number: 0822
Optimal Use of Colchicine in COVID-19 Management from Rheumatologists’ Perspective: A Monocentric Observational Study During the SARS-CoV-2 Delta Variant Pandemic
9:00AM-10:30AM
Abstract Number: 0726
Optimizing Laboratory Medication Safety Monitoring in Patients with JIA to Advance Value-based Care
9:00AM-10:30AM
Abstract Number: 0854
Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study
9:00AM-10:30AM
Abstract Number: 0679
Outcomes of Antiphospholipid Antibody Syndrome and Acute Coronary Syndrome: Analysis of National Inpatient Sample 
9:00AM-10:30AM
Abstract Number: 0866
Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab
9:00AM-10:30AM
Abstract Number: 1082
Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review
9:00AM-10:30AM
Abstract Number: 0850
Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry
9:00AM-10:30AM
Abstract Number: 0662
Partial Correlations Network Models Show Th1, Th2 and Th17 Responses to Be Interlinked in Dermal Pathogenesis of Cutaneous Lupus Erythematous
9:00AM-10:30AM
Abstract Number: 0648
Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients
9:00AM-10:30AM
Abstract Number: 0742
Patient Factors Influencing Recruitment in a Telemedicine Randomized Clinical Trial
9:00AM-10:30AM
Abstract Number: 0610
Patient-derived Organoids Reveal Transcriptional Regulation of Synovial Lining Fibroblast Differentiation
9:00AM-10:30AM
Abstract Number: 0906
Patients with Seronegative Rheumatoid Arthritis Have a Different Ultrasound-assessed Joint Disease Phenotype Than Seropositive Patients
9:00AM-10:30AM
Abstract Number: 0967
Patterns of Breastfeeding Among Women with and Without Systemic Lupus Erythematosus
9:00AM-10:30AM
Abstract Number: 0911
Peer Coach Intervention to Improve Primary Cardiovascular Disease Screening for Patients with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0631
Perfluoroalkyl Substances and Community Vulnerability: Associations with Lupus-Related Autoantibodies and Disease
9:00AM-10:30AM
Abstract Number: 0803
Performance of Adenosine Deaminase Activity in Sinovial Fluid for the Early Diagnosis of Tuberculous Arthritis: A Meta Analysis
9:00AM-10:30AM
Abstract Number: 1037
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies
9:00AM-10:30AM
Abstract Number: 1080
Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials
9:00AM-10:30AM
Abstract Number: 0899
Performance of the Foot Function Index Questionnaire in Patients with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0612
Peripheral Blood and Synovial Fluid Natural Killer (NK) and Natural Killer T (NKT) Cell Immunophenotypes in Active Rheumatoid Arthritis and Their Role as Biomarkers of Methotrexate Response
9:00AM-10:30AM
Abstract Number: 0754
Persistent but Disturbed Germinal Center Reaction Among 3rd SARS-CoV-2 Vaccination After Rituximab Exposure
9:00AM-10:30AM
Abstract Number: 0649
Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity
9:00AM-10:30AM
Abstract Number: 0939
Pilot Study: A Novel Method for Cervical Health Monitoring in African American Women with Systemic Lupus Erythematosus (SLE) Using a Self- Sampling Brush to Assess Cervical HPV Infection and Cervical Cytology
9:00AM-10:30AM
Abstract Number: 0903
Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0709
Population Based Prevalence and Incidence of Mixed Connective Tissue Disease from the Manhattan Lupus Surveillance Program
9:00AM-10:30AM
Abstract Number: 0795
Post-Acute COVID-19 Sequalae (PACS) with New-onset Rheumatological Complications
9:00AM-10:30AM
Abstract Number: 0792
Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)
9:00AM-10:30AM
Abstract Number: 0614
Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
9:00AM-10:30AM
Abstract Number: 0848
Postoperative Flares and Peri-arthroscopic Management of Immunosuppressive Medications in Patients with Rheumatic Disease
9:00AM-10:30AM
Abstract Number: 0840
Postoperative Risk of Immunosuppression in Rheumatic Disease Patients Undergoing Arthroscopy
9:00AM-10:30AM
Abstract Number: 0716
Posttraumatic Stress Disorder Symptoms in Systemic Autoimmune Rheumatic Disease Patients During the Early COVID-19 Pandemic
9:00AM-10:30AM
Abstract Number: 0905
Predicting Disease Activity in Rheumatoid Arthritis Patients Using Machine Learning: Data from the ACR’s RISE Registry
9:00AM-10:30AM
Abstract Number: 0825
Predicting Outcomes in Macrophage Activation Syndrome (MAS): A Retrospective Study on 43 Consecutive Patients with MAS
9:00AM-10:30AM
Abstract Number: 0858
Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis
9:00AM-10:30AM
Abstract Number: 0892
Predicting Value of Circulating Semaphorin 4A for Rheumatoid Arthritis Progression and Response to Treatment
9:00AM-10:30AM
Abstract Number: 0875
Predictive Biomarkers of Tofacitinib Response and Disease Activity in Juvenile Idiopathic Arthritis Subtypes: A Longitudinal Study
9:00AM-10:30AM
Abstract Number: 0817
Predictive Severity Factors of COVID-19 in Patients with Rheumatic Immune Mediated Diseases
9:00AM-10:30AM
Abstract Number: 0919
Predictors of Methotrexate Monotherapy Response in Patients with Active Rheumatoid Arthritis: Results from a Multicentre, Randomized Controlled Trial
9:00AM-10:30AM
Abstract Number: 0845
Predictors of Moderate-Vigorous Physical Activity Following a Physical Therapist Led Physical Activity Intervention for Adults with Total Knee Replacement
9:00AM-10:30AM
Abstract Number: 1015
Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial
9:00AM-10:30AM
Abstract Number: 0952
Pregnancy Course and Outcomes of Patients with Polymyositis and Dermatomyositis (PM/DM) in Our Institution
9:00AM-10:30AM
Abstract Number: 0965
Pregnancy Outcomes in a Diverse Lupus Cohort
9:00AM-10:30AM
Abstract Number: 0741
Prescribing Patterns of SGLT2 Inhibitors for Patients with Autoimmune Rheumatic Disease
9:00AM-10:30AM
Abstract Number: 0676
Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature
9:00AM-10:30AM
Abstract Number: 0760
Prevalence of Autoimmune Conditions in Metastatic Melanoma Patients Starting Checkpoint Inhibitors
9:00AM-10:30AM
Abstract Number: 0674
Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies
9:00AM-10:30AM
Abstract Number: 0727
Primary Prevention of Fractures in Osteoporotic Patients in a Southern California Academic Health System
9:00AM-10:30AM
Abstract Number: 0991
Prior Use of Autoimmune Disease Treatments Among Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Myositis Hospitalized with COVID-19
9:00AM-10:30AM
Abstract Number: 1089
Prognostic Value of Proteinuria Monitoring in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
9:00AM-10:30AM
Abstract Number: 0655
Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents
9:00AM-10:30AM
Abstract Number: 0611
Proteomics Reveals Dysregulated Molecular Mechanisms of Cell Death in Neutrophils in Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0837
Providers’ Adoption of 2017 Guidelines on DMARD Use Perioperatively for Elective Total Hip and Knee Arthroplasty at a Single Academic Center
9:00AM-10:30AM
Abstract Number: 1090
Pulmonary Function Testing (PFT) in Patients with Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis (AAV): Correlation with Radiologic Imaging
9:00AM-10:30AM
Abstract Number: 0823
Pulmonary Manifestations in VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome: A Systematic Literature Review
9:00AM-10:30AM
Abstract Number: 0981
QTc Prolongation in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients Treated with Hydroxychloroquine – Preliminary Results from a Single Center Study
9:00AM-10:30AM
Abstract Number: 0750
Quality Improvement Project to Increase the Rate of Vaccination with Pneumococcal Vaccines (PCV13 prime-PPSV23 Boost Strategy) Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Within Nationwide Health Organization
9:00AM-10:30AM
Abstract Number: 1045
Quantification of the Enthesic Response to Biological Therapies in Patients with Spondyloarthritis by Computer Analysis of Ultrasound Images
9:00AM-10:30AM
Abstract Number: 0728
Racial Disparities in Pain: Severity, Interference with Function, and Response to Guided Imagery
9:00AM-10:30AM
Abstract Number: 0843
Racial Disparities in Patient Satisfaction Following Total Joint Arthroplasty: A Contemporary Trends Analysis from 2013-2021
9:00AM-10:30AM
Abstract Number: 0974
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers
9:00AM-10:30AM
Abstract Number: 0740
Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Secondary Hemophagocytic Lymphohistiocytosis in the United States: The REAL-HLH Study
9:00AM-10:30AM
Abstract Number: 0714
Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0897
Reasons for Multiple Biologic DMARD Switching and Characteristics of “Extreme Treatment Nonresponders” in Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0701
Reduced Humoral but Maintained Cellular Immune Response to a 3rd COVID-19 Vaccination in Patients with Immune-Mediated Inflammatory Diseases as Compared to Healthy Controls over a 3-months Observational Period
9:00AM-10:30AM
Abstract Number: 0637
Reduced IgG Sialic Acid Content: A Distinctive Characteristic of Symptomatic Anti-Nuclear Antibodies Positive Individuals
9:00AM-10:30AM
Abstract Number: 0768
Reevaluating Clinical Outcomes of Patients on Combination Biologics
9:00AM-10:30AM
Abstract Number: 0618
Regulation of IgA Secretion Through PAD2-mediated Citrullination of MZB1
9:00AM-10:30AM
Abstract Number: 0867
Regulatory Haplotype of CXCR4 Is Associated with sJIA and Corelates with Enhanced Neutrophil and CD14+ Monocyte Migration
9:00AM-10:30AM
Abstract Number: 0989
Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
9:00AM-10:30AM
Abstract Number: 0841
Relation of PainDETECT to Unpredictable Pain in People with or at Risk of Knee Osteoarthritis
9:00AM-10:30AM
Abstract Number: 0787
Relationship Between Humoral and Cellular Immune Responses in Persons with Rheumatoid Arthritis Following a Third Dose of COVID-19 Vaccine
9:00AM-10:30AM
Abstract Number: 0811
Reliability of CRP as an Inflammatory Marker in Patients with Immune Mediated Inflammatory Diseases (IMIDs) and Liver Dysfunction
9:00AM-10:30AM
Abstract Number: 0853
Reliability of MRI Lesions Comprising the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRI-SIJ): What Is the Impact of Systematic Reader Calibration?
9:00AM-10:30AM
Abstract Number: 0758
Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study
9:00AM-10:30AM
Abstract Number: 0731
Remote Monitoring of Chronic Inflammatory Musculoskeletal Diseases– Results of the Digireuma Feasibility Study
9:00AM-10:30AM
Abstract Number: 1069
Renal Involvement Other Than Renal Crisis in Systemic Sclerosis: A Retrospective Monocentric Cohort Study
9:00AM-10:30AM
Abstract Number: 1026
Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis
9:00AM-10:30AM
Abstract Number: 0851
Responsiveness of Patient-Reported Physical Function Measures in Juvenile Arthritis
9:00AM-10:30AM
Abstract Number: 0589
Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation
9:00AM-10:30AM
Abstract Number: 0920
Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry
9:00AM-10:30AM
Abstract Number: 0927
Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation
9:00AM-10:30AM
Abstract Number: 0805
Rheumatic Fever and Streptococcal Cutaneous Infection: A Case-control Study in the Loyalty Islands, New Caledonia
9:00AM-10:30AM
Abstract Number: 0756
Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions
9:00AM-10:30AM
Abstract Number: 0891
Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity
9:00AM-10:30AM
Abstract Number: 0910
Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies
9:00AM-10:30AM
Abstract Number: 0623
Rheumatoid Synovial Fibroblasts Display Imprinted Memory of Their Synovial Endotype Which Can Be Plastically Modulated by B-cells Crosstalk
9:00AM-10:30AM
Abstract Number: 0737
Rheumatologic Rashes in Different Skin Types and Confidence in Diagnosis Among Internal Medicine Residents in a New York City Hospital
9:00AM-10:30AM
Abstract Number: 0710
Risk Factors Associated with COVID-19 Breakthrough Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Cohort Study
9:00AM-10:30AM
Abstract Number: 0898
Risk of Aortic Stenosis and Undergoing Aortic Valve Replacement in Rheumatoid Arthritis: An Underrecognized Cardiovascular Complication
9:00AM-10:30AM
Abstract Number: 0723
Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
9:00AM-10:30AM
Abstract Number: 1033
Risk of Mood Disorders in SpA Patients and Correlations with Disease Activity, Quality of Life and Working Ability: Analysis of a Monocentric Cohort
9:00AM-10:30AM
Abstract Number: 1049
Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
9:00AM-10:30AM
Abstract Number: 0720
Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study
9:00AM-10:30AM
Abstract Number: 0781
Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
9:00AM-10:30AM
Abstract Number: 1084
Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with Polyangiitis: A Target Trial Emulation Study
9:00AM-10:30AM
Abstract Number: 0931
Rituximab versus Leflunomide in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment- an Open Label Randomized Controlled Trial
9:00AM-10:30AM
Abstract Number: 0762
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
9:00AM-10:30AM
Abstract Number: 0588
S-nitrosoglutathione Reductase (GSNOR) Regulates Osteoclast Differentiation
9:00AM-10:30AM
Abstract Number: 0985
S100 Serum Protein Expression Is a Useful Indicator of HCQ Treatment Efficacy in SLE
9:00AM-10:30AM
Abstract Number: 0757
Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases
9:00AM-10:30AM
Abstract Number: 1074
Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis
9:00AM-10:30AM
Abstract Number: 0715
Safety and Immunogenicity of Mixed COVID19 Vaccine Regimens in Immune-mediated Inflammatory Diseases: An Observational Cohort
9:00AM-10:30AM
Abstract Number: 1061
Safety and Tolerability of Aminaphtone in Systemic Sclerosis Patients: A Four-year Follow-up
9:00AM-10:30AM
Abstract Number: 1077
Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials
9:00AM-10:30AM
Abstract Number: 1085
Safety of Plasmapheresis as an Adjuvant Therapy in Severe Pediatric Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: A Single Center Cohort
9:00AM-10:30AM
Abstract Number: 0988
Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Enpatoran Doses in a Phase I Study of Healthy Japanese and Caucasian Participants: Feasibility of Including Asian Participants in a Phase II Study of Enpatoran
9:00AM-10:30AM
Abstract Number: 0796
SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?
9:00AM-10:30AM
Abstract Number: 0993
SARS-CoV-2 Vaccine Side Effects and Infections in SLE
9:00AM-10:30AM
Abstract Number: 1046
Scleroderma Heart Disease
9:00AM-10:30AM
Abstract Number: 0665
Screening for Neurocognitive Demands in Childhood-onset Systemic Lupus Erythematosus Patients Using Pediatric Automated Neuropsychological Assessment Metrics and Association with Magnetic Resonance Imaging
9:00AM-10:30AM
Abstract Number: 0896
Screening of Lipids in Patients with Rheumatoid Arthritis: Academic Rheumatology Practice Quality Improvement Analysis
9:00AM-10:30AM
Abstract Number: 1020
Screening Tools for Spondyloarthritis in Patients with Psoriasis, IBD, and Uveitis – A Scoping Review
9:00AM-10:30AM
Abstract Number: 0615
Semaphorin 5A Suppresses Ferroptosis Through Activation of PI3K-AKT-mTOR Signaling in Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0889
Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0960
Serum C3 Level and Glucocorticoid Dose Are Risk Factors for Preterm Birth in Patients with Systemic Lupus Erythematosus
9:00AM-10:30AM
Abstract Number: 0884
Serum Calprotectin Can Differentiate Between Sustained Remission and Low Disease Activity States in Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0883
Serum Cholesterol Loading Capacity on Macrophages Is Dependent on Oxidized Low-density Lipoprotein and Regulated by Seropositivity and C-reactive Protein in Patients with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0652
Serum from Patients with SLE and Anti-MDA5 Antibody-Positive Dermatomyositis Induce Shared Monocyte Cytokine Signature Through Type 1 Interferon Pathway
9:00AM-10:30AM
Abstract Number: 0799
Serum Laboratory Parameters of Hemophagocytic Lymphohistiocytosis Syndrome in Patients with Autoimmune Rheumatic Diseases Infected with SARS-CoV-2: A Retrospective Comparative Study
9:00AM-10:30AM
Abstract Number: 0660
Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study
9:00AM-10:30AM
Abstract Number: 0616
Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes
9:00AM-10:30AM
Abstract Number: 0636
Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment
9:00AM-10:30AM
Abstract Number: 0929
Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases
9:00AM-10:30AM
Abstract Number: 0705
Severity of SARS-CoV-2 Omicron Breakthrough Infections in Patients with Rheumatic Immune-mediated Inflammatory Diseases and Healthy Controls: Data from a Prospective Cohort Study
9:00AM-10:30AM
Abstract Number: 1052
Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey
9:00AM-10:30AM
Abstract Number: 0916
Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis
9:00AM-10:30AM
Abstract Number: 0684
Single Antiphospholipid Antibody Positive Thrombotic APS Patients’ Clinical Characteristics: Retrospective Results from the APS ACTION Clinical Database and Repository (Registry)
9:00AM-10:30AM
Abstract Number: 0632
Single-cell Multiomic Profiling Differentiates Ancestral B Cell Pathologies Contributing to Lupus Disease Activity
9:00AM-10:30AM
Abstract Number: 0642
SLAMF6-SAP Signaling Unit Is Increased in SLE T Follicular Helper Cells
9:00AM-10:30AM
Abstract Number: 0881
Social Cognitive Correlates of Accelerometer-measured and Self-reported Physical Activity in Persons with Systemic Lupus Erythematosus
9:00AM-10:30AM
Abstract Number: 1004
SPARCC, MASES, LEI and MEI Indexes Capture Different Patients with Enthesitis in Axial Spondyloarthritis, Peripheral Spondyloartrhitis and Psoriatic Arthritis
9:00AM-10:30AM
Abstract Number: 0627
Spatial Transcriptomic Analysis Reveals Vascular Zonation of Myofibroblasts in Rheumatoid Arthritis Synovium
9:00AM-10:30AM
Abstract Number: 0868
Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome
9:00AM-10:30AM
Abstract Number: 0691
Structural Differences Exist in Beta-2-Glycoprotein I from APS Patients Compared to Healthy Controls
9:00AM-10:30AM
Abstract Number: 0643
Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare
9:00AM-10:30AM
Abstract Number: 0941
Surveying Adolescents with Rheumatic Disease for At-Risk Behavior
9:00AM-10:30AM
Abstract Number: 0603
Survivin-dependent Regulation of Bivalent Chromatin and Its Relevance for Adaptive Immunity
9:00AM-10:30AM
Abstract Number: 0790
Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study
9:00AM-10:30AM
Abstract Number: 0859
Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe
9:00AM-10:30AM
Abstract Number: 0949
Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic CHallenge (SWITCH): The Systemic Lupus International Collaborating Clinics Experience
9:00AM-10:30AM
Abstract Number: 0996
Tapering of Corticosteroids or Immunosuppressive Therapy in Stable SLE: A Comparison of Complete Remission, Clinical Remission and Lupus Low Disease Activity State in Protection Against Flares
9:00AM-10:30AM
Abstract Number: 0935
Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to CsDMARDs, Enriching CsDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy
9:00AM-10:30AM
Abstract Number: 0746
Telemedicine for Follow-up of Lupus Nephritis in the Covid-19 Outbreak: A Pragmatic Randomized Controlled Trial
9:00AM-10:30AM
Abstract Number: 0835
Temporal Trends in Prosthetic Joint Infection
9:00AM-10:30AM
Abstract Number: 1064
Test-retest Reliability for the Mawdsley Calcinosis Questionnaire for the Measurement of Calcinosis Burden in Patients with Systemic Sclerosis
9:00AM-10:30AM
Abstract Number: 0904
Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0842
The Amount of Fluid in the Retrocalcaneal Area Negatively Correlates with Lower Extremity Function
9:00AM-10:30AM
Abstract Number: 0685
The Association of Antiphospholipid Antibodies with Previous SARS-CoV-2 Infection Among Elective Knee Replacement Patients
9:00AM-10:30AM
Abstract Number: 0908
The Association of Cardiovascular Comorbidities with Remission in Rheumatoid Arthritis Patients Undergoing Treatment with Baricitinib and Conventional Synthetic DMARDs: A Post-Hoc Analysis
9:00AM-10:30AM
Abstract Number: 0650
The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis
9:00AM-10:30AM
Abstract Number: 0629
The Cellular Metabolism of SLE NK Cells Is Primarily Altered at the Level of Mitochondrial Respiration
9:00AM-10:30AM
Abstract Number: 1053
The Collaborative National Quality and Efficacy Registry for Scleroderma: Association of Resource Utilization and Gastrointestinal Tract Symptoms in Early Disease
9:00AM-10:30AM
Abstract Number: 0775
The Distribution and Frequency of Autoreactive B Cells Are Altered in Autoimmune Patients After TNF Inhibitor Treatment
9:00AM-10:30AM
Abstract Number: 0980
The Effect and Outcomes of HCQ Alone and in Combination with Anti-Depressants on QTc
9:00AM-10:30AM
Abstract Number: 0713
The Epidemiology, Clinical Outcomes, and Healthcare Resource Utilization of IgG4-Related Disease Among Commercially Insured People in the United States
9:00AM-10:30AM
Abstract Number: 0914
The Impact of Autoantibodies (RF and ACPA) on the Efficacy of Biological Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Meta-analysis of Randomized Controlled Trials
9:00AM-10:30AM
Abstract Number: 0849
The Impact of Diabetes Status on Pain and Disability Following Total Joint Arthroplasty for Hip and Knee Osteoarthritis: Variation by Sex and Body Mass Index
9:00AM-10:30AM
Abstract Number: 0708
The Impact of Early Antimalarial Adherence on Future Acute Care Utilization Among Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: A Population-based Study
9:00AM-10:30AM
Abstract Number: 0765
The Impact of Immunomodulating Treatment on the Immunogenicity of COVID-19 Vaccines in Patients with Immune-mediated Inflammatory Rheumatic Diseases Compared to Healthy Controls. a Swedish Nationwide Study (COVID19-REUMA)
9:00AM-10:30AM
Abstract Number: 0946
The Impact of Pregnancy Planning and Medical Readiness on Reproductive Outcomes in Women with SLE
9:00AM-10:30AM
Abstract Number: 0692
The Interplay Between Lipid Peroxidation and Neutrophil Extracellular Trap (NET) Formation in APS Pathogenesis
9:00AM-10:30AM
Abstract Number: 0696
The Mortality Trends Related to SLE in the United States – A 20-year Analysis (2001-to 2020) from the WONDER Database
9:00AM-10:30AM
Abstract Number: 0789
The Persistence of Anti-Spike Antibodies Following Two SARS-CoV-2 Vaccine Doses in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy Compared to Healthy Controls: A Prospective Cohort Study
9:00AM-10:30AM
Abstract Number: 0690
The Physiological Ketone Body Beta-Hydroxybutyrate Potently Neutralizes APS-Associated NETosis
9:00AM-10:30AM
Abstract Number: 0613
The Subsets of Synovial Fluid Derived Fibroblasts in Clinical Features of Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0771
The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study
9:00AM-10:30AM
Abstract Number: 0961
The Use of Belimumab Before and During Pregnancy in Patients with Systemic Lupus Erythematosus: An Italian Multicenter Case-series
9:00AM-10:30AM
Abstract Number: 0820
Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study
9:00AM-10:30AM
Abstract Number: 0671
Thrombocytopenia and Autoimmune Hemolytic Anemia in Antiphospholipid Antibody-positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
9:00AM-10:30AM
Abstract Number: 0957
Timeliness of Fetal Echocardiography for Congenital Heart Block Detection in Anti-Ro/La-Positive Pregnancies
9:00AM-10:30AM
Abstract Number: 0778
TNF Inhibitors Display a Modulatory Effect on Serological and Cellular Vaccine Response in Patients with Chronic Inflamatory Diseases
9:00AM-10:30AM
Abstract Number: 0597
TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts
9:00AM-10:30AM
Abstract Number: 1041
Tofacitinib in Refractory Uveitis – an Observational Study
9:00AM-10:30AM
Abstract Number: 0583
Toll-Like Receptor Ligands Stimulated Monocyte-Derived Langerhans Cell-Like Dendritic Cells Induce Psoriasis-Related Molecules, IL-23 and Delta-Like-4
9:00AM-10:30AM
Abstract Number: 0634
Total Interstitial Inflammation Predicts Chronic Kidney Disease Progression in Patients with Lupus Nephritis
9:00AM-10:30AM
Abstract Number: 0586
Transcription Factor Fli-1 Impacts CXCL13 Expression and Renal Inflammation in Lupus-like Nephritis of Adult MRL/lpr Mouse
9:00AM-10:30AM
Abstract Number: 0647
Transcriptomic Analysis of Lupus Nephritis Kidneys Identifies Molecular Endotypes
9:00AM-10:30AM
Abstract Number: 0808
Transitional Care in Juvenile Idiopathic Arthritis: Timing, Prevalence of Subtypes and Treatment Profile in a Spanish Tertiary Hospital
9:00AM-10:30AM
Abstract Number: 1083
Treatment of ANCA-associated Vasculitis with Extreme Impairment of Renal Function: A Case-Control Study Comparing an Intensive B Cell Depletion Regimen with the Standard of Care Using Oral Cyclophosphamide
9:00AM-10:30AM
Abstract Number: 0826
Treatment Pattern and Changes in Oral Glucocorticoid Dose After Tocilizumab Treatment in Patients with Adult Still’s Disease: An Analysis of a Japanese Claims Database
9:00AM-10:30AM
Abstract Number: 0717
Treatment Utilization in Dermatomyositis: An Analysis of Electronic Medical Records in the United States
9:00AM-10:30AM
Abstract Number: 1011
Trends in Fracture Rates Among Veterans with Ankylosing Spondylitis
9:00AM-10:30AM
Abstract Number: 1071
Trimethoprim Sulfamethoxazole Use in Patients with Granulomatosis with Polyangiitis Treated with Rituximab
9:00AM-10:30AM
Abstract Number: 0689
Type I Interferon Stimulated Genes Identify Different Phenotypes of Antiphospholipid Syndrome Patients
9:00AM-10:30AM
Abstract Number: 0798
Uncovering the Relationship Between COVID-19 Outcome Severity and Rheumatic Disease
9:00AM-10:30AM
Abstract Number: 0669
Understanding How Type I Interferon Modulates Langerhans Cell ADAM17 to Promote Photosensitivity in Lupus
9:00AM-10:30AM
Abstract Number: 0729
Understanding the Practice and Process of Patient Reported Outcome Measures Collection in North American Pediatric Rheumatology Clinics: A Survey of the Pediatric Rheumatology-Care and Outcomes Improvement Network
9:00AM-10:30AM
Abstract Number: 0955
Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort
9:00AM-10:30AM
Abstract Number: 0744
University of North Carolina and Piedmont Health Collaborative Tele-Rheumatology Project to Optimize Rural Health Specialty Access
9:00AM-10:30AM
Abstract Number: 0827
Unpublished Clinical Trials of Major Rheumatic Diseases
9:00AM-10:30AM
Abstract Number: 0909
Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs
9:00AM-10:30AM
Abstract Number: 0928
Use of Disease Modifying Anti-rheumatic Drugs and Risk of Multiple Myeloma in US Veterans with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0969
Use of Gonadotropin-releasing Hormone Agonists for Ovarian Preservation in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus: A Meta-analysis
9:00AM-10:30AM
Abstract Number: 0745
Use of Telemedicine in Patients with Systemic Lupus Erythematosus in a Publicly Funded Hospital System
9:00AM-10:30AM
Abstract Number: 0834
Use of the Routine Assessment of Patient Index Data 3 (RAPID3) Questionnaire in the Assessment of Chronic Lower Back Pain
9:00AM-10:30AM
Abstract Number: 1057
Usefulness of REVEAL 2.0 Score as a Prognosis Tool of All-Cause Pulmonary Hypertension in Systemic Sclerosis Patients: A Multicentric Study
9:00AM-10:30AM
Abstract Number: 0725
Utility of Repeat Extractable Nuclear Antigen Antibody Testing- a Retrospective Audit
9:00AM-10:30AM
Abstract Number: 1043
Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis
9:00AM-10:30AM
Abstract Number: 0703
Vaccination Against SARS-CoV2 in Patients with Systemic Autoimmune Diseases: A Safety Report from EULAR COVAX Registry
9:00AM-10:30AM
Abstract Number: 1022
Validation of the SPARCCRETIC E-Tool for Ensuring Scoring Proficiency of MRI Lesions in Axial Spondyloarthritis
9:00AM-10:30AM
Abstract Number: 0595
Validation of Urotensin-2 mRNA Expression as Marker for Tocilizumab Non-Response in Early Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 0962
Variability in Racial Disparities in Pregnancy Outcomes in Women with SLE by Diagnosis Algorithm
9:00AM-10:30AM
Abstract Number: 1029
Virtual Assessment in Axial Spondyloarthritis: Validation of Video Observation of Spinal Metrology
9:00AM-10:30AM
Abstract Number: 0749
Virtual Care in Rheumatology Ambulatory Clinics During the COVID-19 Pandemic: Patient/Family and Healthcare Provider Perspectives and Experiences
9:00AM-10:30AM
Abstract Number: 1059
Vision Transformer Assisting Rheumatologists in Screening for Capillaroscopy Changes in Systemic Sclerosis: An Artificial Intelligence Solution
9:00AM-10:30AM
Abstract Number: 0924
Vitamin B12 Status and Hyperhomocysteinemia in Patients with Rheumatoid Arthritis Treated with Methotrexate and Folic Acid
9:00AM-10:30AM
Abstract Number: 0954
What Drives the BASDAI in Pregnant Patients with Axial Spondyloarthritis? A Pooled Analysis of Four European Pregnancy Registries
9:00AM-10:30AM
Abstract Number: 0997
Withdrawal of Maintenance Glucocorticoid versus Other Immunosuppressants Among Patients with Systemic Lupus Erythematosus in Long Term Clinical Remission: Interim Analysis of a Non-inferiority Randomised Controlled Trial
9:00AM-10:30AM
Abstract Number: 0608
Wnt Pathway Regulators R-spondin 3 and Dickkopf-related Protein 3 Demarcate a Transcriptional Gradient That Drives Synovial Fibroblast Inflammatory Pathology in Rheumatoid Arthritis
11:30AM-1:00PM
Abstract Number: 1112
Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry
11:30AM-1:00PM
Abstract Number: 1114
Computational Drug Repositioning and 3D Skin Models Identify EGFR and PI3K Inhibitors as Anti-fibrotic Targets for Systemic Sclerosis
11:30AM-1:00PM
Abstract Number: 1117
Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
11:30AM-1:00PM
Abstract Number: 1115
Medication Co-pay Modifies Treatment Adherence in Patients with Systemic Lupus Erythematosus
11:30AM-1:00PM
Abstract Number: 1116
Peripheral Blood DNA Methylation-based Machine Learning Models for Prediction of Knee Osteoarthritis Progression: Biospecimens and Data from the Osteoarthritis Initiative and Johnston County Osteoarthritis Project
11:30AM-1:00PM
Abstract Number: 1113
Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
1:00PM-3:00PM
Abstract Number: 1224
‘No Route Map’: The Complex Healthcare Journeys of People with Fibromyalgia – a Record Linkage Study in the UK
1:00PM-3:00PM
Abstract Number: 1346
“Finally, I Can Do Something About It Myself”: A Process Evaluation of the Plants for Joints Lifestyle Intervention
1:00PM-3:00PM
Abstract Number: 1231
[68Ga]- CPCR4 Trifluoroacetate PET/CT Imaging of Chemokine Receptor CXCR4- Expression in Systemic Sclerosis Related Interstitial Lung Disease
1:00PM-3:00PM
Abstract Number: 1414
2022 Revision of the ACR/EULAR Remission Criteria for Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1433
A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1316
A Cluster of Paget Disease of the Bone in Black or African American Patients in a Veteran Population
1:00PM-3:00PM
Abstract Number: 1454
A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study
1:00PM-3:00PM
Abstract Number: 1256
A Machine Learning Pipeline for Prediction of Bone Marrow Oedema Along the Sacroiliac Joints on Magnetic Resonance Imaging
1:00PM-3:00PM
Abstract Number: 1149
A Novel Mitochondrial Variant as a Predictor for the Rapid Progressive Knee Osteoarthritis Phenotype: Development of a Predictive Model and Functional Studies
1:00PM-3:00PM
Abstract Number: 1152
A Novel Serological Biomarker Measuring a Fragment of Cartilage Intermediate Layer Protein 1 Is Highly Upregulated in Rheumatic Diseases
1:00PM-3:00PM
Abstract Number: 1297
A Paediatric-Adult Provider Dyad Care Model Improves Transition from Paediatric to Adult Health Care for Youth with Childhood-Onset Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1350
A Prospective Study on Pain Associated with Injection of Needles: PAIN Study
1:00PM-3:00PM
Abstract Number: 1248
A Retrospective Chart Review Examining How a Change in MRI Protocol Could Affect the Diagnosis of Axial Spondyloarthritis
1:00PM-3:00PM
Abstract Number: 1240
A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy for the Diagnosis of Cardiac Sarcoidosis
1:00PM-3:00PM
Abstract Number: 1370
Abatacept in the Treatment of Refractory Juvenile Dermatomyositis
1:00PM-3:00PM
Abstract Number: 1267
Accuracy of Financial Disclosures in American-Based Rheumatology Journals
1:00PM-3:00PM
Abstract Number: 1429
Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study
1:00PM-3:00PM
Abstract Number: 1358
Adherence to Early DMARD Strategies in Newly Diagnosed RA Patients Seen in Routine Care: Results from the Canadian Early Arthritis Cohort Study
1:00PM-3:00PM
Abstract Number: 1365
Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
1:00PM-3:00PM
Abstract Number: 1204
An Increased Risk of Heart Failure and Heart Failure-Related Death Persists in Rheumatoid Arthritis: A National, Matched Cohort Study from 2000 to 2019
1:00PM-3:00PM
Abstract Number: 1278
ANA Testing Practices in the United States: A Population-Based Study Between 2000 and 2019
1:00PM-3:00PM
Abstract Number: 1133
Ancestry, ACKR1, and Leucopenia in Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1476
Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1523
Anti-RNPC3 Autoantibodies in Mixed Connective Tissue Disease Are Associated with Systemic Sclerosis Skin Involvement
1:00PM-3:00PM
Abstract Number: 1564
Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involvement in Behçet’s Disease
1:00PM-3:00PM
Abstract Number: 1468
Apathy Measurement in a Cohort of Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1272
Application of the Consolidated Framework for Implementation Research (CFIR) to Study Top-Performing Practices in the RISE Registry
1:00PM-3:00PM
Abstract Number: 1287
Are the American College of Rheumatology’s Web-Based Patient Education Materials Easy for Patients to Read and Comprehend?
1:00PM-3:00PM
Abstract Number: 1335
Artificial Intelligence–enabled Sentiment Analysis of Public Attitude Toward Pregnancy in Lupus Social Media Group
1:00PM-3:00PM
Abstract Number: 1515
Assessing the Difference Between Radiographic Axial Spondylorthritis and Non-radiographic Axial Spondylorthritis in a Two-center Descriptive Study with Mexican Patients: The Influence of Clinical, Demographic, Laboratory and Clinimetric Features
1:00PM-3:00PM
Abstract Number: 1257
Assessing the Effectiveness of Tocilizumab in Giant Cell Arteritis by PET: Multicenter Study of 101 Patients of Clinical Practice
1:00PM-3:00PM
Abstract Number: 1237
Assessment of Common Femoral Vein Intima-Media Thickness by Ultrasound in Behçet’s Disease: Comparative Study of Patients with or Without Vascular Involvement in a National Referral Center
1:00PM-3:00PM
Abstract Number: 1502
Assessment of Perceptions and Practices Regarding the Collaborative Management of Patients with Psoriatic Arthritis Among US Dermatology and Rheumatology Teams
1:00PM-3:00PM
Abstract Number: 1302
Assessment of the Transition of Care from Pediatric to Adult Rheumatology in a Tertiary Center
1:00PM-3:00PM
Abstract Number: 1206
Association Between Different Alcoholic Beverages and Serum Urate Level: A Cross-Sectional Study Using Large Medical Checkup Data
1:00PM-3:00PM
Abstract Number: 1222
Association of Fibromyalgia, PTSD and Combat Deployments in Active Duty Military
1:00PM-3:00PM
Abstract Number: 1379
Association of HLA Alleles with Specific Auto-antibodies in an Ancestrally Diverse Population of Childhood Systemic Lupus Erythematosus (SLE)
1:00PM-3:00PM
Abstract Number: 1479
Association of Neuromyelitis Optica and Systemic Lupus Erythematosus: Analysis of National Inpatient Sample 
1:00PM-3:00PM
Abstract Number: 1472
Autoantibodies Against Tripartite-Motif 72 Protein (TRIM72) in Systemic Lupus Erythematosus Patients and in a Lupus Mouse Models with Myocarditis, Can Compromise Membrane Repair in Cardiomyocytes Potentially Contributing to Cardiovascular Disease Progression
1:00PM-3:00PM
Abstract Number: 1201
Autoimmune Serologies, Cell-Bound Complement Activation Products, and Autoimmune Rheumatic Disease Symptoms After COVID-19 Infection
1:00PM-3:00PM
Abstract Number: 1223
Autoimmune Thyroid Disease Associates with Hand Pain in Older Adults in the Third National Health and Nutrition Examination Survey
1:00PM-3:00PM
Abstract Number: 1220
Autonomic Dysfunction in Sjogren’s Disease
1:00PM-3:00PM
Abstract Number: 1154
Axial Spondyloarthritis: Profiling of MiRNAs in Peripheral Blood Mononuclear Cells
1:00PM-3:00PM
Abstract Number: 1157
Bacterial Indole Associated with Spondyloarthritis-Related Dysbiosis Contributes to Enhanced Th17 Immunity
1:00PM-3:00PM
Abstract Number: 1457
Baseline Characteristics of a Longitudinal, Multinational, Multiethnic Study of Lupus Patients, with or Without Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 1416
Bioactive Lipid Profiling Can Identify Dynamic Biomarkers in Response to Biologic Therapy Result of the CorEvitas CERTAIN Comparative Effectiveness Study
1:00PM-3:00PM
Abstract Number: 1534
Blood Flow Assessment of Digital Arterioles and Capillaries in Systemic Sclerosis Patients Using Ultra-high Resolution Doppler Ultrasounds
1:00PM-3:00PM
Abstract Number: 1505
Blue-collar Workers with Psoriatic Arthritis: Disease Activity, Work Disability and Response to Biologics
1:00PM-3:00PM
Abstract Number: 1276
Bone Density Imaging: Evaluation of Equipment and Process of Care Quality in US Veterans
1:00PM-3:00PM
Abstract Number: 1525
Breakthrough Infections in COVID-19 Vaccinated Patients with Systemic Sclerosis: A Survival Analysis from a Multicenter International Patient-Reported Survey
1:00PM-3:00PM
Abstract Number: 1315
Building Stronger Bones: Optimizing Osteoporosis Screening at a Primary Care Clinic
1:00PM-3:00PM
Abstract Number: 1238
Can Thermal Imaging Help Clarify Joint Inflammation at Clinically Quiescent Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis?
1:00PM-3:00PM
Abstract Number: 1466
Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus: Comparison Between QRISK and aGAPSS Scores
1:00PM-3:00PM
Abstract Number: 1124
CD4+ Cytotoxic T Lymphocytes (CTL) Are Present in Sjögren’s Disease Minor Salivary Glands and Associate with Markers of Epithelial Cell Damage near Infiltrates
1:00PM-3:00PM
Abstract Number: 1572
CD40, BLK and BANK1 in the Pathogenesis of Immunoglobulin-A Vasculitis
1:00PM-3:00PM
Abstract Number: 1192
Celiac Disease in Patients with Systemic Lupus Erythematosus: An Analysis of Nationwide Inpatient Sample
1:00PM-3:00PM
Abstract Number: 1174
Cellular Immunotherapy for Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1418
Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry
1:00PM-3:00PM
Abstract Number: 1575
Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis
1:00PM-3:00PM
Abstract Number: 1259
Characteristics of Sacroiliac Joint in Patient with Skin Psoriasis, Without Rheumatological Manifestations: A Controlled Study Using CT Scan
1:00PM-3:00PM
Abstract Number: 1485
Characterization of Regulatory Receptors on Plasmacytoid Dendritic Cells in Lupus
1:00PM-3:00PM
Abstract Number: 1305
Characterizing Bone Microarchitecture with MRI in Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1234
Characterizing Imaging Phenotypes in PsA: The Effect of Age and Sex
1:00PM-3:00PM
Abstract Number: 1378
Childhood-onset Systemic Lupus Erythematosus: Long-term Outcomes in a Large Multi-ethnic Ontario Cohort
1:00PM-3:00PM
Abstract Number: 1144
Circulating miRNAs and Difficult-To-Treat Rheumatoid Arthritis: The Screening Study
1:00PM-3:00PM
Abstract Number: 1417
Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and First-Line TNF Inhibitor versus Abatacept Treatment Choice in Real-World Clinical Practice
1:00PM-3:00PM
Abstract Number: 1385
Clinical and Serologic Characterization of Juvenile Systemic Sclerosis Overlap Disease
1:00PM-3:00PM
Abstract Number: 1262
Clinical and Ultrasound-based Composite Disease Activity Indices and Radiographic Progression in Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1360
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
1:00PM-3:00PM
Abstract Number: 1529
Clinical Nailfold Capillaroscopy Using Dinolite Microscope in Patients with Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1341
Clinical Outcomes of COVID-19 Vaccination and Booster in Patients with Autoimmune Inflammatory Rheumatic Diseases
1:00PM-3:00PM
Abstract Number: 1576
Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis
1:00PM-3:00PM
Abstract Number: 1202
Clinical Profile and Trend of Vasculitis in Patients with Acute Coronary Syndrome – Insight from National Database 2010 to 2019
1:00PM-3:00PM
Abstract Number: 1465
Clinical Profiling and Antiphospholipid Antibody (aPL) Associations in Indian Systemic Lupus Erythematosus (SLE) Cohort
1:00PM-3:00PM
Abstract Number: 1491
Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance
1:00PM-3:00PM
Abstract Number: 1151
Colonic Organoids to Study the Role of HLA-B27 in Gastrointestinal Epithelial Biology
1:00PM-3:00PM
Abstract Number: 1563
Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Incomplete Behçet’s Disease
1:00PM-3:00PM
Abstract Number: 1205
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases
1:00PM-3:00PM
Abstract Number: 1284
Comparative Effectiveness Randomized Controlled Trials in Rheumatology Guidelines
1:00PM-3:00PM
Abstract Number: 1501
Comparative Profiling of Serum Protein Biomarkers and Disease Activity Across Various Disease Domains in Patients with Psoriatic Arthritis (PsA)
1:00PM-3:00PM
Abstract Number: 1395
Comparative Safety of Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Patients Undergoing Treatment for Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1392
Comparing Data on Rheumatoid Arthritis (RA) Disease Status Using Patient Reported Outcome Measures (PROMS) RAID/RAPID-3/Self-Reported DAS28 in Remote Electronic Monitoring During the COVID-19 Pandemic with Face-To-Face Clinical Evaluation (DAS28-CRP) Performed Pre-Pandemic
1:00PM-3:00PM
Abstract Number: 1555
Comparison Between Clinical Features, Acute Phase Reactants, Imaging Between Takayasu and LV-GCA Patients at Diagnosis and During Follow-up in Italian Patients in Monocentric Study
1:00PM-3:00PM
Abstract Number: 1141
Consequences of SLE Heterogeneity on the Epigenome and the Drivers Behind
1:00PM-3:00PM
Abstract Number: 1531
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON
1:00PM-3:00PM
Abstract Number: 1446
Contrast Enhaced Articular Magnetic Resonance Imaging (MRI) and Health Related Quality of Life in SLE Patients
1:00PM-3:00PM
Abstract Number: 1571
Coronary Arteritis and Periarteritis Secondary to IgG4-related Disease in a Large, Single-center Cohort
1:00PM-3:00PM
Abstract Number: 1412
Coronary Microvascular Dysfunction in Patients with Rheumatoid Arthritis and Diabetes Mellitus: A Cross-sectional Study with 13NH3 Myocardial PET/CT
1:00PM-3:00PM
Abstract Number: 1540
Correlations of Soluble Interleukin-2 Receptor Serum Levels with Markers of Inflammation and Pathological High-sensitivity Troponin T and Its Possible Role as a Predictor of Early Clinical Progress in Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1424
Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial
1:00PM-3:00PM
Abstract Number: 1312
Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in US Men at High Risk of Fracture
1:00PM-3:00PM
Abstract Number: 1328
CT Evaluation of Bone Fragility 2 Years After Bariatric Surgery in Patients with Obesity: An Observational Study
1:00PM-3:00PM
Abstract Number: 1538
Decreased Prevalence of Autoimmune Connective Tissue Diseases in Type 1 and Type 2 Diabetes
1:00PM-3:00PM
Abstract Number: 1180
Deficiency and Altered Phenotype of Mucosal-associated Invariant T Cells in Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1451
Delayed Sleep Phase Syndrome Characterizes Circadian Disorder in Patients with Active SLE
1:00PM-3:00PM
Abstract Number: 1481
Dementia in Adults with Systemic Lupus Erythematosus 65 Years of Age and Above: A National Administrative Claims Data Analysis
1:00PM-3:00PM
Abstract Number: 1486
Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis
1:00PM-3:00PM
Abstract Number: 1168
Dermal Fibroblast-derived Exosomes Drive Profibrotic Macrophage Activation in Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1494
Determinants of Clinically Important Worsening in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort over 5 Years
1:00PM-3:00PM
Abstract Number: 1366
Developing a Mobile App to Facilitate Disease Activity Assessment in Localized Scleroderma
1:00PM-3:00PM
Abstract Number: 1526
Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Risk Score
1:00PM-3:00PM
Abstract Number: 1291
Development and Pilot Implementation of a Predictive Model to Identify Visits Appropriate for Telehealth
1:00PM-3:00PM
Abstract Number: 1208
Development and Validation of a Prognostic Model for Methotrexate Discontinuation with Abnormal Monitoring Blood-test Results: A Cohort Study Using Data from Clinical Practice Research Datalink Gold and Aurum
1:00PM-3:00PM
Abstract Number: 1279
Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: A Literature Review and Modified Delphi Consensus Study
1:00PM-3:00PM
Abstract Number: 1273
Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: Data Availability and Preliminary Measure Performance in the RISE Registry
1:00PM-3:00PM
Abstract Number: 1380
Development of Core and Expanded Datasets to Align Registries and Advance International Collaborative Research for Childhood-onset Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1258
Development of International Consensus on a Standardized Image Acquisition Protocol for Diagnostic Evaluation of the Sacroiliac Joints by MRI – an ASAS-SPARTAN Collaboration
1:00PM-3:00PM
Abstract Number: 1561
Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement
1:00PM-3:00PM
Abstract Number: 1351
Development, Implementation, and Usability Testing of a New Rheumatoid Arthritis Patient-Reported Outcomes EHR-based Dashboard: A Mixed-Method Study
1:00PM-3:00PM
Abstract Number: 1188
Diabetes Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting
1:00PM-3:00PM
Abstract Number: 1230
Diabetes Mellitus Nailfold Capillaroscopy Pattern: DM Pattern
1:00PM-3:00PM
Abstract Number: 1507
Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Outcome Measures in Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1467
Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience
1:00PM-3:00PM
Abstract Number: 1337
Dietary Mineral Intake of an Inner-City Population and Its Impact on Disease Activity in Patients with SLE
1:00PM-3:00PM
Abstract Number: 1353
Dietary Practices and Beliefs of Patients with Rheumatic Diseases and Relationship with Symptoms: Results of a Multicenter Cross-sectional Study
1:00PM-3:00PM
Abstract Number: 1383
Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
1:00PM-3:00PM
Abstract Number: 1415
Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study
1:00PM-3:00PM
Abstract Number: 1158
Differential Plasma Levels of S100 Proteins in Male versus Female Patients with Ankylosing Spondylitis
1:00PM-3:00PM
Abstract Number: 1153
Differentially Expressed Genes in Males and Females with Ankylosing Spondylitis (AS): Transcriptomics of IL-17-producing Cells in Patients with AS
1:00PM-3:00PM
Abstract Number: 1487
Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
1:00PM-3:00PM
Abstract Number: 1364
Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the the Juvenile Scleroderma Inception Cohort
1:00PM-3:00PM
Abstract Number: 1565
Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet’s Disease
1:00PM-3:00PM
Abstract Number: 1556
Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
1:00PM-3:00PM
Abstract Number: 1171
Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease
1:00PM-3:00PM
Abstract Number: 1390
Distinct Patterns of Multimorbidity Are Associated with Longitudinal Disease Activity and Functional Status in a Multicenter, Prospective Rheumatoid Arthritis Cohort
1:00PM-3:00PM
Abstract Number: 1228
Distinctive Alterations in the Functional Anatomy of the Cerebral Cortex in Pain-sensitized Osteoarthritis and Fibromyalgia Patients
1:00PM-3:00PM
Abstract Number: 1496
Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?
1:00PM-3:00PM
Abstract Number: 1264
Does Vein Wall Thickness Have Prognostic Value in Behcet’s Disease? A Prospective Follow up Study
1:00PM-3:00PM
Abstract Number: 1169
Downregulated Fli1 in Systemic Sclerosis Myeloid Cells Contributes to Enhanced Transendothelial Migration
1:00PM-3:00PM
Abstract Number: 1195
Duloxetine and the Risk for Acute Myocardial Infarction and Stroke in Medicare Recipients with Non-Cancer Pain
1:00PM-3:00PM
Abstract Number: 1413
Early Muscle Involvement in Patients with Rheumatoid Arthritis: A Large-Scale Cross-Sectional Study
1:00PM-3:00PM
Abstract Number: 1354
Early Real-World Effectiveness of Upadacitinib in Rheumatoid Arthritis Using Patient-Reported Outcomes Collected via Mobile Application
1:00PM-3:00PM
Abstract Number: 1384
Echocardiographic Screening in Childhood Onset Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1376
Eculizumab Is Safe as an Adjunctive Therapy in Systemic Lupus Erythematosus with Severe Refractory Nephritis with or Without Thrombotic Microangiopathy in Children
1:00PM-3:00PM
Abstract Number: 1307
Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results from the FRAME Clinical Trial
1:00PM-3:00PM
Abstract Number: 1553
Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study
1:00PM-3:00PM
Abstract Number: 1435
Effectiveness of Combination Therapy with Tocilizumab and Low-Dose Prednisolone as an Induction Therapy in Biologics-Naïve Patients with Rheumatoid Arthritis: A Prospective, Randomized, Controlled, Open-Label, Multicenter Study
1:00PM-3:00PM
Abstract Number: 1547
Effectiveness of Interleukin-6 Receptor Inhibitors for Polymyalgia Rheumatica
1:00PM-3:00PM
Abstract Number: 1504
Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement
1:00PM-3:00PM
Abstract Number: 1508
Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging
1:00PM-3:00PM
Abstract Number: 1475
Epidemiology of Acute Ischemic Stroke in Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1175
Epigenetic Regulation of MicroRNA-126 in Scleroderma Is Associated with Upregulation of DNA Methyltransferase-1, Repression of Endothelial Nitric Oxide Synthase Expression, and Enhanced Platelet Adhesion to Endothelial Cells
1:00PM-3:00PM
Abstract Number: 1143
Epigenome-wide Analysis of Osteoarthritis in the Multicenter Osteoarthritis Study
1:00PM-3:00PM
Abstract Number: 1155
Epigenome-Wide Integrative Association Study on Spondyloarthritis and Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1229
Erosion Score and Erosive Joint Number Using Radiography: Clinical Implications in Patients with ACPA+ Early RA Treated with Abatacept
1:00PM-3:00PM
Abstract Number: 1483
Etiology of Elevated Serum Creatinine in Patients with Systemic Lupus Erythematosus at Presentation and Association of Crescents in Renal Biopsy with Rapidly Progressive Renal Failure in a Lupus Cohort
1:00PM-3:00PM
Abstract Number: 1268
Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program
1:00PM-3:00PM
Abstract Number: 1289
Evaluating Peri–operative Preferences of Bariatric Surgeons in the Management of Immunosuppressive Therapy During Bariatric Surgery
1:00PM-3:00PM
Abstract Number: 1568
Evaluation for Allogeneic Hematopoietic Stem Cell Transplant Indications and Eligibility in a Prospective Cohort of Patients with VEXAS
1:00PM-3:00PM
Abstract Number: 1182
Evaluation of Efficacy, Immunogenicity, and Toxicity of a Novel Drug Candidate for Scleroderma-associated Interstitial Lung Disease
1:00PM-3:00PM
Abstract Number: 1309
Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid
1:00PM-3:00PM
Abstract Number: 1459
Evolution of Subjective Cognitive Impairment Overtime in SLE Patients: Bayesian Longitudinal Item Response Theory Modelling
1:00PM-3:00PM
Abstract Number: 1123
Excess of Rare Deleterious Variants Within JAK-STAT Pathway – Related Genes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease
1:00PM-3:00PM
Abstract Number: 1164
Expanded CD8+ T Cell Clones from HLA-B*27-positive Patients with Spondyloarthritis Show Signs of Antigen-experience
1:00PM-3:00PM
Abstract Number: 1542
Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry
1:00PM-3:00PM
Abstract Number: 1334
Exploring Canadian Patient Experiences of Living with Lupus Nephritis (LN)
1:00PM-3:00PM
Abstract Number: 1462
Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 1265
External Validation of a Giant Cell Arteritis Probability Score (GCAPS) to Risk Stratify GCA Referrals: Experience from a United Kingdom Fast Track Clinic
1:00PM-3:00PM
Abstract Number: 1361
Factors Associated with Medication-Free Remission in Juvenile Dermatomyositis
1:00PM-3:00PM
Abstract Number: 1235
Fibroblast Activation in Psoriasis Patients Assessed by 68Ga-FAPI-04 PET-CT Is Associated with Progression to Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1197
Folic Acid and Methotrexate Use and Their Association with COVID-19 Diagnosis and Mortality: An Analysis from the UK Biobank
1:00PM-3:00PM
Abstract Number: 1322
Follow up of Incidentally Noted Vertebral Compression Fractures
1:00PM-3:00PM
Abstract Number: 1535
Frequency of Arrhythmias, Abnormal Electrocardiography and Sudden Cardiac Death in Systemic Sclerosis: A Systematic Review and Meta-analysis
1:00PM-3:00PM
Abstract Number: 1283
Frequency of Checking Creatine Kinase in Patients on Statins with Elevated Transaminase for Early Detection of Statin Induced Myopathy
1:00PM-3:00PM
Abstract Number: 1126
Functional NOTCH4 Variants Increase Notch Signaling and Susceptibility for Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1183
Functionally Distinct Fibroblast Populations in Systemic Sclerosis Skin Revealed by Explant Tissue Characterization and Single-cell RNAseq
1:00PM-3:00PM
Abstract Number: 1445
Gastrointestinal Manifestations in Systemic Lupus Erythematosus Are Associated with High Disease Activity and Mortality: A Nationwide Cohort Study from India
1:00PM-3:00PM
Abstract Number: 1219
Gender-Related Clinical Profile of Fibromyalgia Patients
1:00PM-3:00PM
Abstract Number: 1539
Gene Expression Meta-Analysis Reveals Aging and Cellular Senescence Signatures in Scleroderma-associated Interstitial Lung Disease
1:00PM-3:00PM
Abstract Number: 1146
Genetic Interactions Between T-Cell Receptor Polymorphisms and HLA Amino Acids Contribute to the Risk of Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1134
Genome-wide Association Study Identifies Novel Loci for Leukopenia Among TPMT and NUDT15 Normal Metabolizers Taking Azathioprine
1:00PM-3:00PM
Abstract Number: 1125
Genomics of JAK-STAT Signaling in Venous Thromboembolism
1:00PM-3:00PM
Abstract Number: 1304
Glucocorticoids Affect Bone Mass and Strength by Inhibiting Osteoprogenitor Cell Maturation
1:00PM-3:00PM
Abstract Number: 1253
Gray Intensity Ratio Indices as a Method of Discrimination Between Changes Induced by Sport and by Spondyloarthritis in Load-bearing Entheses
1:00PM-3:00PM
Abstract Number: 1148
GWAS Identified New Genes in Synovial Fibroblasts Linked to Early Remission in RA
1:00PM-3:00PM
Abstract Number: 1381
Health Related Quality of Life in Children with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1403
Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study
1:00PM-3:00PM
Abstract Number: 1490
High Throughput Transcriptomic Analysis of Peripheral Mononuclear Cells Identifies Molecular Alterations Associated with the Active Clinical Phenotype of Axial Spondyloarthritis
1:00PM-3:00PM
Abstract Number: 1181
Hippo Pathway Effectors Promote and Maintain Myofibroblast Differentiation and Endothelial-to-mesenchymal Transition in Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1299
Hitting the Target Together: Supporting Shared Decision-Making with Juvenile Idiopathic Arthritis (JIA) Patients Followed in the Out-Patient Rheumatology Setting at the Hospital for Sick Children
1:00PM-3:00PM
Abstract Number: 1368
How Common Is the Coexistence of Juvenile Localized and Systemic Scleroderma? Results of a Multination Survey
1:00PM-3:00PM
Abstract Number: 1516
How Disease Activity Can Affect Workability in Spondyloarthropaties: A Monocentric Cohort Analysis
1:00PM-3:00PM
Abstract Number: 1495
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
1:00PM-3:00PM
Abstract Number: 1497
How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab
1:00PM-3:00PM
Abstract Number: 1288
How Often Do We Provide Relevant and Patient Centric Discharge Instructions in Rheumatology? A Single Academic Center Clinic Experience
1:00PM-3:00PM
Abstract Number: 1177
Identification of a New Type of Pro-phagocytic Macrophages in Patients with Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1394
Identification of Joint Locations in an Early Rheumatoid Arthritis Cohort as a Characteristic of Disease Severity: DATA from the ERA-UCLouvain Brussels Cohort
1:00PM-3:00PM
Abstract Number: 1513
Identification of MRI Lesions Indicative of Spondyloarthritis Diagnosis from the Axial Spondyloarthritis International Society (ASAS) MRImagine Multi-Reader Scoring Dataset Using the Chi-Squared Automatic Interaction Detection Algorithm (CHAID)
1:00PM-3:00PM
Abstract Number: 1130
Identification of Novel Molecular Signatures Associated with the Therapeutic Response to DMARDs and TNFi Therapies in Rheumatoid Arthritis Patients Through High Throughput Proteomics
1:00PM-3:00PM
Abstract Number: 1215
Identifying a Pain Signature in Classical Ehlers-Danlos Syndrome: Preliminary Results from Questionnaires and Experimental Pain Testing
1:00PM-3:00PM
Abstract Number: 1161
IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1245
Imaging Use and Medication Management in Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 1327
Immune Cell Subsets and Risk of Incident Hip Fracture in Older Adults: The Cardiovascular Health Study
1:00PM-3:00PM
Abstract Number: 1548
Immune Cells Are Highly Disturbed in Polymyalgia Rheumatica Patients
1:00PM-3:00PM
Abstract Number: 1455
Immune Thrombocytopenic Purpura and Subsequent Development of Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1212
Immunogenicity After Primary COVID-19 Vaccination in Patients with Immune-mediated Inflammatory Diseases: A Comparative Cohort Study
1:00PM-3:00PM
Abstract Number: 1176
Immunoglobulins G from Systemic Sclerosis Patients May Alter the Secretome of Dermal Fibroblasts
1:00PM-3:00PM
Abstract Number: 1409
Impact of a Hybrid Medical Care Model in the Rheumatoid Arthritis Patient-Reported Outcomes: A Non-inferiority Crossover Randomized Study
1:00PM-3:00PM
Abstract Number: 1263
Impact of Cardiovascular Risk on the Diagnostic Accuracy of the Ultrasound Halo Score for Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 1211
Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of RA Patients
1:00PM-3:00PM
Abstract Number: 1209
Impact of Change in Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients
1:00PM-3:00PM
Abstract Number: 1326
Impact of COVID-19 Severity on Bone Mineral Density, Sarcopenia and Physical Performance Among Older Adults Following Hospitalization: A Pilot Study
1:00PM-3:00PM
Abstract Number: 1330
Impact of COVID-19 Severity on Physical Function, Mobility, Falls and Fractures Among Older Patients After Hospitalization: A Longitudinal Study
1:00PM-3:00PM
Abstract Number: 1577
Impact of Cutaneous Vasculitis on Health-Related Quality-of-Life
1:00PM-3:00PM
Abstract Number: 1493
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry
1:00PM-3:00PM
Abstract Number: 1300
Impact of Demographics and Health Literacy on Transition Readiness for Adolescents with Rheumatic Disease
1:00PM-3:00PM
Abstract Number: 1227
Impact of Pain Sensitivity and Expectations on Predicting Response to Acupuncture in Fibromyalgia
1:00PM-3:00PM
Abstract Number: 1363
Impact of SARS-CoV-2 on the Clinical Presentation of Juvenile Idiopathic Inflammatory Myopathies
1:00PM-3:00PM
Abstract Number: 1339
Impact of the COVID-19 Pandemic on Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
1:00PM-3:00PM
Abstract Number: 1450
Impact of Time to Remission, Flares and Time on Immunosuppressives on the Estimated Glomerular Filtration Rate in Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 1431
Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1427
Impact of Upadacitinib versus Abatacept on Individual Disease Outcomes in Patients with Rheumatoid Arthritis and Inadequate Responses to Biologic DMARDs
1:00PM-3:00PM
Abstract Number: 1296
Impacting Demand Through Supply: An Evaluation of the Types of Pediatric Rheumatology Referrals at a Single Institution
1:00PM-3:00PM
Abstract Number: 1269
Implementing RAPID-3 Using Electronic Patient Portal and Point of Care Entry
1:00PM-3:00PM
Abstract Number: 1162
Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthritis After One Year of Biological Treatment
1:00PM-3:00PM
Abstract Number: 1352
Improving Completion Rates of Routine Mental Health Screening for Depression and Anxiety in Paediatric Lupus Outpatient Clinic to Enhance Patient Mental Health Care
1:00PM-3:00PM
Abstract Number: 1306
Improving Osteoporosis Screening in Individuals of Color
1:00PM-3:00PM
Abstract Number: 1277
Improving Patient Appropriate Osteoporosis Screening with Dual Energy X-ray Absorptiometry Scans in an Academic Internal Medicine Practice
1:00PM-3:00PM
Abstract Number: 1274
Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
1:00PM-3:00PM
Abstract Number: 1246
Improving Radiologic Interpretation of Diffuse Lung Disease in Pediatric Rheumatologic (PR) Patients Using Trained Scoring with Semi-quantitative Chest Computed Tomography (CT) Analysis
1:00PM-3:00PM
Abstract Number: 1405
In Contrast to Anti-CCP, Then MMP Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and Treatment Response Biomarker
1:00PM-3:00PM
Abstract Number: 1408
In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Traditional Risk Factors: A 20-year Follow up in the CARRÉ Cohort Study
1:00PM-3:00PM
Abstract Number: 1214
In-hospital Outcomes of Autoimmune Diseases Complicated by Interstitial Lung Disease: A National Inpatient Sample Analysis
1:00PM-3:00PM
Abstract Number: 1391
Inadequate Cardiovascular Disease Risk Screening and Preventative Treatment in Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1422
Incidence and Determinants of Infection in Rheumatoid Arthritis (RA) Patients (Pts) Treated with Subcutaneous Golimumab (GLM) in Canadian Real-World Practice
1:00PM-3:00PM
Abstract Number: 1449
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
1:00PM-3:00PM
Abstract Number: 1489
Incidence of Herpes Zoster Events After the Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis
1:00PM-3:00PM
Abstract Number: 1244
Incidence of Radiographic Spinal Damage in Psoriatic Arthritis Patients Compared to Spondyloarthritis Patients: Which Patients Are More Affected?
1:00PM-3:00PM
Abstract Number: 1545
Increased Neutrophil Activation in Patients with Polymyalgia Rheumatica
1:00PM-3:00PM
Abstract Number: 1373
Increased Patient Contact May Mitigate Flares Among jSLE Patients
1:00PM-3:00PM
Abstract Number: 1286
Increasing Biosimilar Uptake in the Rheumatology Clinics Within a Large Academic Medical Center
1:00PM-3:00PM
Abstract Number: 1488
Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study
1:00PM-3:00PM
Abstract Number: 1290
Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage and Patient Distress Are as Prominent in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist
1:00PM-3:00PM
Abstract Number: 1399
Inflammatory Arthritis Genetic Risk Factors to Predict Treatment Patterns in Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1129
Integrated High-throughput Proteomics and Machine Learning Analysis in Systemic Lupus Erythematosus Patients Identify Distinctive Clinical Profiles and Novel Biomarkers Related to Cardiovascular Risk and Lupus Nephropathy
1:00PM-3:00PM
Abstract Number: 1131
Integrating Genome and Transcriptome-Wide Associations with Real-World Data to Assess Risk for Leukopenia in Patients Taking Azathioprine
1:00PM-3:00PM
Abstract Number: 1406
Integrative Multi-omic Phenotyping in Blood Identifies Molecular Signatures and Candidate Biomarkers of ACPA-negative Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1196
Interaction of Cumulative Inflammation with Smoking and Lipids in Risk Modification of Dementia Among Patients with Rheumatoid Arthritis: A Population-based Cohort Study
1:00PM-3:00PM
Abstract Number: 1132
Interaction of LOC100507053, ADH1B, and ADH1C with Alcohol Consumption for Elevated Serum Urate Levels and Gout in People of European Ethnicity
1:00PM-3:00PM
Abstract Number: 1185
Interleukin-11 Promotes Fibrosis Through Classic and Trans-signaling Pathway in Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1252
Interrater Agreement of Hand Ultrasounds in Inflammatory Arthritis
1:00PM-3:00PM
Abstract Number: 1440
Interrelation of T-cell Cytokines and Autoantibodies in Lupus Nephritis: A Cross-sectional Study
1:00PM-3:00PM
Abstract Number: 1184
Intracellular Calcium Signals Regulate the Pro-fibrotic Phenotype of Scleroderma Fibroblasts via Calcium/calmodulin-dependent Kinase II
1:00PM-3:00PM
Abstract Number: 1121
Intricate Roles of Low Gene Copy Numbers for Complement C4, C4A Deficiency and HLA-DRB1*03 as Genetic Risk Factors for Myositis, Its Subgroups and Autoantibodies
1:00PM-3:00PM
Abstract Number: 1119
Investigating Macrophage Heterogeneity in the Esophagus and Lungs of SSc Patients
1:00PM-3:00PM
Abstract Number: 1500
Investigating Serum Lipids Classifying Psoriatic Arthritis Disease Activity Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry
1:00PM-3:00PM
Abstract Number: 1550
Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
1:00PM-3:00PM
Abstract Number: 1503
Is Inflammation-driven Bone Loss Associated with Two-year Bone Formation at the Same Vertebra in Axial Spondyloarthritis? – a Multilevel MRI and Low Dose CT Analysis from the Sensitive Imaging of Axial Spondyloarthritis (SIAS) Cohort
1:00PM-3:00PM
Abstract Number: 1544
Is It Possible to Evaluate Polymyalgia Rheumatica Without C-reactive Protein? Concordance and Agreement Between Different PMR Activity Scores in Polymyalgia Rheumatica
1:00PM-3:00PM
Abstract Number: 1480
Is Lupus Podocytopathy a New Variant of Lupus Nephritis?
1:00PM-3:00PM
Abstract Number: 1345
Is Perceived Stress Associated with COVID-19 or Having a Systemic Rheumatic Disease?
1:00PM-3:00PM
Abstract Number: 1310
Is the Trabecular Bone Score (TBS) a Useful Tool in Patients with Diffuse Idiopathic Skeletal Hyperostosis (DISH)?
1:00PM-3:00PM
Abstract Number: 1511
Is There a Correlation Between Skin and Musculoskeletal Activity in Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1293
Is Virtual Care Here to Stay? : Rheumatology Patients’ Satisfaction in Early vs Late Pandemic
1:00PM-3:00PM
Abstract Number: 1285
Joint Injection Workflow in Rheumatology – an Opportunity to Improve Efficiency and Physician Satisfaction
1:00PM-3:00PM
Abstract Number: 1382
Juvenile Eosinophilic Fasciitis: A Single-Center Cohort
1:00PM-3:00PM
Abstract Number: 1371
Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1178
Key Features of Human Fibrosing Interstitial Lung Disease Are Captured in a Preclinical Mouse Model upon Repetitive, but Not Single Intratracheal Bleomycin Dosing
1:00PM-3:00PM
Abstract Number: 1194
Key Self-reported Determinants of COVID-19 Vaccine Acceptance Among Persons with and Without Autoimmune Disease
1:00PM-3:00PM
Abstract Number: 1402
Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry
1:00PM-3:00PM
Abstract Number: 1482
Latent Tuberculosis Infection and Its Associations with Clinical and Serological Parameters in Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1456
Latin-American Systemic Lupus Erythematosus Clusters
1:00PM-3:00PM
Abstract Number: 1281
Less Than Half of Cryoglobulin Tests Ordered at a Tertiary Hospital Network Are Successfully Completed: An Opportunity for Improvement
1:00PM-3:00PM
Abstract Number: 1559
Long Term Clinical Effects of Apremilast on Behcet’s Disease and Changes in Serum Cytokines
1:00PM-3:00PM
Abstract Number: 1578
Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
1:00PM-3:00PM
Abstract Number: 1521
Long-term Follow-Up of Participants of the Phase II Study That Evaluated Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis (ASSET Trial)
1:00PM-3:00PM
Abstract Number: 1423
Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting
1:00PM-3:00PM
Abstract Number: 1407
Longitudinal Lipid Profile and NT-proBNP Changes from Pre-clinical to Established Rheumatoid Arthritis: A 12 Years Follow up Explorative Study
1:00PM-3:00PM
Abstract Number: 1318
Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on Bone Mineral Density: Baseline Findings in a Cohort of Rheumatic Disease Patients with Prior Glucocorticoid Exposure
1:00PM-3:00PM
Abstract Number: 1393
Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA Prospective Study
1:00PM-3:00PM
Abstract Number: 1569
Lung Involvement in VEXAS Syndrome
1:00PM-3:00PM
Abstract Number: 1247
Lung Ultrasound in Patients with Connective Tissue Disease-associated Interstitial Lung Disease; Utility of Single Evaluation in Clinical Practice
1:00PM-3:00PM
Abstract Number: 1443
Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features
1:00PM-3:00PM
Abstract Number: 1439
Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections
1:00PM-3:00PM
Abstract Number: 1400
Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1404
Machine Learning Model to Accurately Identify Rheumatoid Arthritis Patients Using Raw Electronic Health Record Data
1:00PM-3:00PM
Abstract Number: 1527
Maintained Complete B Cell Depletion Is Associated with Rituximab Efficacy in Connective Tissue Disorder Interstitial Lung Disease
1:00PM-3:00PM
Abstract Number: 1484
Management of the Heightened Risk for Clinical Events from Atherosclerotic Cardiovascular Disease (ASCVD) in an Established Cohort of Lupus Erythematosus Patients
1:00PM-3:00PM
Abstract Number: 1160
Mapping Spondyloarthritis Susceptibility Loci in B10.RIII Mice
1:00PM-3:00PM
Abstract Number: 1270
MDHAQ/RAPID3 Is a Feasible Tool to Estimate High Comorbid Fatigue and Residual Fatigue in Rheumatoid Arthritis Patients
1:00PM-3:00PM
Abstract Number: 1570
Memory CD4+T Cell Signature Is Associated with Unfavorable Prognosis in IgG4-related Disease: Risk Stratification by Machine-learning
1:00PM-3:00PM
Abstract Number: 1377
Mental Health Screening in Juvenile Myositis: Preliminary Analysis of a Multicenter Pilot Study
1:00PM-3:00PM
Abstract Number: 1137
MHC Class I Polypeptide-Related Sequence a Variant Predicts Real-World Response to Anti-TNF Therapy
1:00PM-3:00PM
Abstract Number: 1557
Microvascular Involvement in Behçet’s Disease: Study of Nailfold Capillaroscopy in Patients from a National Referral Center
1:00PM-3:00PM
Abstract Number: 1510
Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries
1:00PM-3:00PM
Abstract Number: 1560
Modulation of NKG2D Expression on NK, NKT and CD8+ T Lymphocytes by in Vitro Treatments of Immune Cells from Patients with Behçet Disease
1:00PM-3:00PM
Abstract Number: 1428
Molecular and Clinical Profiling of Rheumatoid Arthritis Patients Predicts the Response to Rituximab
1:00PM-3:00PM
Abstract Number: 1139
Molecular Pathways Identified from Risk Alleles Identify Mechanistic Differences in Systemic Lupus Erythematosus Patients of East Asian and European Ancestry
1:00PM-3:00PM
Abstract Number: 1118
Monocyte Transcriptomic Analysis Uncovers Heterogeneous Gene Expression Profiles in Systemic Lupus Erythematous (SLE) with and Without Subclinical Atherosclerosis
1:00PM-3:00PM
Abstract Number: 1541
MRI Digital Artery Volume Index (DAVIX) Predicts Future Digital Ulcers and Disease Progression in Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1221
Multi-Center Validation of Cell-Bound Complement Activation Products and a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia
1:00PM-3:00PM
Abstract Number: 1506
Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study
1:00PM-3:00PM
Abstract Number: 1190
Multimorbidity in Systemic Sclerosis: Burden and Trends in Prevalence from an Incident Population-based Cohort (1980-2018)
1:00PM-3:00PM
Abstract Number: 1398
Myokine Myostatin Is a Novel Predictor of One-year Radiographic Progression in Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1189
Natural Language Processing of Chest CT Reports as a Novel Method of Identifying RA-ILD in Real-World Data
1:00PM-3:00PM
Abstract Number: 1460
Neuropsychiatric Lupus in Late and Early Onset Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-analysis
1:00PM-3:00PM
Abstract Number: 1528
Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial
1:00PM-3:00PM
Abstract Number: 1340
Nutrition-Related Behaviors and Beliefs – A Survey of Rheumatic Disease Patients
1:00PM-3:00PM
Abstract Number: 1187
Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters by Obesity Status in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting
1:00PM-3:00PM
Abstract Number: 1566
Outcome of Vascular Involvement of Behçet Syndrome Treated with Infliximab: A Retrospective Cohort Study
1:00PM-3:00PM
Abstract Number: 1420
Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
1:00PM-3:00PM
Abstract Number: 1165
Pathogenicity of IL-17 Producing Cells in HLA-B27 Transgenic Rat Model of Spondyloarthritis
1:00PM-3:00PM
Abstract Number: 1367
Patient and Physician Reported Outcomes of Juvenile Systemic Sclerosis Patients Significantly Improve over 12 Months Observation Period in the Juvenile Systemic Scleroderma Inception Cohort
1:00PM-3:00PM
Abstract Number: 1509
Patient Clusters Identified by Machine Learning from a Pooled Analysis of the Clinical Development Program of Secukinumab in Psoriatic Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis with Axial Manifestations
1:00PM-3:00PM
Abstract Number: 1333
Patient Perceptions of Rheumatoid Arthritis Blood Work: A Cross-sectional Survey in the ArthritisPower Registry
1:00PM-3:00PM
Abstract Number: 1356
Patient-perceived Disease Burden and Self-reported Medication Adherence in Systemic Autoimmune Diseases: A Monocentric Observational Study
1:00PM-3:00PM
Abstract Number: 1344
Patient-reported Outcomes in Lupus Low Disease Activity State: Impact of Fatigue
1:00PM-3:00PM
Abstract Number: 1464
Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations
1:00PM-3:00PM
Abstract Number: 1444
Patients with Lupus Pericarditis Have the Impact on the Poor Survival Outcome: A Retrospective Cohort Study
1:00PM-3:00PM
Abstract Number: 1280
Patients with Systemic Lupus Erythematosus Perceive the Quality of Care They Receive to Be Suboptimal
1:00PM-3:00PM
Abstract Number: 1338
Patients’ Perspectives and Experiences of Medication Use in Osteoporosis – a Qualitative Systematic Review and Thematic Synthesis
1:00PM-3:00PM
Abstract Number: 1452
Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis
1:00PM-3:00PM
Abstract Number: 1298
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Outcome Improvement for Children with Juvenile Idiopathic Arthritis
1:00PM-3:00PM
Abstract Number: 1320
Performance of FRAX® Brazil and NOGG Methodology with and Without Bone Mineral Density upon Predicting Fractures on a Community-Dwelling Elderly Population with High Incidence of Osteoporotic Fractures: The São Paulo Ageing and Health (SPAH) Study
1:00PM-3:00PM
Abstract Number: 1432
Pharmacokinetic Evaluation of a Proposed Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product: Results of a Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial in Healthy Subjects
1:00PM-3:00PM
Abstract Number: 1421
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of a Proposed Tocilizumab Biosimilar (MSB11456) versus US‑licensed Tocilizumab: Results of a Randomized, Double-blind, Parallel‑group, Single‑intravenous Dose Study in Healthy Adults (APTURA II)
1:00PM-3:00PM
Abstract Number: 1250
Physiologic Adaptive Change of the Patellar and Achilles Tendons: Sensitivity to Change Detected by Computer Analysis of Sequential Static Images
1:00PM-3:00PM
Abstract Number: 1303
Planning Transition in Times of Transition: Is There a Virtual Pathway from Pediatric to Adult Care?
1:00PM-3:00PM
Abstract Number: 1275
Pneumococcal Vaccination Compliance Rate Among Lupus and Rheumatoid Arthritis Patients in Rheumatology Fellow’s Cllinic
1:00PM-3:00PM
Abstract Number: 1347
Poor Health-Related Quality of Life in Patients with Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 1282
Practice Patterns for Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Among Nephrologists and Rheumatologists – an International Survey Study
1:00PM-3:00PM
Abstract Number: 1436
Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1411
Predictors of Achieving Clinical Remission in ACPA-positive RA-patients Treated with Abatacept and Methotrexate or Methotrexate Monotherapy
1:00PM-3:00PM
Abstract Number: 1453
Prevalence and Associations of Myositis in an Indian Inception Cohort of Lupus
1:00PM-3:00PM
Abstract Number: 1218
Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry
1:00PM-3:00PM
Abstract Number: 1477
Prevalence and Risk Factors of Fragility Fractures in Systemic Lupus Erythematosus: A Longitudinal Study over 12 Years
1:00PM-3:00PM
Abstract Number: 1308
Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study
1:00PM-3:00PM
Abstract Number: 1329
Prevalence of Bone Fragility on DXA and CT in Patients with Obesity
1:00PM-3:00PM
Abstract Number: 1441
Prevalence of Secondary Connective Tissue Diseases and Autoantibodies Among Racial and Ethnic Groups in Systemic Lupus Erythematosus Patients in the Manhattan Lupus Surveillance Program
1:00PM-3:00PM
Abstract Number: 1558
Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain
1:00PM-3:00PM
Abstract Number: 1518
Prevalence, Risk Factors and Treatment Patterns of Digital Ischemic Complications in Systemic Sclerosis: A Single Center Cross-Sectional Study
1:00PM-3:00PM
Abstract Number: 1349
Priority Educational Topics to Deliver Information About Immune Checkpoint Inhibitors for Patients with Cancer and a Pre-Existing Autoimmune Disease
1:00PM-3:00PM
Abstract Number: 1336
Productivity Analysis in Patients with Idiopathic Inflammatory Myopathies and Relationship with Quality of Life and Emotional Domain: Preliminary Data from a Monocentric Cohort
1:00PM-3:00PM
Abstract Number: 1319
Prognostic Utility of Metacarpal Bone Mineral Density Measurement in Patients with Recent-onset Arthritis by Assessment of Radiographic Progression at 2-year Follow Up
1:00PM-3:00PM
Abstract Number: 1536
Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages in Systemic Sclerosis Patients from EUSTAR
1:00PM-3:00PM
Abstract Number: 1163
Proteomic Investigation to Identify Urinary Biomarker for Ankylosing Spondylitis
1:00PM-3:00PM
Abstract Number: 1537
Proteomic Profiling of Plasma Microvesicles Isolated from Patients with Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1342
Quality Improvement: Communicating Risk Regarding JAK Inhibitor Use in Rheumatology Patients
1:00PM-3:00PM
Abstract Number: 1474
Quinolinic Acid, a Kynurenine/Tryptophan Pathway Metabolite, Correlates with Abnormalities in Brain Structure and Function in SLE
1:00PM-3:00PM
Abstract Number: 1552
Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis
1:00PM-3:00PM
Abstract Number: 1374
Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study
1:00PM-3:00PM
Abstract Number: 1387
Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe
1:00PM-3:00PM
Abstract Number: 1236
Reduced Inflammation Following 4-weeks TNF-α Inhibitor Treatment Restore Aberrant Cerebral Pain Processing in Rheumatoid Arthritis Patients: A Randomized Double-Blind Placebo-Controlled fMRI Study
1:00PM-3:00PM
Abstract Number: 1567
Refractory Macular Edema Due to Behçet’s Disease. Multicenter Comparative Study of Adalimumab and Certolizumab Pegol
1:00PM-3:00PM
Abstract Number: 1401
Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
1:00PM-3:00PM
Abstract Number: 1355
Relationships Between Work Productivity, Activity Impairment, and Select Patient-Reported Outcomes in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of Two Placebo-Controlled Trials
1:00PM-3:00PM
Abstract Number: 1232
Reliability and Validity of Single Axial Slice vs. Multiple Slice Quantitative Measurement of the Volume of Effusion-Synovitis on 3T Knee MRI in Knees with Osteoarthritis
1:00PM-3:00PM
Abstract Number: 1301
Reliable Transition Policy Distribution and Transition Readiness Assessment Questionnaire Completion Using a Digital Intervention in a Pediatric Rheumatology Clinic
1:00PM-3:00PM
Abstract Number: 1543
Resolution of PMR Signs and Symptoms in Patients Treated with Sarilumab: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR) in Relapsing PMR
1:00PM-3:00PM
Abstract Number: 1314
Response Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Density with Abaloparatide in Men: Results from the ATOM Study
1:00PM-3:00PM
Abstract Number: 1434
Retrospective Analysis of Tocilizumab-induced Neutropenia in Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1255
Rheumatologists Overcall Sacroiliitis on X-ray and MRI in Axial Spondyloarthritis Patients: Data from the BelGian Inflammatory Arthritis and SpoNdylitis cohorT (Be-GIANT)
1:00PM-3:00PM
Abstract Number: 1469
Risk Factors for Herpes Zoster Among Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1524
Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort
1:00PM-3:00PM
Abstract Number: 1207
Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid
1:00PM-3:00PM
Abstract Number: 1331
Risk Factors for Osteoporotic Fracture in Women with Established Long-Term Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1396
Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
1:00PM-3:00PM
Abstract Number: 1520
Rituximab and Tocilizumab and Their Effect on Lung Disease Progression in Scleroderma. a Retrospective Cohort Study at a Single Centre
1:00PM-3:00PM
Abstract Number: 1442
Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1343
Satisfaction with Rheumatoid Arthritis Care Is Related to Discordance with Providers’ Treatment Goals and Patients’ Reasons for Disagreement
1:00PM-3:00PM
Abstract Number: 1166
Scleroderma Fibroblasts Induce Alternative Macrophage Activation via an ERK1/2-dependent Mechanism
1:00PM-3:00PM
Abstract Number: 1530
Scleroderma Renal Crisis: Time to Initiation of Therapy Does Not Affect Mortality
1:00PM-3:00PM
Abstract Number: 1261
Scoring Structural Damage in Rheumatoid Arthritis by Ultrasound: Results from a Delphi Process and Web-Based Reliability Exercise by the OMERACT Ultrasound Working Group
1:00PM-3:00PM
Abstract Number: 1193
Seasonal Variation of Hospitalizations and In-Hospital Mortality Related to Systemic Lupus Erythematosus Among Adults in the United States: An Analysis of Nationwide Inpatient Sample
1:00PM-3:00PM
Abstract Number: 1323
Secondary Prevention of Vertebral Fractures Sustained Efficacy over Time
1:00PM-3:00PM
Abstract Number: 1514
Self-referral Strategy for Early Diagnosis of Axial Spondyloarthritis- Preliminary Analysis from Finding Axial Spondyloarthritis Study
1:00PM-3:00PM
Abstract Number: 1554
Serum Biomarkers in Association with Clinical and Vascular Disease Activity in Takayasu’s Arteritis
1:00PM-3:00PM
Abstract Number: 1447
Serum Cytokine Profiling Reveals Elevated Levels of S100A8/A9 and MMP-9 in Systemic Lupus Erythematosus Patients with Cognitive Impairment Independently of Disease Activity and Inflammatory Markers
1:00PM-3:00PM
Abstract Number: 1156
Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in Patients with Active Ankylosing Spondylitis (AS) and Persists Despite Anti-TNF Treatment
1:00PM-3:00PM
Abstract Number: 1122
Short Peripheral Blood Leukocyte Telomere Length in Rheumatoid Arthritis – Interstitial Lung Disease
1:00PM-3:00PM
Abstract Number: 1463
Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria
1:00PM-3:00PM
Abstract Number: 1375
Short-term Efficacy of Baricitinib in Children with Refractory And/or Severe Juvenile Dermatomyositis
1:00PM-3:00PM
Abstract Number: 1249
Short-term Variations in Subchondral Tibial Bone Texture of Conventional X-Rays Predicts Knee Osteoarthritis Progression
1:00PM-3:00PM
Abstract Number: 1179
Single Cell RNA Sequencing Analysis of Cryopreserved versus Fresh Skin Biopsy Samples from Systemic Sclerosis Patients and Healthy Controls
1:00PM-3:00PM
Abstract Number: 1173
Single-cell Multi-omic Analysis of a 3D Skin-Like Tissue Model Provides Insights into Molecular and Cellular Drivers of Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1150
Spatial Transcriptomics Stratifies Health and Psoriatic Disease Severity by Emergent Cellular Ecosystems
1:00PM-3:00PM
Abstract Number: 1225
Sphygmomanometry for Fibromyalgia Detection in a Rheumatology Outpatient Clinic. a Cross-sectional Study
1:00PM-3:00PM
Abstract Number: 1136
Stratification of Systemic Lupus Erythematosus (SLE) Patients Based on the Molecular Patterns of Mouse Models
1:00PM-3:00PM
Abstract Number: 1410
Subclinical Atherosclerosis Is Not Related with Acid Uric in Rheumatoid Arthritis: Study of 1005 Patients of a Single University Hospital
1:00PM-3:00PM
Abstract Number: 1216
Subclinical Vascular Disease Is More Prevalent in above-30 Adult Fibromyalgia: A Preliminary Report of a Hospital-based Cross-sectional Study from South India
1:00PM-3:00PM
Abstract Number: 1369
Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting
1:00PM-3:00PM
Abstract Number: 1321
Systemic Inflammatory-based Scores and Bone Turnover Ratio as Novel Diagnostic Tools for Chronic Nonbacterial Osteomyelitis (CNO) of the Sternocostoclavicular Region in Adults
1:00PM-3:00PM
Abstract Number: 1458
Systemic Lupus Erythematosus (SLE) Patients with Cognitive Impairment Experience More Fatigue Compared to Patients Without Impairment
1:00PM-3:00PM
Abstract Number: 1170
Systemic Sclerosis Dermal Fibroblast-derived Exosomes Trigger a Type 1 Interferon Rresponse in Keratinocytes Through TBK1
1:00PM-3:00PM
Abstract Number: 1295
Targeting Barriers That Prevent Contraception Counseling in an Academic Rheumatology Practice
1:00PM-3:00PM
Abstract Number: 1372
Telemedicine Use in the Assessment of Juvenile Dermatomyositis and Polymyositis: A Survey of Caregivers and Patients
1:00PM-3:00PM
Abstract Number: 1292
Telemedicine’s Impact on Radiologic Ordering in an Academic Rheumatology Practice During the COVID-19 Pandemic
1:00PM-3:00PM
Abstract Number: 1260
Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1357
The ANCA-Associated Vasculitis Patient-Reported Outcome (AAV-PRO) Captures Depression and Health-Related Quality of Life More Than Disease Activity and Damage
1:00PM-3:00PM
Abstract Number: 1203
The Association Between Anti-Citrullinated Peptide Antibodies and Subclinical Interstitial Lung Disease in Community-Dwelling Adults: The Multi-Ethnic Study of Atherosclerosis
1:00PM-3:00PM
Abstract Number: 1498
The Association Between Sonographic Enthesitis with Sonographic Synovitis and Tenosynovitis in Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1386
The Association of Depression with Executive Function Skills and Health-Related Quality of Life in Youth with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1128
The Causal Association Between Osteoarthritis and Common Comorbidities: A Mendelian Randomisation Study
1:00PM-3:00PM
Abstract Number: 1522
The Collaborative National Quality and Efficacy Registry for Scleroderma: Association of Medication Use on Gastrointestinal Tract Symptoms in Early Disease
1:00PM-3:00PM
Abstract Number: 1317
The Epidemiology of Old versus Young Males Referred for BMD Assessment
1:00PM-3:00PM
Abstract Number: 1461
The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocytopenic Purpura: A Systematic Meta-analysis
1:00PM-3:00PM
Abstract Number: 1499
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry
1:00PM-3:00PM
Abstract Number: 1397
The Impact of Disease Activity on Patient-Reported Cognitive Dysfunction in Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1243
The Impact of MRI Slice Thickness on the Detection of Spinal Syndesmophytes in Axial Spondyloarthritis
1:00PM-3:00PM
Abstract Number: 1142
The Lupus Risk Allele Associated Xq28 Haplotype Identifies the Molecular Endotype of a Cohort of European SLE Patients with Enhanced IRAK1 Signaling
1:00PM-3:00PM
Abstract Number: 1389
The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors
1:00PM-3:00PM
Abstract Number: 1532
The Primary Cardiomyopathy of Systemic Sclerosis on Cardiovascular Magnetic Resonance Imaging
1:00PM-3:00PM
Abstract Number: 1217
The Problem of Pain in Rheumatology: Clinical Profiles Associated with Concomitant Diagnoses with Chronic Overlapping Pain Conditions
1:00PM-3:00PM
Abstract Number: 1145
The Prostate Plays a Role in Serum Urate Levels and the Risk of Gout in Men
1:00PM-3:00PM
Abstract Number: 1438
The Ratio Between Biological and Glucocorticoid Use in Different Countries Worldwide: Results from the METEOR Registry
1:00PM-3:00PM
Abstract Number: 1191
The Risk of Major Adverse Cardiovascular Events in Patients with Systemic Sclerosis: A Population-Based, Matched Cohort Study
1:00PM-3:00PM
Abstract Number: 1325
The Risks of Osteoporotic Fracture After Lung Transplant: A Retrospective Cohort Study at an International Transplant Center
1:00PM-3:00PM
Abstract Number: 1313
The Role of Tryptophan and Its Metabolites in Risk for Incident Hip Fractures and Frailty: The Cardiovascular Health Study
1:00PM-3:00PM
Abstract Number: 1186
The Trajectory of Multimorbidity in Patients with Systemic Lupus Erythematosus in the United States
1:00PM-3:00PM
Abstract Number: 1239
The Utility of Dual-Energy Computed Tomography in the Diagnosis of Gout
1:00PM-3:00PM
Abstract Number: 1551
The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis
1:00PM-3:00PM
Abstract Number: 1419
Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
1:00PM-3:00PM
Abstract Number: 1430
Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1266
Time-course Ultrasonography to Predict Flare After Discontinuation of Biologics in Patients with Rheumatoid Arthritis Achieving Stringent Remission
1:00PM-3:00PM
Abstract Number: 1549
Toward Safer Glucocorticoid Therapy
1:00PM-3:00PM
Abstract Number: 1241
Towards a Simplified Fluid-sensitive MRI Protocol in Small Joints of the Hand in Early Arthritis Patients: Reliability Between mDixon and Regular FSE Fat Saturation MRI-sequences
1:00PM-3:00PM
Abstract Number: 1167
Towards an Autologous 3D Skin-like Tissue Harboring Patient-Derived Fibroblasts, Keratinocytes, T-cells and Macrophages
1:00PM-3:00PM
Abstract Number: 1172
Transcription Analysis of Macrophages Reveals Important Changes Induced by Systemic Sclerosis Fibroblasts
1:00PM-3:00PM
Abstract Number: 1120
Transcriptome-Wide Association Study of Sjögren’s Disease Risk Alleles Identifies Novel Genes with Altered Expression in Minor Salivary Gland and Other Tissues
1:00PM-3:00PM
Abstract Number: 1147
Transcriptomic Changes Induced by Tocilizumab in Ex-Vivo PBMCs from Patients with GCA in Remission. Predictors of Response
1:00PM-3:00PM
Abstract Number: 1294
Translation and Cross-cultural Adaptation of the CORS into Spanish
1:00PM-3:00PM
Abstract Number: 1546
Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry
1:00PM-3:00PM
Abstract Number: 1324
Treatment Patterns in Women with Post-Menopausal Osteoporosis Using Abaloparatide: A Real-world Observational Study
1:00PM-3:00PM
Abstract Number: 1425
Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA®) in German Patients with Rheumatic Diseases
1:00PM-3:00PM
Abstract Number: 1492
Treatment with Non-steroidal Anti-inflammatory Drugs Is Associated with Retardation of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: 10-year Results from the GErman SPondyloarthritis Inception Cohort
1:00PM-3:00PM
Abstract Number: 1471
Trends and Predictors of Hospitalizations Due to Acute Myocardial Infarction in Systemic Lupus Erythematosus Patients
1:00PM-3:00PM
Abstract Number: 1213
Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021
1:00PM-3:00PM
Abstract Number: 1254
Ultra High‐Frequency Ultrasound of Labial Salivary Glands in Primary Sjögren’s Syndrome: A Promising Tool to Identify Lymphoproliferative Lesions in Unusual Sites
1:00PM-3:00PM
Abstract Number: 1233
Ultrasound Is Reliable in the Assessment of Muscle Echogenicity in Patients with Rheumatic Diseases: Results of a Multicenter International Web-based Study
1:00PM-3:00PM
Abstract Number: 1127
Unsupervised Clustering Analysis of the Serum Proteome Identifies Systemic Sclerosis Patients with Distinctive Clinical Features
1:00PM-3:00PM
Abstract Number: 1473
Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment
1:00PM-3:00PM
Abstract Number: 1388
Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10 Diagnostic Codes
1:00PM-3:00PM
Abstract Number: 1271
Uptake of Rheumatology-Specific Quality Measures Submitted to National Pay-for-Performance Programs: An Analysis of Participants in the RISE Registry
1:00PM-3:00PM
Abstract Number: 1478
Urine ALCAM Is a Strong Predictor of Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 1135
Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
1:00PM-3:00PM
Abstract Number: 1359
Usability and Acceptability of a Digital Behavioral Therapy for the Management of Fibromyalgia
1:00PM-3:00PM
Abstract Number: 1210
Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1533
Use of Body Mass Index in Prediction of Interstitial Lung Disease Related to Systemic Sclerosis Revealed by Decision Trees
1:00PM-3:00PM
Abstract Number: 1519
Using Galacetin-3 (Gal-3) and Cardiotrophin-1 (CT-1) for Early Detection of Primary Heart Involvement in Systemic Sclerosis as Seen on Cardiac MRI
1:00PM-3:00PM
Abstract Number: 1448
Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares
1:00PM-3:00PM
Abstract Number: 1159
Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center
1:00PM-3:00PM
Abstract Number: 1242
Validation of a Novel Ultrasound Scoring System for the Evaluation of Pediatric Knee Arthritis
1:00PM-3:00PM
Abstract Number: 1562
Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification
1:00PM-3:00PM
Abstract Number: 1199
Validation of New Medication User Definitions in Single-Specialty EHR Data
1:00PM-3:00PM
Abstract Number: 1198
Validation of Remote Physical Performance and Cognitive Functioning Measures Among Individuals with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1362
Validation of the 2016 ACR/EULAR Myositis Response Criteria in Juvenile Dermatomyositis (JDM) Clinical Trials and Consensus Profiles
1:00PM-3:00PM
Abstract Number: 1517
Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain
1:00PM-3:00PM
Abstract Number: 1574
Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System
1:00PM-3:00PM
Abstract Number: 1251
Venous Halo Sign Detected with Superb Microvascular Imaging in Behçet Syndrome
1:00PM-3:00PM
Abstract Number: 1200
Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial: Outcomes over 7 Years
1:00PM-3:00PM
Abstract Number: 1573
Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis
1:00PM-3:00PM
Abstract Number: 1348
We Asked Patients and Families: What Is the Job of a Pediatric Rheumatologist?
1:00PM-3:00PM
Abstract Number: 1332
What Education Topics and Smartphone App Functions Do Rheumatology Patients Consider Important? Survey of Patients in a Community-Based Practice Network
1:00PM-3:00PM
Abstract Number: 1512
What Is the Best Referral Strategy for Axial Spondyloarthritis? A Prospective Multicenter Study of 515 Patients with Suspicious Chronic Low Back Pain
1:00PM-3:00PM
Abstract Number: 1138
Whole-Blood DNA Methylation Analysis Reveals Respiratory Environmental Traits Involved in COVID-19 Severity Following SARS-CoV-2 Infection and Common Molecular Signatures with Autoimmune Diseases
1:00PM-3:00PM
Abstract Number: 1470
Work Disability and Function in Systematic Lupus Erythematosus (SLE): Results from a Mixed-Methods Exploratory Canadian Study
1:00PM-3:00PM
Abstract Number: 1426
Year-two Follow-up Results of an Observational Study Conducted in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis Patients Treated with Infliximab Biosimilar CT-P13 in a Real-life Setting
9:00AM-10:30AM
Abstract Number: L03
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: L02
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
9:00AM-10:30AM
Abstract Number: L05
Effect of Denosumab on Structure Modification in Erosive Hand Osteoarthritis: Results of a 48-Week, Monocentric, Randomized, Placebo-controlled, Double-blind Phase 2 Study and Open Label Extension Phase
9:00AM-10:30AM
Abstract Number: L01
Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study
9:00AM-10:30AM
Abstract Number: L04
Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis
9:00AM-10:30AM
Abstract Number: L06
Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib vs TNF Inhibitors in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
11:30AM-1:00PM
Abstract Number: 1678
A Genome-Wide Association Analysis of 2,622,830 Individuals Reveals New Pathogenic Pathways in Gout
11:30AM-1:00PM
Abstract Number: 1677
Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
11:30AM-1:00PM
Abstract Number: 1675
Effectiveness of Intensive Diet and Exercise on Knee Pain Among Communities with Knee Osteoarthritis, Overweight, and Obesity: The WE-CAN Pragmatic Randomized Clinical Trial
11:30AM-1:00PM
Abstract Number: 1680
Module Signatures of Synovial Single-cell States Identify Disease Phenotypes in Early Treatment-naive Rheumatoid Arthritis
11:30AM-1:00PM
Abstract Number: 1676
Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
11:30AM-1:00PM
Abstract Number: 1679
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes
1:00PM-3:00PM
Abstract Number: 1853
A Comparitive Study of NLRP3- and NLRP12-autoinflammatory Disease
1:00PM-3:00PM
Abstract Number: 1687
A Core Inflammation Program Conserved Across Human and Murine Neutrophils
1:00PM-3:00PM
Abstract Number: 1936
A De Novo Dominant-negative PSMB8 mutation is Linked to a More Severe CANDLE-like Phenotype
1:00PM-3:00PM
Abstract Number: 2158
A Decade of Caring for SSc Patients: Do Outcomes Improve? Data from the Leiden CCISS Cohort
1:00PM-3:00PM
Abstract Number: 1822
A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia
1:00PM-3:00PM
Abstract Number: 1858
A Multi-center Clinical Cohort Study of Chinese Anti-synthetase Syndrome Patients
1:00PM-3:00PM
Abstract Number: 2083
A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy
1:00PM-3:00PM
Abstract Number: 2168
A Novel Pharmaco-Interventional Approach for the Treatment of Refractory Digital Ischemia in Systemic Sclerosis – Percutaneous Revascularization Combined with Intravenous Vasodilatory Therapy
1:00PM-3:00PM
Abstract Number: 1894
A Phase 2, 104-Week Study of Repeat Lorecivivint Injections Evaluating Safety, Efficacy, and Bone Health Utilizing Quantitative Computed Tomography (qCT) in Knee Osteoarthritis (OA-06)
1:00PM-3:00PM
Abstract Number: 2008
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs
1:00PM-3:00PM
Abstract Number: 1899
A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (OA-10) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
1:00PM-3:00PM
Abstract Number: 1684
A Potent Inhibitor of PAD4 Suppresses Histone Citrullination in Vitro and in Vivo
1:00PM-3:00PM
Abstract Number: 1897
A Preliminary Estimate of Objectively Measured Sedentary Behavior in Knee Osteoarthritis
1:00PM-3:00PM
Abstract Number: 2082
A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy
1:00PM-3:00PM
Abstract Number: 1917
A Remote Behaviorally-Designed Intervention to Promote Physical Activity in Patients with Knee Osteoarthritis: Results of a Pilot Randomized Clinical Trial
1:00PM-3:00PM
Abstract Number: 1708
A Role for the RAGE Receptor in Chronic Neurotoxicity After Exposure to SLE Antibodies That Cross React with dsDNA and the NMDA Receptor
1:00PM-3:00PM
Abstract Number: 1777
A Symptom Checker App Is Better at Classifying Inflammatory Disease Than Physicians Who Are Presented Identical Information
1:00PM-3:00PM
Abstract Number: 2044
Abnormalities of Extracellular Matrix Modeling Gene Expression in Salivary Gland Epithelial Cells of Patients with Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2118
Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
1:00PM-3:00PM
Abstract Number: 2088
Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort
1:00PM-3:00PM
Abstract Number: 1914
Acoustic Classification of Early and Advanced Osteoarthritis of the Knee in Clinical Settings
1:00PM-3:00PM
Abstract Number: 1817
Acute Coronary Syndrome in Calcium Pyrophosphate Deposition Disease Patients: A Cross-sectional Study from the National Inpatient Sample
1:00PM-3:00PM
Abstract Number: 1937
Adult Rheumatologists’ Knowledge, Comfort Level, and Perceived Barriers in Supporting Newly Transitioned Youth with Chronic Rheumatic Diseases in Canada
1:00PM-3:00PM
Abstract Number: 1756
Adverse Events in Patients with Inflammatory Joint Diseases: Results from the EULAR Coronavirus Vaccine (COVAX) Physician-reported Registry
1:00PM-3:00PM
Abstract Number: 2046
Agreement Between Labial Biopsy and the OMERACT Grey-scale Ultrasound Scoring System for Salivary Glands in a Single-center Cohort of Patients with Suspected Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 1896
Alkylresorcinol, a Biomarker for Whole Grain Intake, and Its Association with Osteoarthritis: The MOST Study
1:00PM-3:00PM
Abstract Number: 2068
All-Cause Mortality in a Systemic Lupus Erythematosus Cohort
1:00PM-3:00PM
Abstract Number: 2161
Alterations of Nutritional Status of Scleroderma Patients and Associations with Disease-specific Features
1:00PM-3:00PM
Abstract Number: 2154
An Exploratory Phosphoproteomic and Immunohistochemical Analysis of Receptor Tyrosine Kinases and Downstream Signaling Pathways in Systemic Sclerosis Skin
1:00PM-3:00PM
Abstract Number: 2098
Analysis of Cutaneous Lupus Hospitalizations: A United States National Population-based Study
1:00PM-3:00PM
Abstract Number: 1926
Analysis of New Patient Referrals to a Large Pediatric Rheumatology Clinic
1:00PM-3:00PM
Abstract Number: 2148
Analysis of Serum Proteomics Data Identifies Beta-Defensin 2 as a Predictive Biomarker of Clinical Response to IL-17 Blockade in Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1879
Analysis of the Association Between the Atrophic Factors Tripartite Motif Containing (TRIM) 63 and Atrogin-1 and the Clinical and Inflammatory Features of Patients with Idiopathic Inflammatory Myopathies
1:00PM-3:00PM
Abstract Number: 1786
Anterior Knee Pain Is Associated with 2-year Compartment Specific Patellofemoral Cartilage Worsening: The MOST Study
1:00PM-3:00PM
Abstract Number: 2003
Anti-rheumatic Treatment Modulates Expression of the Glycolytic Enzyme PFKFB3 in CD14+ Monocytes of Patients with Rheumatoid Arthritis, Which Contributes to Dissimilarities of the IFN Signature
1:00PM-3:00PM
Abstract Number: 1983
Anti-S1 Antibody Levels Two Weeks After the Second Dose of an mRNA anti-SARS-CoV2 Vaccine Predict Maintenance of a Potent Neutralizing Activity over 24 Weeks in RA Patients
1:00PM-3:00PM
Abstract Number: 1893
Antihistamine Use and Structural Progression of Knee OA: A Post-Hoc Analysis of Two Phase 3 Clinical Trials
1:00PM-3:00PM
Abstract Number: 1839
Appendicitis Still a Challenge for FMF Patients?
1:00PM-3:00PM
Abstract Number: 2130
Apremilast in Bio-Naïve Patients with Early Psoriatic Arthritis: A National, Real-Life, Multicenter, Non-Interventional, Prospective, 52-week Cohort Study
1:00PM-3:00PM
Abstract Number: 1863
Aromatase Inhibitor Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model
1:00PM-3:00PM
Abstract Number: 1699
Arthritis-associated Synovial CD64-Ly6c- myeloid Cells Comprise 2 Subpopulations
1:00PM-3:00PM
Abstract Number: 1990
Artificial Intelligence Applied to Transcriptomics Profiling of Synovial Tissue Biopsies Accurately Predicts Rheumatoid Arthritis Patients Who Will Respond or Be Refractory to Standard Biological Treatments
1:00PM-3:00PM
Abstract Number: 1930
Assessing the Number of Children Evaluated for Recurrent Fevers During the COVID-19 Pandemic in North America
1:00PM-3:00PM
Abstract Number: 1808
Assessing the Role of the NLRP3 Inflammasome in Driving Inflammation in Affected Joints of Patients with Inter-critical Gout
1:00PM-3:00PM
Abstract Number: 1816
Assessing Urate Deposition and Inflammation in the Vasculature of Gout Patients Using Dual Energy Computed Tomography and Positron Emission Tomography Pre and Post Pegloticase- a Pilot Study
1:00PM-3:00PM
Abstract Number: 1875
Assessment of Antibody Levels to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) in Patients with Idiopathic Inflammatory Myopathies Receiving Treatment with Intravenous Immunoglobulin
1:00PM-3:00PM
Abstract Number: 2116
Assessment of the Ultrasound and Clinical Response to Apremilast Using a Joint-periarticular-nail Ultrasound Index and Clinical Evaluation in Patients with Active Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1973
Association Between Activity Limitations, Sleep Disturbance, Pain Sensitivity, Pain Intensity, and Widespread Pain in Adults with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1750
Association Between Appendicitis and the Risk of Systemic Lupus Erythematosus: A Population-based, Case-control Study
1:00PM-3:00PM
Abstract Number: 1921
Association Between Knee Osteoarthritis and Health-Related Quality of Life in Persons with Type 2 Diabetes
1:00PM-3:00PM
Abstract Number: 1895
Association Between Synovial Tissue Metabolomic Profile and Pain in Patients with Knee Osteoarthritis
1:00PM-3:00PM
Abstract Number: 1754
Association of Cognitive Impairment and Symptomatic Lower Extremity Osteoarthritis by Level of Physical Activity: Preliminary Data from the Johnston County Health Study
1:00PM-3:00PM
Abstract Number: 1826
Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 2059
Association of Hydroxychloroquine with the Incidence of Infectious Disease in Systemic Lupus Erythematosus: Data from the LUNA Registry
1:00PM-3:00PM
Abstract Number: 2097
Association of Renal Biopsy NIH Activity and Chronicity Scores with Clinical Outcomes in a Cohort of Patients with Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 2103
Association of Telomere Length with Phenotypic Frailty in Adults with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1881
Association Study Between anti-TIF1γ Antibody and Development of Neoplasia in Three Tertiary Hospitals
1:00PM-3:00PM
Abstract Number: 1912
Associations of Nociceptive Dysfunction with Physical Activity in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
1:00PM-3:00PM
Abstract Number: 1883
Auto-antibodies Targeting Membrane Repair Proteins Enhances Myositis Phenotype
1:00PM-3:00PM
Abstract Number: 1965
Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis
1:00PM-3:00PM
Abstract Number: 1874
Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease
1:00PM-3:00PM
Abstract Number: 2167
Autoantibodies in Patients with Early Systemic Sclerosis in the Collaborative National Quality and Efficacy Registry
1:00PM-3:00PM
Abstract Number: 2020
Autophagy-related Risk Loci in Systemic Lupus Erythematous and Sjögren’s Disease
1:00PM-3:00PM
Abstract Number: 1868
B Cell Count in Juvenile Dermatomyositis: A Biomarker of Disease
1:00PM-3:00PM
Abstract Number: 1713
Bank1 Signaling Shapes the Gut Microbiota Composition by Controlling the Gut Mucosal B-cell Response in Lupus
1:00PM-3:00PM
Abstract Number: 1995
Baricitinib Improves Bone Biomechanical Properties in Rheumatoid Arthritis (RA) – Results of a Prospective Interventional Study
1:00PM-3:00PM
Abstract Number: 2133
Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1911
Baseline Bone Curvature a Biomarker for the Prediction of Knee Osteoarthritis Cartilage Volume Loss at One-Year. Use of Machine Learning
1:00PM-3:00PM
Abstract Number: 1727
BATF Represses BIM Expression to Sustain the T Cell Anergy Program
1:00PM-3:00PM
Abstract Number: 1906
Bile Acid Profile Is Associated to Synovitis in Knee Osteoarthritis
1:00PM-3:00PM
Abstract Number: 2117
Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies
1:00PM-3:00PM
Abstract Number: L14
Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
1:00PM-3:00PM
Abstract Number: 2122
Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
1:00PM-3:00PM
Abstract Number: 2119
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
1:00PM-3:00PM
Abstract Number: 1844
Biological Therapy in Neurosarcoidosis: Study of 30 Patients from a Series of 234 Systemic Sarcoidosis from a University Hospital
1:00PM-3:00PM
Abstract Number: 1688
Biomechanical Phenotype of Circulating Neutrophils Is Altered in ANCA Associated Vasculitis
1:00PM-3:00PM
Abstract Number: 2178
BNT162b2 mRNA Vaccine Against Covid 19, Humoral Response, Safety and Efficacy in Scleroderma Patients
1:00PM-3:00PM
Abstract Number: L08
Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
1:00PM-3:00PM
Abstract Number: 2091
Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Community Population-Based Cohort: The Lupus Midwest Network
1:00PM-3:00PM
Abstract Number: 1952
Burden of Disease in Refractory Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1992
Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry
1:00PM-3:00PM
Abstract Number: 1690
Butyric Acid Suppresses Migration of Human Monocyte Derived Dendritc Cell by Inhibiting Actin Polymerization via mDia1 Inhibition
1:00PM-3:00PM
Abstract Number: 1819
Calcium Pyrophosphate Deposition Disease Is Associated with an Increased Prevalence of Nephrolithiasis
1:00PM-3:00PM
Abstract Number: 1834
Canakinumab Treatment in Familial Mediterranean Fever Patients with Colchicine Resistance: A Single-center Study
1:00PM-3:00PM
Abstract Number: 1752
Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER
1:00PM-3:00PM
Abstract Number: 2169
Cardiac Rhythm and Conduction Abnormalities in Systemic Sclerosis-meta-analysis
1:00PM-3:00PM
Abstract Number: 1846
Cardiac Sarcoidosis: An Underdiagnosed, Life-threatening yet Treatable Disease
1:00PM-3:00PM
Abstract Number: 2001
Cardiovascular Risk Factors and Therapeutic Outcome in Rheumatoid Arthritis – Real World Data
1:00PM-3:00PM
Abstract Number: 1710
CCL2 Drives Interferon-enhanced Monocytosis in UV-mediated Skin Injury in Murine Lupus
1:00PM-3:00PM
Abstract Number: 1993
Changes in Omega-6- and Omega-3-Derived Bioactive Lipids in Response to an Anti-Inflammatory Dietary Intervention
1:00PM-3:00PM
Abstract Number: 2108
Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA
1:00PM-3:00PM
Abstract Number: 1747
Changes in the Number and Phenotype of Citrullinated-Antigen Specific T Cells Correlate with Treatment Outcome in Seropositive Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1806
Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing
1:00PM-3:00PM
Abstract Number: 2017
Characteristics and Prognosis Factors of Relapse or Death for Non-Hodgkin Lymphomas in Primary Sjögren Syndrome
1:00PM-3:00PM
Abstract Number: 1830
Characteristics of Arthritis in Familial Mediterranean Fever Patients
1:00PM-3:00PM
Abstract Number: 1849
Characteristics of Patients with Primary Retinal Vasculitis at a Tertiary Referral Center
1:00PM-3:00PM
Abstract Number: 1794
Characteristics of Patients with Repeat Visits for Acute Gout at a University Hospital Emergency Department
1:00PM-3:00PM
Abstract Number: 1738
Characterization of T Cell Subsets in the Synovium of Chronic Inflammatory Joint Diseases
1:00PM-3:00PM
Abstract Number: 1848
Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope
1:00PM-3:00PM
Abstract Number: 1925
Characterizing Phenotypic Changes by SARS-CoV-2 Variant in Multisystem Inflammatory Syndrome in Children (MIS-C): A Single Institution Case Series
1:00PM-3:00PM
Abstract Number: 2037
Childhood-onset Sjögren’s Syndrome Is Characterised by Dysregulated of B and T Memory Cell Frequencies: A Pilot Immunophenotyping Analysis of This Rare Disease Phenotype
1:00PM-3:00PM
Abstract Number: 1740
Chronic Inflammation in Patients with Rheumatoid Arthritis or Spondyloarthritis Alters Regulatory T Cells Identity
1:00PM-3:00PM
Abstract Number: 1706
Clinical and Immunological Factors Associated with Chronic Post-COVID19 Syndrome 12 Months After Acute Infection
1:00PM-3:00PM
Abstract Number: 2156
Clinical Benefits of Lung Transplantation in Systemic Sclerosis-related Interstitial Lung Disease; A Single-Center Retrospective Study
1:00PM-3:00PM
Abstract Number: 1948
Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort
1:00PM-3:00PM
Abstract Number: 1852
Clinical Efficacy and Safety of Guselkumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease: Week 48 Analyses from the Phase 2 GALAXI 1 Study
1:00PM-3:00PM
Abstract Number: 1835
Clinical Features of Patients with Sarcoidosis and Concomitant Connective Tissue Disease
1:00PM-3:00PM
Abstract Number: 1870
Clinical Outcomes Following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Vaccination in Patients with Anti-Melanoma Differentiation Associated Gene 5 (MDA5) Antibody Positive Dermatomyositis
1:00PM-3:00PM
Abstract Number: 1855
Clinical Outcomes in an Observational Retrospective Cohort of Patients with Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) Who Taper Immunosuppressive Therapy
1:00PM-3:00PM
Abstract Number: 1735
Clonally Expanded Cytotoxic CD8+ T Cells Recognize Citrullinated Antigens in ACPA+ Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1923
Co-fluctuations of Knee Pain Between Knees in the Same Person: Data from the Osteoarthritis Initiative (OAI)
1:00PM-3:00PM
Abstract Number: 1821
Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout
1:00PM-3:00PM
Abstract Number: 1900
CoLchicine for Treatment of OsteoArthritis of the Knee (CLOAK)-A Double-blind, Placebo-controlled Trial
1:00PM-3:00PM
Abstract Number: 1769
Comparative Evaluation of Adverse Events Associated with Subcutaneous Infliximab (CT-P13 SC) and Intravenous Infliximab: A Real-world Analysis of Post-marketing Surveillance Data
1:00PM-3:00PM
Abstract Number: 2105
Comparison of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and the FRAIL Scale for Identifying Frailty Among Individuals with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2005
Comparison of Treatment and Disease Activity in the Early Stage of Onset in Patients with Elderly-onset vs Younger-onset Rheumatoid Arthritis Using Data of National Database of Rheumatic Diseases in Japan (NinJa)
1:00PM-3:00PM
Abstract Number: 1972
Comprehensive Investigation of Pain and Inflammation in Rheumatoid Arthritis from a Multidisciplinary Approach
1:00PM-3:00PM
Abstract Number: 1815
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
1:00PM-3:00PM
Abstract Number: 2128
Consistent Long-Term Guselkumab Efficacy Across Psoriatic Arthritis Domains Irrespective of Baseline Patient Characteristics
1:00PM-3:00PM
Abstract Number: 1792
Contemporary Racial/Ethnic Disparities in Emergency Department Visits and Hospitalizations for Gout in the United States – 2019 Nationwide Analysis
1:00PM-3:00PM
Abstract Number: 1909
Corticosteroids with or Without Hyaluronic Acid Injections in the Treatment of Trapeziometacarpal (TMC) Osteoarthritis : The Randomised Multicentre RHIZ’ART Trial Study Protocol
1:00PM-3:00PM
Abstract Number: 1776
COVID-19 Cases in Patients Treated with Secukinumab: Analysis from the Global Safety Database
1:00PM-3:00PM
Abstract Number: 1766
COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis
1:00PM-3:00PM
Abstract Number: 2081
COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave
1:00PM-3:00PM
Abstract Number: 1961
COVID-19 mRNA Vaccine Induced Antibody Titers and IFN-g Responses Are Decreased in Persons with Rheumatoid Arthritis and Older Age
1:00PM-3:00PM
Abstract Number: 2084
COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2147
Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study
1:00PM-3:00PM
Abstract Number: 1971
Cumulative Joint Inflammation Is Associated with Local Joint Damage Progression in Rheumatoid Arthritis Despite Long-Term Targeted Treatment
1:00PM-3:00PM
Abstract Number: 1938
Current Approach to COVID-19 and Other Vaccinations in Children with Previous Multisystem Inflammatory Syndrome (MIS-C): An International Survey
1:00PM-3:00PM
Abstract Number: 2053
Current State and Completeness of Reporting Clinical Prediction Models Using Machine Learning in Systemic Lupus Erythematosus: A Systematic Review
1:00PM-3:00PM
Abstract Number: 1723
CXCR4-targeted Functionally Selective Immunomodulator Shows Robust Efficacy in Pristane-induced Murine Lupus Model
1:00PM-3:00PM
Abstract Number: 2149
Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rheumatic Diseases Portuguese Register
1:00PM-3:00PM
Abstract Number: 2150
Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study
1:00PM-3:00PM
Abstract Number: 1748
Deep Immune Profiling of Cytotoxic T Cells (CTL) from Patients with Ankylosing Spondylitis Revealed a Subset of CTL Co-Expressing PD-1 and TIGIT That Resists Immune Exhaustion
1:00PM-3:00PM
Abstract Number: 1717
Deficiency of IL-23 Receptor in Podocytes of MRL/lpr lupus-prone Mice Abrogates the Development of Lupus Nephritis Despite IgG Deposition in the Glomeruli
1:00PM-3:00PM
Abstract Number: 1916
Defining Early-stage Knee Osteoarthritis: A Scoping Review
1:00PM-3:00PM
Abstract Number: 2152
Depression and Other Neurological Disorders Are Associated with Biologic DMARD Failure in Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1695
Dermatomyositis (DM) Macrophages Upregulate Genes Involved in the Remodeling of the Extracellular Matrix and Activate Keratinocytes in a Novel 3D Tissue Model of DM Skin Disease
1:00PM-3:00PM
Abstract Number: 1944
Description and Delays in Care in the Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program
1:00PM-3:00PM
Abstract Number: 2030
Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 1957
Detangling Heterogeneity in Contemporary Undifferentiated Arthritis – a Large Cohort Study Using Latent Class Analysis
1:00PM-3:00PM
Abstract Number: 1970
Detecting Inflammatory Changes in Seronegative Inflammatory Arthritis with Use of Musculoskeletal Ultrasound Studies
1:00PM-3:00PM
Abstract Number: 1945
Determinants of Patient’s Global Assessment of Disease Severity and Predictors of Disease Course in Juvenile Fibromyalgia
1:00PM-3:00PM
Abstract Number: 1887
Determining the Long-term Safety and Efficacy of JAK Inhibitors in the Treatment of Dermatomyositis: A Retrospective Cohort Study
1:00PM-3:00PM
Abstract Number: 2134
Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program
1:00PM-3:00PM
Abstract Number: 2136
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components
1:00PM-3:00PM
Abstract Number: 1915
Development of an MRI-based Definition of Knee Osteoarthritis: Data from the Multicenter Osteoarthritis Study
1:00PM-3:00PM
Abstract Number: 2036
Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon
1:00PM-3:00PM
Abstract Number: 1954
Development of the Patient-Important Outcomes Data Repository (PIONEER) for Rheumatic Diseases; An Enhanced Database Combining Electronic Medical Data with Insight from Chart Reviews
1:00PM-3:00PM
Abstract Number: 1760
Diagnoses Rates in Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients During COVID-19
1:00PM-3:00PM
Abstract Number: 1751
Diagnosing the Cardiovascular Risk of VIOXX: A Place for Rofecoxib in Pain Management
1:00PM-3:00PM
Abstract Number: 1847
Differences in Key Patient-reported Outcome Domains Identified by the Patient Acceptable Symptom State in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study)
1:00PM-3:00PM
Abstract Number: 1763
Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination
1:00PM-3:00PM
Abstract Number: 2014
Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up
1:00PM-3:00PM
Abstract Number: 2047
Discriminative Power of Salivary Gland Ultrasound in Relation to Symptom-based Endotypes in Suspected and Definite Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2106
Disparities of African American Mortality Trends in South Carolina Lupus Cohort
1:00PM-3:00PM
Abstract Number: 2029
Distinctive Clinical Profiles Associated with anti-SSA/Ro60, anti-Ro52/TRIM21 and Anti-SSB/La Reactivity
1:00PM-3:00PM
Abstract Number: 2002
Do SMS and Email Reminders Increase the Rate of Seasonal Influenza Vaccination in RA Patients Treated with Biologics: A Nested Randomized Controlled Trial Within the ART Registry?
1:00PM-3:00PM
Abstract Number: 2045
Does Ancestry Influence Primary Sjögren’s Syndrome Phenotype or Severity?
1:00PM-3:00PM
Abstract Number: 2077
Does Early Complete Remission Preclude Adverse Outcomes in Lupus Nephritis?
1:00PM-3:00PM
Abstract Number: 1905
Does Exercise Before Surgery Predict Trajectories of Physical Activity After Knee Replacement?
1:00PM-3:00PM
Abstract Number: 1903
Does Pain Sensitization by Pressure Pain Thresholds and Temporal Summation Predict Persistent Pain in Persons with Hand OA?
1:00PM-3:00PM
Abstract Number: 2102
Does Remission According Definition of Remission in SLE (DORIS) 2021 Match the Treating Rheumatologist Judgment? Analysis at Recruitment of a Prospective Study of 500 SLE Patients from a Spanish Multicenter Cohort
1:00PM-3:00PM
Abstract Number: 2109
Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
1:00PM-3:00PM
Abstract Number: 2013
Drug Free Remission in Rheumatoid Arthritis: Data from the Randomized Controlled ARCTIC REWIND Trial
1:00PM-3:00PM
Abstract Number: 2099
Drug Repurposing for Treating Lupus Nephritis Based on Transcriptome Profiling and Autoimmunity-Related Serological Markers
1:00PM-3:00PM
Abstract Number: 1968
Dysregulation of γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1837
Eales Disease and Vogt-Koyanagi-Harada Syndrome: Not Everything Is Anterior Uveitis in Rheumatology
1:00PM-3:00PM
Abstract Number: 2114
Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
1:00PM-3:00PM
Abstract Number: 2021
Early Histopathological Changes of the Salivary Glands Associated with the Development of Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2115
Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study
1:00PM-3:00PM
Abstract Number: 1986
Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment
1:00PM-3:00PM
Abstract Number: 1998
Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical Activity, and Stress Management in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial
1:00PM-3:00PM
Abstract Number: 2085
Effect of Osteoporosis on Major Adverse Cardiovascular Events (MACEs) and Mortality in Systemic Lupus Erythematosus: A Longitudinal Study
1:00PM-3:00PM
Abstract Number: L15
Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study
1:00PM-3:00PM
Abstract Number: 1805
Effect of Short-Term Fruit Juice and Sugared Beverage Intake on Risk of Recurrent Gout Flares
1:00PM-3:00PM
Abstract Number: 2143
Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
1:00PM-3:00PM
Abstract Number: 1949
Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine Among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases
1:00PM-3:00PM
Abstract Number: 1745
Effects of Excess IL-18 in Mixed Inflammatory Environments
1:00PM-3:00PM
Abstract Number: 1997
Effects of Short Chain Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and New Onset Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 2125
Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials
1:00PM-3:00PM
Abstract Number: 1829
Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study
1:00PM-3:00PM
Abstract Number: 2145
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials
1:00PM-3:00PM
Abstract Number: 2031
Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
1:00PM-3:00PM
Abstract Number: 1832
Efficacy and Safety Similarity of Biosimilar Adalimumab-aqvh to Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Phase III Study
1:00PM-3:00PM
Abstract Number: 1882
Efficacy of Immune-apheresis in Patients with Inflammatory Myopathies: A Case Series
1:00PM-3:00PM
Abstract Number: 1876
Efficacy of JAK Inhibitors in Idiopathic Inflammatory Myopathies (other Than Dermatomyositis)
1:00PM-3:00PM
Abstract Number: 1932
Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients
1:00PM-3:00PM
Abstract Number: 2146
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
1:00PM-3:00PM
Abstract Number: L10
Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)
1:00PM-3:00PM
Abstract Number: 1824
eGFR Changes in Uncontrolled Gout Patients Undergoing Pegloticase + Methotrexate Co-therapy
1:00PM-3:00PM
Abstract Number: 2035
Elucidating the Factors That Influence the Use of Minor Salivary Gland Biopsy for the Evaluation of Childhood Sjögren’s Disease
1:00PM-3:00PM
Abstract Number: 2100
Employment Trajectory of Canadian Young Adults with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2080
Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample
1:00PM-3:00PM
Abstract Number: 1773
Epidemiology and Outcomes of Raynaud’s Phenomenon Hospitalizations in the US
1:00PM-3:00PM
Abstract Number: 1767
Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study
1:00PM-3:00PM
Abstract Number: 1831
Establishing a Scientific Bridge to Historic VIOXX to Enable a Reintroduction of Rofecoxib: Pharmacokinetic Evaluation of TRM‑201 (Rofecoxib)
1:00PM-3:00PM
Abstract Number: 2072
Estimating Corticosteroid-Related Morbidity in Lupus Nephritis: The Glucocorticoid Toxicity Index
1:00PM-3:00PM
Abstract Number: L17
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
1:00PM-3:00PM
Abstract Number: 1799
Evaluation of Adherence to and Agreement with the 2020 American College of Rheumatology Guideline for the Management of Gout by US Rheumatologists
1:00PM-3:00PM
Abstract Number: 2135
Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1910
Evaluation of Dynamic Effects of Depressive Symptoms on Functional Outcomes in Knee Osteoarthritis
1:00PM-3:00PM
Abstract Number: 2157
Evaluation of Functional Disability over Time in the Leiden Systemic Sclerosis (CCISS) Cohort
1:00PM-3:00PM
Abstract Number: 2090
Evaluation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) vs. SLEDAI-2K Glucocorticoids (SLEDAI-2KG) on Patient Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE)
1:00PM-3:00PM
Abstract Number: 2175
Evaluation of the Distribution of Haemodynamic Parameters and Prognostic Impact in a Cohort of Patients with Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 2058
Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1783
Exploring How and Why Organizations Identify, Adopt, Disseminate, and Sustain Evidence-based Programs for Latinos with Arthritis
1:00PM-3:00PM
Abstract Number: 1707
Exploring the Role of Lipocalin-2 in Neuropsychiatric SLE
1:00PM-3:00PM
Abstract Number: 2140
Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast
1:00PM-3:00PM
Abstract Number: 1715
Ezh2 Knockout in B Cells Impairs Plasmablast Differentiation and Ameliorates Lupus-like Disease in MRL/lpr Mice
1:00PM-3:00PM
Abstract Number: 1759
Factors Affecting Success of Behavioral Interventions to Improve Physical Activity in Patients with Knee Osteoarthritis
1:00PM-3:00PM
Abstract Number: 1797
Factors Driving Opioid Use in United States Veterans with Gout
1:00PM-3:00PM
Abstract Number: 2177
Familial Clustering of Systemic Sclerosis, Autoimmunity, and Cancer History
1:00PM-3:00PM
Abstract Number: 1720
FASlpr Gene Dosage Differentiates Lymphoproliferative from Non-lymphoproliferative Autoimmunity – a Novel Mouse Model of Lupus
1:00PM-3:00PM
Abstract Number: 1966
Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
1:00PM-3:00PM
Abstract Number: L13
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
1:00PM-3:00PM
Abstract Number: 2019
Fine Mapping of the Sjögren’s Disease and Systemic Lupus Erythematosus DDX6-CXCR5 Risk Interval Reveals Common SNPs with Functional Significance in Immune and Salivary Gland Cells
1:00PM-3:00PM
Abstract Number: L12
First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background
1:00PM-3:00PM
Abstract Number: 2018
Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 1946
Focused Clinical Correlation of Autoantibody Testing in Juvenile Systemic Sclerosis and Localized Scleroderma Using the Euroimmun™ Scleroderma Disease Profile
1:00PM-3:00PM
Abstract Number: 1810
Frequency and Patterns of Opioid Use in the Management of Gout: A Population-Based Study
1:00PM-3:00PM
Abstract Number: 1956
Functional Disabilities in Hands Precede Those in Feet in Patients Progressing from Clinically Suspect Arthralgia to Rheumatoid Arthritis; A Longitudinal Observational Study
1:00PM-3:00PM
Abstract Number: 1784
Gait Alterations Associated with Worsening Physical Function over 2 Years: A Machine-learning Approach in the Multicenter Osteoarthritis (MOST) Study
1:00PM-3:00PM
Abstract Number: 1920
Gait and Physical Activity Predictors of Knee Replacement: A Machine Learning Analysis in the Multicenter Osteoarthritis Study
1:00PM-3:00PM
Abstract Number: 2159
Gastroesophageal Reflux Disease in an Australian Scleroderma Cohort – Associations and Effect of Treatment
1:00PM-3:00PM
Abstract Number: 1940
Genetic Variants and Cytokine Signatures in Patients with Syndrome of Undifferentiated Recurrent Fevers
1:00PM-3:00PM
Abstract Number: 1892
Genicular Nerve Block for Pain Management in Patients with Knee Osteoarthritis: A Randomised Double-blind Placebo Controlled Trial
1:00PM-3:00PM
Abstract Number: 1789
Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
1:00PM-3:00PM
Abstract Number: 1733
Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
1:00PM-3:00PM
Abstract Number: 2092
Greater Social Vulnerability Associates with Greater Glucocorticoid Use in Patients with SLE
1:00PM-3:00PM
Abstract Number: 2110
Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
1:00PM-3:00PM
Abstract Number: 2127
Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years
1:00PM-3:00PM
Abstract Number: 1850
Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
1:00PM-3:00PM
Abstract Number: 2093
Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Nephritis Cohort
1:00PM-3:00PM
Abstract Number: 2070
Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis
1:00PM-3:00PM
Abstract Number: 1798
Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post- Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
1:00PM-3:00PM
Abstract Number: 2006
Healthcare Resource Utilization and Economic Burden of Patients with Adequate and Inadequate Responses to Advanced Therapies for Rheumatoid Arthritis in Japan
1:00PM-3:00PM
Abstract Number: 1818
Hepatic Steatosis and Fibrosis in Patients with Gout Detected by Elastography
1:00PM-3:00PM
Abstract Number: 1864
Hepatitis B Exposure and Infection in Idiopathic Inflammatory Myopathies: Prevalence, Presentation, and Treatment Response
1:00PM-3:00PM
Abstract Number: 2123
Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis
1:00PM-3:00PM
Abstract Number: 1801
High Frequency of Structural Damage in the Lower Spine of Patients with Chondrocalcinosis
1:00PM-3:00PM
Abstract Number: 1701
High TNFAIP3-Transfected Cell Activity: An In Vitro Model for Phagocyte Study of Monogenic Behçet’s Disease Pathophysiology
1:00PM-3:00PM
Abstract Number: 1885
Histopathological Patterns of Muscle Involvement and Clinical Correlations in a Retrospective Cohort of Scleroderma Patients
1:00PM-3:00PM
Abstract Number: 1871
Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)
1:00PM-3:00PM
Abstract Number: 2141
How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study
1:00PM-3:00PM
Abstract Number: 1743
Identification of Immune Cell Types in the Peripheral Blood of Rheumatoid Arthritis Patients Associated with Susceptibility and Response to Treatment
1:00PM-3:00PM
Abstract Number: 1878
Identification of Serum Biomarkers Associated with Muscle Inflammation Detected on MRI in Polymyositis/dermatomyositis
1:00PM-3:00PM
Abstract Number: 1734
Identification of Sjögren’s Disease-Associated T Cell Receptors Through Deep Sequencing and Single-Cell Transcriptomics
1:00PM-3:00PM
Abstract Number: 1975
Identifying MicroRNAs Associated with Neuropathic Pain in Patients with Rheumatoid Arthritis (RA)
1:00PM-3:00PM
Abstract Number: 1884
Idiopathic Inflammatory Myopathies in Alaska Native/American Indian People in Alaska
1:00PM-3:00PM
Abstract Number: 1928
Idiopathic Pulmonary Capillaritis Within the Spectrum of Pediatric Diffuse Alveolar Hemorrhage
1:00PM-3:00PM
Abstract Number: 1962
Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease
1:00PM-3:00PM
Abstract Number: 1700
IL-21/STAT3 Pathway Mediated Th2-like Vδ2 T Cells Promote Plasmablasts Differentiation in IgG4-Related Disease
1:00PM-3:00PM
Abstract Number: 1736
IL-23 Signaling Induces Autoimmune Disease Genes in Mucosal-Associated Invariant T Cells
1:00PM-3:00PM
Abstract Number: 2049
ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive
1:00PM-3:00PM
Abstract Number: 1744
Immune Responses to mRNA Vaccines Against SARS-CoV-2 in Patients with Immune-mediated Inflammatory Rheumatic Diseases
1:00PM-3:00PM
Abstract Number: 2124
Immunological Differences Between PsA Patients Who Are Tumor Necrosis Factor Inhibitor-Naïve and Who Have Inadequate Response to Tumor Necrosis Factor Inhibitors
1:00PM-3:00PM
Abstract Number: 1809
Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients: A Secondary Analysis of CARES Trial
1:00PM-3:00PM
Abstract Number: 1960
Impact of Delaying Initiation of Methotrexate by One Month on the Outcome of RA at One Year
1:00PM-3:00PM
Abstract Number: 1812
Impact of Misclassification on the US Prevalence of Gout: Bayesian Sensitivity Analysis of the National Health & Nutrition Examination Survey (NHANES)
1:00PM-3:00PM
Abstract Number: 2137
Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 2126
Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
1:00PM-3:00PM
Abstract Number: 2061
Impact of Time to Remission, Flares and Exposure to Immunosuppressives on the Development of Advanced Chronic Kidney Disease (Stage IV or Worse) in Lupus Nephritis
1:00PM-3:00PM
Abstract Number: L09
Impact on Access to Methotrexate in the Post-Roe Era
1:00PM-3:00PM
Abstract Number: 1726
Impaired Dynamic X-Chromosome Inactivation Maintenance in T Lymphocytes Is a Feature of Spontaneous Lupus in Female Mice and Is Exacerbated in Female-Biased Disease Models
1:00PM-3:00PM
Abstract Number: 1780
Improved Overall Survival in Patients with Lung Cancer and Autoimmune Rheumatic Diseases
1:00PM-3:00PM
Abstract Number: 2113
Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies
1:00PM-3:00PM
Abstract Number: 1755
Improving Quality of Life Through Connection: A Scoping Review of Peer Coaching Interventions in the Field of Rheumatology
1:00PM-3:00PM
Abstract Number: 1737
In Vitro Response to Disease Modifying Antirheumatic Drugs Link Molecular Drug Target with Synovial Transcriptional Signature
1:00PM-3:00PM
Abstract Number: 1746
Increased CD39+FoxP3+CD4+ Regulatory T Cells in Early Rheumatoid Arthritis Provide a Slot for Prompt Initiation of Methotrexate and Serve as Early Biomarkers of Clinical Response
1:00PM-3:00PM
Abstract Number: 1728
Increased Frequency of Highly Differentiated T Effector Memory Cells Re-expressing CD45RA (Temra) and Cytomegalovirus Seropositivity Are Associated with Persistent Disease Specifically Refractory to Anti-TNF Therapy in Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1959
Increased Mortality in Patients with RA-Associated Interstitial Lung Disease: Data from a French Administrative Healthcare Database
1:00PM-3:00PM
Abstract Number: 2060
Increased Risk of Adverse Renal Outcomes in Patients of African Ancestry with Systemic Lupus Erythematosus (SLE) – Role of APOL1
1:00PM-3:00PM
Abstract Number: 1857
Increasing Proportion of MDA-5 Associated Conditions in a Tertiary Myositis Centre Following Onset of the Covid-19 Pandemic
1:00PM-3:00PM
Abstract Number: 1996
Individual Patient Data Meta-analysis on Continued Use of Glucocorticoids After Their Use as Bridging Therapy in Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 2166
Inflammatory Arthritis in an Australian Scleroderma Cohort – Patient Characteristics, Associations and Treatments
1:00PM-3:00PM
Abstract Number: 2174
Influence of Immunosuppressive Therapy on Gastrointestinal Symptoms in Patients with Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: L16
Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
1:00PM-3:00PM
Abstract Number: 1758
Intake of Dairy Products as a Risk Factor for Rheumatoid Arthritis; A Nested Case-Control Study
1:00PM-3:00PM
Abstract Number: 1704
Interaction of Macrophages and Natural Killer Cells in Pathogenesis of HIV-1-Associated Inflammatory Arthritis
1:00PM-3:00PM
Abstract Number: 1692
Interferon Alpha Promotes Ultraviolet Light-Mediated Keratinocyte Apoptosis in a Caspase-8 Dependent Manner via Upregulation of Interferon Regulatory Factor 1
1:00PM-3:00PM
Abstract Number: 1951
Interleukin 1 Receptor Antagonist Relation to Cardiovascular Disease in Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1865
Internet-based Enrollment for Myositis Studies Utilizing Patient Self-reported Diagnostic Criteria
1:00PM-3:00PM
Abstract Number: 1833
Intraarticular Morphine in Knee-arthritis – Results of a Randomized Placebo-controlled Trial
1:00PM-3:00PM
Abstract Number: 1889
Investigating a Possible Bi-Directional Causal Relationship Between Gout and Osteoarthritis for the European Population: Two-Sampled Mendelian Randomization Analysis Study
1:00PM-3:00PM
Abstract Number: 1994
Is Glucocorticoid Bridging Associated with Later Glucocorticoid and Biological DMARD Use in Patients with Rheumatoid Arthritis?
1:00PM-3:00PM
Abstract Number: 1904
Is Treating Painful Hand Osteoarthritis with Hormone Replacement Therapy Feasible? Primary Results from a Randomised Controlled Trial in Post-menopausal Women
1:00PM-3:00PM
Abstract Number: 2151
Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial
1:00PM-3:00PM
Abstract Number: 2144
JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 2015
JAK Selectivity Did Not Affect to the Incidence of Malignancies in the Real-World Setting: Data from a Multicenter Observational Study in Japan
1:00PM-3:00PM
Abstract Number: 2153
Key Differences Between US Rheumatologists’ and Dermatologists’ Management of Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1781
Knee Pain Is Highly Associated with Ankle/Foot Pain, Arch Height, and Arch Flexibility: The Johnston County Osteoarthritis Project
1:00PM-3:00PM
Abstract Number: 2027
Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 1862
Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial
1:00PM-3:00PM
Abstract Number: 1860
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis
1:00PM-3:00PM
Abstract Number: 1698
LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses
1:00PM-3:00PM
Abstract Number: 2163
Lipid Profile in Scleroderma Patients and the Associations of Its Changes with Disease-specific Features
1:00PM-3:00PM
Abstract Number: 1963
Lipid Screening and Statin Use in Rheumatoid Arthritis Patients in an Underserved Population
1:00PM-3:00PM
Abstract Number: 2056
Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
1:00PM-3:00PM
Abstract Number: 2111
Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 2009
Long-term Outcome of a Treat-to-target Strategy in Elderly-onset Rheumatoid Arthritis with Chronic Lung Diseases
1:00PM-3:00PM
Abstract Number: 2121
Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
1:00PM-3:00PM
Abstract Number: 1869
Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity
1:00PM-3:00PM
Abstract Number: 2010
Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy
1:00PM-3:00PM
Abstract Number: 2032
Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 1984
Malignancies Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a National Study: RELATION Study
1:00PM-3:00PM
Abstract Number: 1683
Malondialdehyde-Acetaldehyde (MAA) Modified Matrix Gla Protein (MGP) Increases Citrullination by Human Macrophages
1:00PM-3:00PM
Abstract Number: 1749
Mass Spectrometry-Based HLA Peptidomics Analysis Reveals Both Expected and Novel Citrullinated Antigen Targets in Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1942
Maybe Silent: Spine Disease in Chronic Recurrent Multifocal Osteomyelitis, Clinical Features, Risk Factors, and Red Flags
1:00PM-3:00PM
Abstract Number: 1697
Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE
1:00PM-3:00PM
Abstract Number: 2066
Measuring Sexual Dysfunction as an Indicator of Frailty in Systemic Lupus Erythematosus Population
1:00PM-3:00PM
Abstract Number: 2063
Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
1:00PM-3:00PM
Abstract Number: 1947
Medication Use in Childhood Sjogren Disease
1:00PM-3:00PM
Abstract Number: 2078
Mesangial Lupus Nephritis: Long Term Outcomes
1:00PM-3:00PM
Abstract Number: 2040
Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study
1:00PM-3:00PM
Abstract Number: 1991
Mice Do Not Develop CIA: Knocking out of Kv1.3 Renders CD4+TEMCells Resistant to Activation
1:00PM-3:00PM
Abstract Number: 2131
Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
1:00PM-3:00PM
Abstract Number: 1950
Morbidities Associated with Serious Infections in Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 2011
More Meticulously Following Treat-to-target in RA Does Not Lead to Less Radiographic Progression: A Longitudinal Analysis in BIODAM
1:00PM-3:00PM
Abstract Number: 1775
More Than Half of Patients with Osteoarthritis Have Positive Screening for Fibromyalgia And/or Depression, Feasibly Assessed in Routine Care on Indices Within a Single MDHAQ (multidimensional Health Assessment Questionnaire)
1:00PM-3:00PM
Abstract Number: 1778
More Than Half of RA Patients with a Lifetime History of Mood Disorders or Anxious and Depressed During COVID-19 Pandemic
1:00PM-3:00PM
Abstract Number: 1953
Mortality in Rheumatoid Arthritis: Changing Causes and Predictive Factors. Study of a Cohort Followed Prospectively
1:00PM-3:00PM
Abstract Number: 1845
Mortality Prognostic Factors of Critically Ill Patients with Systemic Autoimmune Diseases Admitted in a Medical Intensive Care Unit: A 20-year Cohort Study
1:00PM-3:00PM
Abstract Number: 1922
Multi-Joint Osteoarthritis Phenotypes by Race/Ethnicity and Sex: Preliminary Descriptive Data from the Johnston County Health Study
1:00PM-3:00PM
Abstract Number: 1741
Mutated Nod2 Controls T Cell Function and Promotes Uveitis in a Blau Syndrome Mouse Model
1:00PM-3:00PM
Abstract Number: 1877
Nailfold Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in Patients with Idiopathic Inflammatory Myopathies
1:00PM-3:00PM
Abstract Number: 2025
Natural History of Sjögren’s Disease from the National Institutes of Health Cohort
1:00PM-3:00PM
Abstract Number: 1918
Neurobiological Mechanisms of a Remote-Delivered Mind-body Intervention for Knee Osteoarthritis
1:00PM-3:00PM
Abstract Number: 1803
Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials
1:00PM-3:00PM
Abstract Number: 1854
Nipocalimab’s Selective Targeting of FcRn and IgG Clearance Preserves Key Immune Functions
1:00PM-3:00PM
Abstract Number: 1719
NLRP12 Deficiency Mice Present Severer Lupus Nephritis in a Pristane-Induced Lupus Like Model
1:00PM-3:00PM
Abstract Number: 1931
NOD2 Mutations Are Associated with Upregulated Type 1 Interferon Gene Expression and Development of Granulomatous Hepatitis in Children with Autoimmune Hepatitis
1:00PM-3:00PM
Abstract Number: 2033
Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology
1:00PM-3:00PM
Abstract Number: 1732
Novel Human Class II MHC Tetramers Detect Rare, Self-Reactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
1:00PM-3:00PM
Abstract Number: 1888
Novel Small Molecule Modulator of the gp130 Receptor Shows Dose-dependent Therapeutic Efficacy in a Canine Model of Osteoarthritis
1:00PM-3:00PM
Abstract Number: 2176
Novel Tissue Turnover Blood Markers Are Associated with Pulmonary Arterial Hypertension and NYHA Stages in Patients with Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1689
Oral Ginger Supplementation Counteracts NETosis in Autoimmune Mouse Models and in Healthy Humans
1:00PM-3:00PM
Abstract Number: 1891
Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab: A Randomized Placebo-Controlled Trial
1:00PM-3:00PM
Abstract Number: 1872
Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study
1:00PM-3:00PM
Abstract Number: 2022
Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study
1:00PM-3:00PM
Abstract Number: 1929
Outcomes and Safety of Anakinra for the Treatment of Multisystem Inflammatory Syndrome in Children
1:00PM-3:00PM
Abstract Number: 2101
Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
1:00PM-3:00PM
Abstract Number: 1976
Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019
1:00PM-3:00PM
Abstract Number: 2057
Outpatient Visit Adherence and Impact on Disease-related Morbidity in Childhood-onset Systemic Lupus Erythematosus (cSLE)
1:00PM-3:00PM
Abstract Number: 1718
Parenchymal INFγ Response Regulates Murine Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 1927
Patient and Parent Perceptions of an Established Rheumatology Transition Clinic for Adolescents and Young Adults
1:00PM-3:00PM
Abstract Number: 1813
Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
1:00PM-3:00PM
Abstract Number: 1999
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
1:00PM-3:00PM
Abstract Number: 2165
Patients with Systemic Sclerosis Have Impaired Forced Vital Capacity, Even in the Absence of Interstitial Lung Disease
1:00PM-3:00PM
Abstract Number: 1933
PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
1:00PM-3:00PM
Abstract Number: 1941
Pediatric Idiopathic Pulmonary Hemosiderosis – a Single-Center, Retrospective Study Comparing Use of Commonly Used Steroid-Sparing Agents
1:00PM-3:00PM
Abstract Number: 1814
Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial
1:00PM-3:00PM
Abstract Number: 1691
Pentagalloyl Glucose Inhibits MSU-Induced Inflammation via Transforming Growth Factor-β-Activated Kinase 1 (TAK1)
1:00PM-3:00PM
Abstract Number: 1705
Peptidoglycan Amplifies CD4+ T Cell Activation by MHCII+ Fibroblast-like Synoviocytes in an in Vitro Model of Lyme Arthritis
1:00PM-3:00PM
Abstract Number: 1682
Peptidyl Arginine Deiminase Expression and Macrophage Polarization Following Stimulation with Citrullinated and Malondialdehyde-acetaldehyde Modified Fibrinogen
1:00PM-3:00PM
Abstract Number: 1774
Performance of an Early Triage System for Identification of Patients with Inflammatory Rheumatic Diseases
1:00PM-3:00PM
Abstract Number: 1796
Peripheral Vascular Disease and Sequelae in Individuals with Gout, Diabetes, or Both Among US Veterans
1:00PM-3:00PM
Abstract Number: 1724
Perivascular Adipose Tissue Promotes Vascular Dysfunction in Murine Lupus
1:00PM-3:00PM
Abstract Number: 1851
Phenotype and Genotype of Adult-onset Adenosine Deaminase 2 Deficiency Patients
1:00PM-3:00PM
Abstract Number: 1982
Pluripotency Marker PBX1 Predicts Treatment Effect in Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1791
Point-of-Care Multi-Energy Photon-Counting CT for Earlier Non-Invasive Diagnosis of Gout and Calcium Pyrophosphate Deposition Disease
1:00PM-3:00PM
Abstract Number: 1866
Polymyositis/Dermatomyositis Readmissions: Analysis of the Nationwide Readmission Database
1:00PM-3:00PM
Abstract Number: 2074
Poor Executive Function Correlates with Increased Disease Damage and Impaired Patient-Reported Outcomes in Youth with Childhood-Onset Lupus: A Cross-Sectional Study
1:00PM-3:00PM
Abstract Number: 1686
Post-translational Modification of Matrix-gla Protein with Malondialdehyde-Acetaldehyde Alters Cellular Responses by Human Fibroblasts
1:00PM-3:00PM
Abstract Number: 1703
Potential Regulation of NK Cells by CD1c+ Dendritic Cells Through RIG-I/DDX60 Pathway Involved in Th17 Responses in Primary Sjögren Syndrome
1:00PM-3:00PM
Abstract Number: 2062
Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US
1:00PM-3:00PM
Abstract Number: 1955
Predictive Factor of Spontaneous Regression in Methotorexate-associated Lymphoproliferative Disorders with RA Patients
1:00PM-3:00PM
Abstract Number: 1989
Predictors of Flare in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
1:00PM-3:00PM
Abstract Number: 2094
Predictors of Health-Related Quality of Life (HRQoL) in Adults with Juvenile- and Adult-onset Systemic Lupus Erythematosus: Results from a Multiethnic US Cohort (LUMINA)
1:00PM-3:00PM
Abstract Number: 2067
Predictors of Organ Damage Accrual by Domains
1:00PM-3:00PM
Abstract Number: 2012
Predictors of Remission in Rheumatoid Arthritis Patients Treated with Biologics: A Systematic Review and Meta-analysis
1:00PM-3:00PM
Abstract Number: 1987
Prednisone Use and the Incidence of Hyperglycemia or Diabetes in Patients with Rheumatoid Arthritis; A 10-year Sub Analysis of the BeSt Study
1:00PM-3:00PM
Abstract Number: 2107
Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus (SLE): Impact of Preexisting Hypertension
1:00PM-3:00PM
Abstract Number: 1943
Prevalence and Evolution of Undifferentiated Periodic Fever Syndromes in an Academic Pediatric Rheumatology Practice
1:00PM-3:00PM
Abstract Number: 1770
Prevalence and Incidence of Depression in Patients with Rheumatoid Arthritis: A Systematic Review
1:00PM-3:00PM
Abstract Number: 1793
Prevalence of HLA B*5801 Allele Among African American Patients with Gout in an Academic Health Center
1:00PM-3:00PM
Abstract Number: 2164
Profibrotic Alveolar Macrophages as a Potential Biomarker in Systemic Sclerosis-associated Interstitial Lung Disease
1:00PM-3:00PM
Abstract Number: 1785
PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort
1:00PM-3:00PM
Abstract Number: 2087
Prospective Study of Clinical, Laboratory, and Patient-Reported Outcomes of Patients with Systemic Lupus Erythematosus Undergoing Total Hip and Total Knee Arthroplasty
1:00PM-3:00PM
Abstract Number: 1721
Protective Effects of the Natural Antioxidant Taxifolin in Models of Lupus and Antiphospholipid Syndrome
1:00PM-3:00PM
Abstract Number: 1779
Psychosocial and Health Measures in Systemic Lupus Erythematosus: COVID-19 Pandemic Trends in the Georgians Organized Against Lupus Cohort
1:00PM-3:00PM
Abstract Number: 2172
Pulmonary Function in Patients Diagnosed of Early Systemic Sclerosis: 10 Years-Experience
1:00PM-3:00PM
Abstract Number: 1788
Pulmonary Vascular Dysfunction Occurs in Association with Hyperuricaemia: Assessment by a Novel Non-Invasive Measurement of Pulmonary Pulse Wave Transit Time
1:00PM-3:00PM
Abstract Number: 1861
Racial Disparities in Diagnosis and Treatment of Patients with Dermatomyositis of Different Skin Tones
1:00PM-3:00PM
Abstract Number: 1935
Racial Disparities Influence Healthcare Utilization in Pediatric Rheumatology Clinic
1:00PM-3:00PM
Abstract Number: 1898
Radiographic Osteoarthritis Progression Can Be Predicted via Pyrosequencing Analysis of Baseline Peripheral Blood
1:00PM-3:00PM
Abstract Number: 1804
Raman Spectroscopy Integrated with Polarized Light Microscopy for Diagnosis of Crystallopathies
1:00PM-3:00PM
Abstract Number: 1924
Reading the Waves: Identifying Distinct Phenotypes of Multisystem Inflammatory Syndrome in Children During the 2020-2021 COVID-19 Pandemic
1:00PM-3:00PM
Abstract Number: 2138
Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
1:00PM-3:00PM
Abstract Number: 1838
Real-World Treatment Patterns Among Adult Patients with Dermatomyositis in the United States
1:00PM-3:00PM
Abstract Number: 1807
Reduction in Monosodium Urate Crystal Deposit Volume During the MIRROR RCT Trial in Patients Treated with Pegloticase Plus Methotrexate Co-therapy: A Serial Dual-Energy Computed Tomography (DECT) Analysis
1:00PM-3:00PM
Abstract Number: 1873
Relationship Between Baseline Characteristics of Rheumatoid Arthritis and Types of Mortality: Study of Cohort Followed Prospectively
1:00PM-3:00PM
Abstract Number: 2086
Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2069
Responsiveness of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
1:00PM-3:00PM
Abstract Number: 2007
Rheumatoid Arthritis Associated Lymphoproliferative Disorders: Current Features and It’s Changing Pattern Due to the Influence of Anti-rheumatic Drugs
1:00PM-3:00PM
Abstract Number: 2173
Rheumatology Telemedicine Consults: Impact of Demographic Variability on Patient Perception in Systemic Sclerosis versus Rheumatoid Arthritis Pts
1:00PM-3:00PM
Abstract Number: 1981
Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment
1:00PM-3:00PM
Abstract Number: 2075
Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Moderate to High Dose Glucocorticoids
1:00PM-3:00PM
Abstract Number: 2096
Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1709
Role of Corneal Langerhans Dendritic Cells in Lupus Keratitis
1:00PM-3:00PM
Abstract Number: L11
Romosozumab versus Denosumab in High-risk Patients with Glucocorticoid-induced Osteoporosis: A Pilot Randomized Controlled Trial
1:00PM-3:00PM
Abstract Number: 2016
Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
1:00PM-3:00PM
Abstract Number: 1939
Safety and Humoral Response Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-onset Autoimmune Inflammatory Rheumatic Diseases
1:00PM-3:00PM
Abstract Number: 2132
Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters – Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis
1:00PM-3:00PM
Abstract Number: 2120
Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis
1:00PM-3:00PM
Abstract Number: 1765
Safety of the Recombinant Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with JAKi Drugs
1:00PM-3:00PM
Abstract Number: 2023
Salivary Autoantibodies in Sicca Patients Are Associated with Dry Symptoms
1:00PM-3:00PM
Abstract Number: 2024
Salivary Gland Ultrasound May Lead to a More Accurate Stratification of Patients with the Same Serological Profile in Sjögren’s Syndrome: Towards a Personalized Approach
1:00PM-3:00PM
Abstract Number: 1836
Schizophrenia and Its Relationship with Autoimmunity: A Nationwide Analysis
1:00PM-3:00PM
Abstract Number: 2155
Sclerodermoid Reaction Following Immune Checkpoint Inhibitor Therapy: A Case Series from MD Anderson Cancer Center
1:00PM-3:00PM
Abstract Number: 1980
Seroconversion After a Third COVID-19 Vaccination in Rheumatoid Arthritis Patients Treated with (ultra-)low Dose Rituximab with a Previous Insufficient Humoral Response Is Associated with Rituximab Dosage
1:00PM-3:00PM
Abstract Number: 2048
Serology Driven Pulmonary Phenotype Characterization of Sjögren Syndrome-associated Interstitial Lung Disease: A Monocentric Cohort Study
1:00PM-3:00PM
Abstract Number: 2026
Serum and Tear Autoantibodies from nor Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 2129
Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
1:00PM-3:00PM
Abstract Number: 2171
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1725
Sex Differences in Autoimmune Pathogenesis and Systemic Response to High Fat Diet in Lupus-prone Mice
1:00PM-3:00PM
Abstract Number: 1967
Sex Differences in Employment Outcomes in Patients with Recent Onset Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1768
Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study
1:00PM-3:00PM
Abstract Number: 1742
Shared Epitope Allomorphs Directly Influence Antigen-specific T-cell Responses in RA
1:00PM-3:00PM
Abstract Number: 1908
Should Osteoarthritis Patients with Pain Scores More Than 8/10 Be Analyzed Separately or Excluded from Clinical Trial Protocols, as 72% Screen Positive for Fibromyalgia And/or Depression on a Multidimensional Health Assessment Questionnaire (MDHAQ)?
1:00PM-3:00PM
Abstract Number: 2041
Single Cell Atlas of Minor Salivary Glands Reveals Key Differential Cellular and Functional Players in Sjögren’s and Sicca Syndrome
1:00PM-3:00PM
Abstract Number: 2038
Single Cell RNA Sequencing Points to a Role for Fibroblasts Early in Salivary Gland Dysfunction in Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 1696
Single Cell RNA-seq Identifies Major Shifts in Myeloid Cells in Dermatomyositis Skin and Peripheral Blood Compared to Systemic Lupus
1:00PM-3:00PM
Abstract Number: 1739
Single-Cell Characterization of the TCR Repertoire Across Tissue and Blood in Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 2042
Sjögren’s Disease and Mitochondrial Function
1:00PM-3:00PM
Abstract Number: 1694
Skin Exposure to UV Light Triggers Podocyte and Distal Tubular Injury, in the Presence of CD177+ Neutrophil Cell Cluster
1:00PM-3:00PM
Abstract Number: 1693
Skin Pigmentation Association with Regulation of Cyclic-GMP-AMP Following Skin Exposure to UV Light
1:00PM-3:00PM
Abstract Number: 1729
SLAMF4+ CCR5+ Effector Memory CD4+ T Cells Are Polyfunctional, Resistant to Exhaustion, and Expanded in Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1782
Sociocultural and Moral Factors Influencing the Decision to Vaccinate Among Rheumatic Patients: A Qualitative Study
1:00PM-3:00PM
Abstract Number: 2055
SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?
1:00PM-3:00PM
Abstract Number: 1762
Stability of Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Other Autoimmune Biomarkers Among Clinical Patients Throughout the SARS-CoV-2 Pandemic and Vaccination Campaigns
1:00PM-3:00PM
Abstract Number: 1886
Statin-induced Immune-mediated Miopathy: Treatment with Glucocorticoid-free Protocols and Role of Muscle Biopsy in the Follow-up
1:00PM-3:00PM
Abstract Number: 2050
Stratification on Baseline Interferon Scores and Use of CRESS to Improve the Design of Future Trials in Sjögren’s Syndrome: Post Hoc Analysis from a Randomized Controlled Trial
1:00PM-3:00PM
Abstract Number: 1907
Strength Training Associates with Less Knee Osteoarthritis: Data from the Osteoarthritis Initiative
1:00PM-3:00PM
Abstract Number: 2112
Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
1:00PM-3:00PM
Abstract Number: 2142
Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial
1:00PM-3:00PM
Abstract Number: 1902
Structural Severity in Knee Osteoarthritis Impacts Treatment Response: A Post Hoc Pooled Analysis of Lorecivivint Clinical Trials
1:00PM-3:00PM
Abstract Number: 1856
Subclinical Coronary Artery Disease in Patients with Idiopathic Inflammatory Myopathies: A Cross-Sectional Study Evaluation by Computer Tomography Coronary Angiogram
1:00PM-3:00PM
Abstract Number: 1800
Successful Establishment of Chronic Gouty Arthritis Model in C57BL/6 Mice
1:00PM-3:00PM
Abstract Number: 1681
Supernatants from Activated Macrophages Contain Citrullinated Vimentin and Induce Extracellular Matrix Deposition from Fibroblasts
1:00PM-3:00PM
Abstract Number: 2079
Survey to Prioritize and Generate Domains in Preparation to Update the OMERACT Core Domain Set for Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2065
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
1:00PM-3:00PM
Abstract Number: 2139
Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
1:00PM-3:00PM
Abstract Number: 1964
Systematic Screening of Multimorbidities Results in an Increased Intake of Comorbidity Preventive Medications and a Decreased Hospitalization Rate
1:00PM-3:00PM
Abstract Number: 2162
Systemic Sclerosis in Alaska Native/American Indian People in Alaska
1:00PM-3:00PM
Abstract Number: 1731
Systemic Sclerosis-Associated Class II HLA Alleles Restrict the Diversity of the CDR3 and the T Cell Receptor Repertoire in African American Patients
1:00PM-3:00PM
Abstract Number: 1730
T Cell-Macrophage Interactions Play a Critical Role in a Mouse Model of Histidyl-tRNA Synthetase-Induced Myositis
1:00PM-3:00PM
Abstract Number: 2000
Tapering of Long-term, Low Dose Glucocorticoids in Senior Rheumatoid Arthritis Patients: Follow up of the Pragmatic, Multicentre, Placebo-controlled GLORIA Trial
1:00PM-3:00PM
Abstract Number: 1820
Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls
1:00PM-3:00PM
Abstract Number: 1702
Targeting CD6-CD318 Axis with UMCD6 (anti-CD6) Enhances in Vivo Killing of Cancer Cells Through Direct Activation of NK Cells
1:00PM-3:00PM
Abstract Number: 2051
Targeting Janus Kinase Pathway in Sjogren’s Disease Corrects IFN-Driven Inflammation and Epithelial Dysfunction
1:00PM-3:00PM
Abstract Number: 1979
Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients
1:00PM-3:00PM
Abstract Number: 1977
Tc99m Tilmanocept Imaging Predicts Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy
1:00PM-3:00PM
Abstract Number: L07
Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study
1:00PM-3:00PM
Abstract Number: 1753
Temporal Trends of SLE Mortality Among Various Ethnic Categories Across the United States: 2001-to 2020 Analysis from WONDER Database
1:00PM-3:00PM
Abstract Number: 1840
The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease Perform Lower Than Expected: Data from a Norwegian Cohort
1:00PM-3:00PM
Abstract Number: 1913
The Association of Radiographic Chondrocalcinosis with Localized Structural Outcomes in Knee OA: The Multicenter Osteoarthritis Study
1:00PM-3:00PM
Abstract Number: 1985
The BEGIN Study: A Double-blind, Multi-center, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks of Treatment with AP1189 in Early Rheumatoid Arthritis (RA) Patients with Active Joint Disease
1:00PM-3:00PM
Abstract Number: 1711
The Cellular Basis for Type I Interferon Production Following Ultraviolet Light Stimulated Cyclic-GMP-AMP Synthase Activation in the Skin
1:00PM-3:00PM
Abstract Number: 1714
The Circadian Clock Gene Bmal1 Negatively Regulates Autoantibody Production in SLE
1:00PM-3:00PM
Abstract Number: 1771
The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
1:00PM-3:00PM
Abstract Number: 1890
The Efficacy of Intra-articular Triamcinolone Acetonide 10 mg vs. 40 mg in Patients with Knee Osteoarthritis: a Non-inferiority, Randomized, Controlled, Double-blind, Multicenter Study
1:00PM-3:00PM
Abstract Number: 1722
The ERβ Agonist, WT-IV-012, Suppresses the Inflammatory Response in Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1787
The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum Calcium, and C-Reactive Protein (CRP) During an Acute Gout Flare – a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study
1:00PM-3:00PM
Abstract Number: 2089
The Implication of Skin Involvement on Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
1:00PM-3:00PM
Abstract Number: 2073
The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies
1:00PM-3:00PM
Abstract Number: 1958
The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry
1:00PM-3:00PM
Abstract Number: 1757
The Independent Impact of Gout on Mortality and Risk of Coronary Heart Disease Among Women – a Prospective Cohort Analysis of Women over 34 Years
1:00PM-3:00PM
Abstract Number: 1712
The Lymph Node Microenvironment in SLE Mice Is Altered and Impairs Egress of T Lymphocytes
1:00PM-3:00PM
Abstract Number: 1969
The Potential Diagnostic Value of C-X-C Motif Chemokine 13 (CXCL13) in Seronegative Arthritis
1:00PM-3:00PM
Abstract Number: 1685
The Presence of Anti-MAA Antibodies to Extracellular Matrix Proteins in Synovial Fluid and Sera of Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 2160
The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients
1:00PM-3:00PM
Abstract Number: 2071
The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), American College of Rheumatology (ACR), and Lupus Foundation of America (LFA) Damage Index Revision – Item Generation Phase
1:00PM-3:00PM
Abstract Number: 1716
The Transcriptomic Landscape of Nephritic Kidneys Reveals Mechanisms for End Organ Resistance to Damage in Lupus-prone Mice
1:00PM-3:00PM
Abstract Number: 2039
The Tubarial Glands Resemble the Palatal Salivary Glands Based on Further Histological Characterization, and May Represent an Organ of Interest in Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 1827
The Updated Cardiovascular Risk Tool SCORE2 Provides No Advantage in Identifying Patients with Gout and Carotid Atheroma Plaques
1:00PM-3:00PM
Abstract Number: 2104
The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE
1:00PM-3:00PM
Abstract Number: 1802
The Utility of Dual-energy Computed Tomography in Gout Patients During Urate Lowering Therapy
1:00PM-3:00PM
Abstract Number: 2028
The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome
1:00PM-3:00PM
Abstract Number: 1795
Therapeutic Strategies for Patients with Chronic Manifestations of Calcium Pyrophosphate Deposition Disease
1:00PM-3:00PM
Abstract Number: 1841
To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis
1:00PM-3:00PM
Abstract Number: 2054
Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process
1:00PM-3:00PM
Abstract Number: 2064
Trajectories of Disease Activity in a Longitudinal Registry of Pediatric SLE
1:00PM-3:00PM
Abstract Number: 1934
Transition Readiness Before versus After Adolescents with Rheumatic Disease Transition to Adult Care
1:00PM-3:00PM
Abstract Number: 1761
Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1843
Trends in the Cumulative Exposure to Corticosteroids in Polymyalgia Rheumatica (PMR) Patients: A Single Academic Center Experience
1:00PM-3:00PM
Abstract Number: 1790
Ultrasound Diagnosis of Calcium Pyrophosphate Crystal Deposition: Which Sites Should Be Scanned?
1:00PM-3:00PM
Abstract Number: 1919
Underdiagnosis and Undertreatment of Knee Osteoarthritis in Persons with Type 2 Diabetes: A Cross-sectional Study
1:00PM-3:00PM
Abstract Number: 2076
Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 1823
Unsupervised Cluster Analysis of Clinical and Ultrasound Features Reveals Unique Gout Subtypes: Results from the Egyptian College of Rheumatology (ECR)
1:00PM-3:00PM
Abstract Number: 1811
Urate Lowering Therapy Initiation in Hospitalized Patients with Acute Gout Flares
1:00PM-3:00PM
Abstract Number: 1828
Urate-lowering Therapy Reduces Non-Episodic Foot Pain in Patients Who Fail to Meet ACR/EULAR 2015 Gout Classification Criteria: An Effect Predicted by Ultrasound
1:00PM-3:00PM
Abstract Number: 1859
Urinary Beta-2 Microglobulin Is a Sensitive Prognostic Marker in Dermatomyositis Patients with Interstitial Lung Disease Positive for Anti-MDA-5 Antibody
1:00PM-3:00PM
Abstract Number: 1978
Using Administrative Health Data to Construct a Frailty Index as a Measure of Susceptibility to Adverse Health Outcomes Among Individuals with Rheumatoid Arthritis
1:00PM-3:00PM
Abstract Number: 1764
Utilization of Electronic Health Record Data to Evaluate the Impact of Urban Environment on Risk of Systemic Lupus Erythematosus Symptoms
1:00PM-3:00PM
Abstract Number: 1842
Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry
1:00PM-3:00PM
Abstract Number: 1880
Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys
1:00PM-3:00PM
Abstract Number: 2052
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population
1:00PM-3:00PM
Abstract Number: 2095
Validation Analysis of the Physician Global Assessment (PGA) Scale in Patients with Systemic Lupus Erythematosus Included in RELESSER-PROS Registry
1:00PM-3:00PM
Abstract Number: 2170
Validation of Ranked Composite Important Difference (RCID) Score in Early Diffuse Cutaneous Systemic Sclerosis
1:00PM-3:00PM
Abstract Number: 1825
Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study
1:00PM-3:00PM
Abstract Number: 2043
What Does Isolated Anti-Ro52 Antibody Positivity Mean in Sjögren’s Syndrome?
1:00PM-3:00PM
Abstract Number: 1901
What Does Radiographic Minimum JSW Actually Measure? Comparison of Radiographic and MRI Measures Using Data from the OAI
1:00PM-3:00PM
Abstract Number: 2034
What Is the Best Initial Screening for Suspected Sjögren’s Disease?
1:00PM-3:00PM
Abstract Number: 1974
Which ACR Response Definition Should Be Used for Disease Activity Claims in Approval Studies of Rheumatoid Arthritis? A Systematic Evaluation
1:00PM-3:00PM
Abstract Number: 2004
Which Route and Dose of Corticosteroids Is Most Effective in Inducing Remission in Early Rheumatoid Arthritis? A Systematic Literature Review and Meta-analysis
1:00PM-3:00PM
Abstract Number: 1867
YKL-40-mediated Inflammatory Pathogenesis Common to Polymyositis / Dermatomyositis

« View all sessions from this meeting